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WITNESS SEMINARS:
MEETINGS AND PUBLICATIONS1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine
Group, as part of the Academic Unit of the Wellcome Institute for the History
of Medicine, to bring together clinicians, scientists, historians and others
interested in contemporary medical history. Among a number of other
initiatives the format of Witness Seminars, used by the Institute of
Contemporary British History to address issues of recent political history, was
adopted, to promote interaction between these different groups, to emphasize
the potential benefits of working jointly, and to encourage the creation and
deposit of archival sources for present and future use. In June 1999 the
Governors of the Wellcome Trust decided that it would be appropriate for the
Academic Unit to enjoy a more formal academic affiliation and turned the
Unit into the Wellcome Trust Centre for the History of Medicine at University
College London from 1 October 2000. The Wellcome Trust continues to fund
the Witness Seminar programme via its support for the Centre.
The Witness Seminar is a particularly specialized form of oral history, where several
people associated with a particular set of circumstances or events are invited to
come together to discuss, debate, and agree or disagree about their memories. To
date, the History of Twentieth Century Medicine Group has held 40 such
meetings, most of which have been published, as listed on pages  xiii–xx.
Subjects are usually proposed by, or through, members of the Programme
Committee of the Group, and once an appropriate topic has been agreed,
suitable participants are identified and invited. This inevitably leads to further
contacts, and more suggestions of people to invite. As the organization of the
meeting progresses, a flexible outline plan for the meeting is devised, usually
with assistance from the meeting’s chairman, and some participants are invited
to ‘set the ball rolling’ on particular themes, by speaking for a short period to
initiate and stimulate further discussion. 
Each meeting is fully recorded, the tapes are transcribed and the unedited
transcript is immediately sent to every participant. Each is asked to check his
or her own contributions and to provide brief biographical details. The editors
turn the transcript into readable text, and participants’ minor corrections and
comments are incorporated into that text, while biographical and
bibliographical details are added as footnotes, as are more substantial
comments and additional material provided by participants. The final scripts
are then sent to every contributor, accompanied by forms assigning copyright
to the Wellcome Trust. Copies of all additional correspondence received
during the editorial process are deposited with the records of each meeting in
Archives and Manuscripts, Wellcome Library, London.
As with all our meetings, we hope that even if the precise details of some of the
technical sections are not clear to the non-specialist, the sense and significance
of the events will be understandable. Our aim is for the volumes that emerge
from these meetings to inform those with a general interest in the history of
modern medicine and medical science; to provide historians with new insights,
fresh material for study, and further themes for research; and to emphasize to
the participants that events of the recent past, of their own working lives, are
of proper and necessary concern to historians.
x
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INTRODUCTION
We had hoped that this introduction would be written by John Vane. Sadly,
he died in November 2004 after a prolonged illness. His enormous
contributions to the field of prostaglandins, and their influences in platelet
behaviour, were referred to many times during the meeting and were very
much in everyone’s minds throughout it. 
An interesting account of the early recognition of platelets in thrombosis is
given by the late John French in his chapter on thrombosis in Florey’s General
Pathology – a wonderful book with a star-studded cast of authors that Lord
Florey gathered around him in the Sir William Dunn School of Pathology in
Oxford. French recounts how in 1851 Wharton-Jones described an artery
becoming blocked ‘by a mass composed apparently of colourless corpuscles
and fibrin’.1 In 1875, Zahn (who described the lines of platelets in thrombi
that bear his name) observed cells deposited on the inner wall of a vessel
injured by pressure or salt. However, both Wharton-Jones and Zahn mistook
the cells for leukocytes, since the platelets in frog’s blood have nuclei. It was
thought that what were in fact non-nucleated mammalian platelets were
simply cell fragments not normally present in the circulation. In 1882,
Bizzozero repeated Zahn’s experiment, this time using guinea-pigs or young
rabbits, whose platelets are non-nucleated. Recognition of platelets as one of
the cellular elements of blood was therefore established, along with their
potential for being ‘agglutinated’ and stabilized at sites of injury. 
The modern era of platelet research started with the introduction of ex vivo
methods for studying platelet behaviour. Helen Payling Wright developed her
technique for assessing platelet adhesiveness to glass.2 However, it was of
course the introduction of the platelet aggregometer by Gustav Born,
described in 1962, that marks the beginning of the detailed study of the way
platelets behave and respond to various stimuli, and that is where the
proceedings of this meeting really start.3 There is no doubt whatever about the
role of platelets in thrombosis and in clinically manifest vascular disease, not
only heart attacks and strokes but also in venous thrombosis. The
1 French (1958): 185.
2 Wright (1941).
3 Born (1962b). See also Smith (2004).
demonstration that aspirin reduces platelet aggregability led to an enormous
number of laboratory and clinical studies on its value and also to a series of
randomized controlled trials that have shown its great value in both the
primary and secondary prevention of thrombotic disorders. John Vane’s
elucidation of the effects of aspirin on prostaglandins, for which he won the
Nobel Prize,4 opened up a new direction for studies that have – among many
other things – enabled rational decisions about aspirin dosage to be made. 
We know a great deal about the biochemistry and physiology of platelets and
how to modify them to good effect. It remains a paradox that we still lack a
validated test for clinical use to identify those whose thrombotic episodes are
due to the sensitivity or activity of their platelets. Maybe this no longer
matters! Anyway, these proceedings will I hope raise questions for future
endeavours in the platelet field as well as presenting an interesting and
authoritative account of its recent history.
Tom Meade
London School of Hygiene and Tropical Medicine
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4 Vane (1971, 1983).
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Dr Tilli Tansey: This meeting was suggested by Professor Gustav Born and was
agreed to by the Programme Committee, and we are very grateful to him for
suggesting such an interesting topic. My colleague Daphne Christie has
worked very closely with Professor Born and with Professor Meade in
organizing this meeting, and I would like to thank them all for that work. It’s
very important to identify a suitable chairman for these meetings, someone
who knows the subject and who is going to be able to keep control of all the
participants. I am delighted that Tom Meade has agreed to chair this meeting
and so without further ado we will hand over to Tom.
Professor Tom Meade:1 Welcome to this meeting, which I think will certainly
be extremely interesting. There are several topics that we should address,
though obviously there will be quite a lot of overlap between different aspects.
After I have asked Gustav Born and Stan Heptinstall to introduce their topic
and after we have had some discussion about that, I shall say a few words about
platelets and the prediction of thrombotic disorders.2 I will ask Duncan
Thomas and Clive Page to follow and that will take us up to tea. After tea we
will start off with Rod Flower. And, Salvador Moncada (who has just come at
very short notice, for which we are most grateful), obviously we would like you
to say something about the historical aspects of the prostaglandin story. 
We will start off with Gustav Born who is, of course, the person most
associated in many ways with the whole platelet story. As to the clinical side of
things, I suggest we stick to coronary heart disease and stroke, but that is only
a suggestion. Obviously, aspirin with its effects on platelets has now been
implicated in a number of other conditions – perhaps large bowel cancer is the
one that is attracting most attention at the moment, but let’s not stray too far
from platelets. So, Gus, would you like to start off by introducing the question
of platelets, aggregometry and biochemical aspects.
Professor Gustav Born: In my work on platelets, I have enjoyed the
collaboration and friendship of more than 40 co-workers from this and many
other countries. They and our publications are listed and our work is
summarized in the ‘Afterword’, which I was invited to contribute to the 1000-
page tome on Platelets in 2002.3 What follows is a selection from research on
platelets and other circulatory topics done from the 1960s to the 1980s.
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1 Biographical notes appear on pages 143–53.
2 For details on the discovery of platelets, see Robb-Smith (1967). 
3 Professor Gustav Born based his introductory remarks on ‘Afterword: Platelets, a personal story’ in
Gresele et al. (2002): 1063–71.
During that period descriptive knowledge of platelets was superseded by
understanding of their pathophysiological mechanisms and functions.
How does one come to platelets? The most common route has been through
clinical haematology; and until platelets became prominent players in coronary
heart disease and stroke, their medical importance was mainly in absentia,
because platelet deficiency causes bleeding. There are many causes of platelet
deficiency, one being radiation. As an Army Medical Officer posted close to
atom-bombed Hiroshima in defeated Japan after the Second World War,
deadly haemorrhages from radiation sickness first made me aware of platelets
and how much we need them. 
My own long-term relationship with platelets came through postdoctoral
initiation into pharmacological research. In 1956 I was working in the Oxford
Pharmacology Department with Hugh Blaschko on the recently discovered
association of adrenaline with adenosine triphosphate (ATP) in adrenal
granules, which contain about three molecules of the cationic amine for each
molecule of ATP3–, suggesting ionic binding.4 It occurred to me that other
endogenous amines might be stored similarly elsewhere in the body. I had
heard or read of platelets containing large amounts of the vasoconstrictor
amine serotonin (5-hydroxytryptamine, 5-HT). So the initial intention was to
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Figure 1: (Above left)   Scanning electron micrograph of platelets [x 15 000], c. 1965.
Figure 2: (Above right) Scanning electron micrograph of aggregated platelets [x 15 000], c. 1965.
utilize this circulating pseudocell [platelet] for pharmacological purposes. I was
the first person in Britain to use the firefly luminescence method, recently
introduced by McElroy in the US, for measuring ATP.5 With the platelet
extract adjusted to ATP concentrations expected from other cell types, the
galvanometer pointer flew off the scale – an unforgettable moment.6 The
discovery of excess platelet ATP was indeed followed by evidence for its
stoichiometric association with 5-HT, again suggesting ionic binding. 
By far the largest and most enduring part of my work on platelets had to do
with their role in haemostasis and thrombosis, both the physiological and the
pathological processes that happen through aggregation of the platelets. My
interest in platelet aggregation was awakened by the coming together of two
previously unconnected observations. One was our discovery of excess ATP in
platelets and the demonstration of its rapid breakdown in clotting blood.7 The
other was the Norwegians’ discovery of the platelet-aggregating effect of
adenosine diphosphate (ADP).8 By then we were aware that the primary
function of platelets is their haemostatic aggregation. I suggested that the two
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5 Strehler and Totter (1954).
6 Born (1956a).
7 Born (1956b).
8 Gaarder et al. (1961).
Figure 3: (Above left)  Platelets aggregating as a ‘haemostatic plug’ [x 650].
Figure 4: (Above right) Platelets aggregating as an intravascular thrombus [x 3000].
processes are connected through the formation of ADP from ATP released
from platelets and from other cells involved in vascular injury.9 Nevertheless,
over the years the hypothesis that ADP contributes to platelet aggregation in
haemostasis and thrombosis has been supported by experiments and by clinical
trials of drugs which inhibit platelet activation by ADP, notably the
‘Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events’ (CAPRIE)
trial published in the Lancet as recently as 1996.10
For investigations of platelet physiology I invented and developed the optical
aggregometer for quantifying and analysing platelet reactions in vitro. The idea
came to me from so-called ‘turbidimetric’ measurements of ribonuclease activity in
Streptomyces culture filtrates that I had done for my DPhil in Oxford. I made the
simple adaptations appropriate for measuring platelet aggregation in plasma. The
method is simple, indeed quite banal, and nothing to be proud of intellectually.11
But it became an amazing success, by bringing exciting results quickly and
reproducibly. Having had an important part of my scientific upbringing in
Professor Harold Burn’s excellent Pharmacology Department in Oxford, where
free and noisy communication between members and visitors was strongly
encouraged, I had no hesitation in demonstrating the technique immediately to
anybody who asked.12 The method was published in 196213 and the first detailed
description of observations made with it appeared in the following year.14 We
quantified the relation of aggregate formation to the optical changes15 and showed
that they could be accounted for by classical light-scattering theory.16
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9 Professor Gustav Born wrote: ‘This has turned out to be an oversimplification as far as the platelets
themselves are concerned, which release ADP mostly from a different pool than that in which ATP
breaks down. The evidence is that ADP and thromboxane A2 contribute about equally to
haemostatic aggregation in vivo.’ Note on draft transcript, 25 February 2005. Born (1962b).
10 CAPRIE (1996).
11 Optical aggregometry is a technique to measure platelet aggregation, where a platelet agonist such
as adrenaline, ADP or collagen is added to platelet-rich plasma to induce aggregation. See Figure 5.
The most easily interpreted measurement is the initial velocity of increase in light. Results vary
according to the platelet count and agonist used. See page 27 for its use to investigate the
pharmacology of a single human cell type. 
12 A letter from Sir John Vane, 2 May 2001, on this subject has been deposited along with the records
of this meeting in GC/253, Archives and Manuscripts, Wellcome Library, London.
13 Born (1962a and b).
14 Born and Cross (1963b).
15 Born and Hume (1967); Michal and Born (1971).
16 Latimer et al. (1977).
The optical aggregometer has ever since been used worldwide in fundamental,
clinical and epidemiological investigations.17 Within a few years the original papers
became Citation Classics,18 and by January 2001 the Nature paper had been cited
3796 times and the Journal of Physiology paper 1902 times. (This information is
from Peter Richardson.)19 Many more papers, probably thousands, have been based
on optical aggregometry without reference to the original publications.20
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17 Among those who have manufactured Born aggregometers commercially are Alpha Laboratories,
Eastleigh, Hants, UK; H Upchurch & Co., Leicester, UK; Entec GmbH, Ilmenau, Germany;
Bryston Manufacturing Limited, Rexdale, Ontario, Canada; Payton Associates, Scarborough,
Ontario, Canada; and Payton Scientific, Inc., Buffalo, NY; Bio/Data Corp., Horsham, PA; Chrono-
log, Havertown, PA; and Sienco Inc., Morrison, CO.
18 A Citation Classic is a frequently cited article chosen by Science Citation Index, a journal that 
first appeared in 1963, as among the top most frequently cited articles, featuring a commentary 
on its influence and a facsimile of the article, freely available at www.garfield.library.upenn.edu/classics.html
(visited 15 April 2005) and published in Current Contents; for an essay on citation indexing, see
http://garfield.library.upenn.edu/essays/V1p158y1962-73.pdf (visited 15 April 2005). See also Born
(1977, 1989).
19 Professor Gustav Born wrote: ‘In 2004 the latter was the sixth most cited paper ever published in the
Journal (this information is from Stewart Sage, the Editor).’ Note on draft transcript, 25 February 2005.
20 Professor Gustav Born suggested three possible reasons that this paper is one of the most cited
articles ever published, see Gresele et al. (2002): 1065–6. 
Figure 5:The first aggregometer made in the workshop at the Royal College of Surgeons
in 1961. Born (1962b).
I have been told that there are thousands of optical aggregometers around the
world, and am often asked why I did not patent the device. The reason I give is
that before the Thatcherite degradation of everything in life to money, it did not
occur to me, nor to most members of the medical research community, to patent
inventions or discoveries; indeed my Oxford Professor, Howard Florey, was against
patenting anything of potential medical value.21 So the idea just never came up. 
Up to the molecular biology era it is probably true to say that much if not most
of the new information about platelets has depended on optical aggregometry.22
We characterized aggregation with respect to velocity and temperature and pH
dependence, and discovered two essential cofactors of aggregation, namely
calcium and fibrinogen;23 and the suggestion that fibrinogen formed ‘bridges’
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21 See Macfarlane (1979). For further discussion about patents, see, for example,
http://biotech.about.com/library/weekly/aa_penicillinpatent.htm (visited 14 October 2004).
22 See note 11.
23 Born and Cross (1964); Cross (1964).
Figure 6:The first optical record of platelet aggregation by ADP showing the increase in
transmitted light, illustrated here as downward deflection.
Different concentrations of ADP was added at time O: (A) 2.5 x 10-7 M; (B) 5 x 10-7 M; (C) 1 x 10-6 M; (D) 2.5 x 10-6 M.
Born (1962b).
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Figure 7: A modern single-channel aggregometer, 1970.
Figure 8: Professor Gustav Born standing near the portrait of Lord Florey at the Dunn School
of Pathology at Oxford, 2004.
linking aggregating platelets was later confirmed at the electron microscopic
and molecular levels.24
The rapid shape change of platelets (time constant of about 1 second at 37ºC),
the first visual evidence of their activation, was quantified and shown to
conform to Michaelis–Menten kinetics.25 The results suggested that aggregation
agonists such as ADP react with specific membrane receptors leading to
structural changes. Now, of course, these receptors are fully identified.26
Optical aggregometry made possible the discovery by Macmillan and Oliver in
1965 of the second phase of aggregation27 – Michael Cross and I had failed to
notice, or to think about, the anomalous deformations in our manually plotted
aggregometer tracings (this was before the availability of continuous
recording), which turned out to be the optical manifestation of the platelet
release reaction.28 It is this second phase of aggregation that is inhibited by
aspirin.29 Therefore optical aggregometry is at the beginning of a very
important medical story.
Optical aggregometry soon led also to our discovery of the first aggregation
inhibitors, namely ATP and adenosine, looked at first because of their close
chemical relationship to proaggregatory ADP.30
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24 Professor Gustav Born wrote: ‘Nowadays this bridging function, and thereby platelet aggregation,
can be prevented by various molecules which inhibit binding of fibrinogen to its receptor, the
activated conformer of glycoprotein IIb-IIIa, on the platelet surface.’ Note on draft transcript, 
25 February 2005. Born (1965).
25 Born (1970). 
26 Professor Gustav Born wrote: ‘ The shape change paper [note 25] also contains the proof, by means
of a novel thrombocrit technique for determining cell volume directly, that the rapid shape change
is not accompanied by an increase in mean platelet volume, as had been widely accepted on the basis
of Coulter Counter measurements. Such a rapid increase in cell volume would, to my knowledge, be
unique in cell biology and indeed impossible because of cell lysis.’ Note on draft transcript, 
25 February 2005. 
27 Macmillan and Oliver (1965). 
28 Professor Gustav Born wrote: ‘In this reaction, enough ADP is released (and thromboxane A2
formed) to account for the positive feedback mechanism of aggregation proposed earlier.’ Note on
draft transcript, 25 February 2005. See Figure 14 and note 162.
29 See note 27.
30 Born (1962b); Clayton et al. (1963).
As it has turned out, inhibition was the most exciting and far-reaching discovery
because it established the therapeutic possibility of preventing arterial
thrombosis by means of antiplatelet drugs and initiated the era of their use for
the prevention of myocardial infarction (MI) and stroke. We devoted much
effort to inhibitory mechanisms. To demonstrate this rigorously required
correlating optical aggregometry with quantitative electron microscopy.31
For quantifying aggregation in vivo, novel techniques were developed for
reproducible bleeding time determinations from small arteries in the superior
mesenteric territory of rats and rabbits. In both species local infusions of active
but not of inactive ADP-removing enzyme systems increased bleeding time
significantly, supporting the conclusion that platelet aggregation in primary
haemostasis involves ADP.32 In rats these bleeding times were also prolonged
by ADP receptor antagonists.33 This work was done, incidentally, with a great-
granddaughter of Charles Darwin, Carola, a charming girl. With ultra-
sensitive luminescence measurements, blood at arterial puncture sites was
shown to contain micromolar ATP for at least two or three seconds.34 Its rapid
dephosphorylation supported the proposition35 that ADP is involved in
initiating the haemostatic aggregation.36
Quantifying platelet adhesiveness and aggregation in uninjured vessels
required a further methodological innovation. This was to apply ADP by
micro-iontophoresis to the outsides of small blood vessels.37 ADP thus applied
showed that platelet thrombi can be made to form many times on the same site
without damaging the endothelial lining, thereby disposing of claims to the
contrary. Aggregates grew exponentially, the rate constant providing a measure
of the effects of blood flow and of inhibitors.38 The technique also permitted a
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31 Professor Gustav Born wrote: ‘We did, inter alia, experiments on ourselves which could
conceivably have been harmful and would now be strictly forbidden. These showed that the relative
potency of adenosine analogues as aggregation inhibitors and as arterial vasodilators was the same.
Born et al. (1965). See also Born et al. (1978).
32 Zawilska et al. (1982); Begent and Born (1983).
33 Born et al. (1986)
34 Born and Kratzer (1984); Kratzer and Born (1985).
35 Born (1962a).
36 Born (1962b).
37 Duling et al. (1968).
38 Begent and Born (1970).
first determination of platelet activation time (of the order of 100 milliseconds,
since revised downwards).39
As it has turned out, the demonstration that inhibitors of in vitro aggregation
are also effective in vivo has been of great importance. Regional administration
of aggregation inhibitors prevented thrombosis formation in artificial organs,
work done with Peter Richardson.40
For platelet people, the most important discoveries in the 1970s were
proaggregatory thromboxane A2 produced by platelets and antiaggregatory
prostacyclin produced by vessel walls; and of course the Nobel Prize-winning
discovery by John Vane of the action of aspirin in inhibiting prostaglandin
biosynthesis,41 plus the immediate demonstration of its applicability to
platelets by our graduate students Bryan Smith and Jim Willis.42
Looking back,43 I suppose that the greatest change to have happened to
platelets is their enormously increased importance in clinical medicine – from
somehow being involved in the rather uncommon conditions of idiopathic
thrombocytopaenia and radiation sickness to being recognized as a dominant
factor in arterial thromboses causing MI and stroke, which together cause
The Recent History of Platelets in Thrombosis and Other Disorders
12
39 Born and Richardson (1980).
40 Richardson et al. (1976).
41 Professor Gustav Born wrote: ‘These events are very well known, and the therapeutic advances
they brought are very great: through its antiplatelet action aspirin reduces the risk of heart attacks
and strokes by up to 40 per cent. This prostaglandin period also renewed interest in the influence of
diet on platelet thrombogenesis, which Dick Philip and I had shown some years before to be
accelerated in fat-fed rats [Born and Philip (1965)]. In the early 1980s Margareta Thorngren and I
produced human evidence that a fish diet of a month did not diminish platelet-derived
thromboxane A2 in bleeding time blood, and that the increased haemorrhagic tendency of fish-
eating populations has less to do with platelets than with vascular contractility – at a time a heretical
proposition which has presumably been confirmed since [Begent et al. (1984)].’ Note on draft
transcript, 25 February 2005.
42 Vane (1971); Smith and Willis (1971); Ferreira et al. (1971). See also, Willis and Smith (1981);
for a description of Vane’s reasoning on the action of aspirin, see Vane (1992).
43 Professor Gustav Born wrote: ‘By the mid-1980s understanding of the physiological behaviour
and pharmacological control of platelets was well advanced. New questions were increasingly
answered by the techniques of molecular biology, with which I was not familiar. So it seemed natural
to devote my last research decade to atherosclerosis, the more so because to the extent that it will
become preventable, the clinical importance of arterial thrombosis and therewith of platelets will
diminish. These contributions have been reviewed [Born et al. (2003)].’ Note on draft transcript, 
25 February 2005.
almost half the deaths in industrialized populations. It is gratifying that the
feedback hypothesis of platelet aggregation turned out to be the explanation of
the remarkable effectiveness of antiplatelet drugs of the aspirin type in the
prevention of heart attacks and strokes. 
Platelet research has been continuously interesting in itself, and it has also
permitted following promising side alleys.44 I am glad to have contributed in a
small way to knowledge of a vital physiological process – haemostasis – and to
an advance in medicine, which Dr Samuel Johnson rightly called the greatest
benefit to mankind.45
Meade: There’s obviously a lot there that we will want to come back to, but I
will now ask Stan Heptinstall to say a few words on the same subject.
Professor Stan Heptinstall: I am sorry that I am here, in one sense, in that I
am not old enough. I look around and I see people whom for the whole of my
career I have thought of as my seniors. I didn’t come on the scene until 1972. I
went from Newcastle to Nottingham to work with Tony Mitchell [see Figure 9]
on an Medical Research Council (MRC) programme grant. There was a guy
there before me called David Nichols, but he was a mitochondriologist and he
soon discovered that platelets didn’t have many mitochondria, so he saw the
light and went off somewhere else. I answered the advert that resulted from his
departure. Then I started to meet the people that I see today in this room. 
I don’t think I have really done very much in my career. When I started to
work on platelets, a lot of what Gustav has just been talking about had already
been described. We knew that platelets aggregated. We knew that ADP and a
long, long list of other things induced aggregation. John Hampton discovered
that noradrenaline aggregated platelets. John and I worked together with Tony
Mitchell in Nottingham. I remember looking at a table in a publication by
Fraser Mustard – I think it was in Pharmacological Reviews, dated 1970.46 It
contained a long list of things that made platelets aggregate together. So we
knew about aggregation, we knew about glycoprotein deficiencies, we knew
about Glanzmann’s thrombasthaenia, we knew about Bernard–Soulier
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44 Professor Gustav Born wrote: ‘A totally unexpected, extraordinarily interesting development has
been a continuing burst of research on trypanosomiasis, African sleeping sickness.’ Note on draft
transcript, 25 February 2005. See James and Born (1980); Born (2003b).
45 Chantler (2002) questions whether medicine can still make this claim.
46 Mustard and Packham (1970). 
syndrome and so on. We knew that platelets underwent vicious
metamorphosis. Later on, this became known as the release reaction. We knew
that platelets were associated with bleeding problems as a consequence of
glycoprotein deficiencies. We had a good idea that platelets were involved in
thrombosis, and the idea was developing that agents that modulate platelet
function, antiplatelet agents, might be used as antithrombotic agents. The
whole of my career was based upon moving all of that forward
I like to think of myself as having been an enabler, as opposed to a discovering
scientist. For example, getting involved in the grouping that Duncan Thomas
and Colin Prentice put together following the International Society for
Thrombosis and Haemostasis (ISTH) conference in the UK back in 1979, when
the British Society for Haemostasis and Thrombosis came into existence in
1980.47 Later on I became Secretary and then President of that society. A lot of
the work that was performed by UK people was presented at the British Society
of Haemostasis and Thrombosis meetings. I also feel that I have made an impact
on the European dimension, because years ago, back in 1981, I went to the old
East Germany (a really exciting thing to do at that time, to go behind the Iron
Curtain) to meet people there. In collaboration with the people in Erfurt, East
Germany, we set up a series of European conferences which people from the UK
attended. These were successful, because they brought together people from
eastern and western Europe. Latterly I became editor of the journal Platelets.
I have been asked to speak about aggregation. My first look at aggregation was
at Nottingham. I didn’t know what a platelet was. I just wanted to go and work
on something relevant to physiology and/or disease, and platelets seemed to fit
the bill. I was introduced to Gustav Born’s equipment [the aggregometer],
which in those days was nothing more than a stirring device and a
galvanometer. The platelet-rich plasma was put in the stirring device and it was
stirred for a bit. You didn’t worry too much about temperature and every now
and then you took it out and plunged it in the galvanometer to read the optical
density. Then you plotted out the results. It’s amazing what results could be
obtained from such a crude system. I am not being disparaging at all to Gustav,
but it was a crude system. A few years later, in collaboration with the late John
Adams, who was a technician, and also Peter Jessop at the University of
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47 The inaugural meeting of the British Society for Haemostasis and Thrombosis was held in London
in 1980, with Professor Gustav Born as the first President and Dr Duncan Thomas as the first
Secretary. See www.bsht.bham.ac.uk/History.htm (visited 13 April 2005). For the background of the
ISTH, see Glossary, page 163.
Nottingham, we built our own six-channel automated platelet aggregometer
which was based upon the Born principle. We published that in 1975.48 We
used that machine for many years until we bought one of the more modern
commercial instruments later on. And I have to say that even now Born
aggregometry is the gold standard. There are other techniques that are available
for measuring platelet aggregation, but Born aggregometry continues to be the
gold standard. It is not perfect. It only measures what I like to call
macroaggregation, that is the formation of large aggregates that can be seen by
the naked eye.49 It’s at that point that the optical density of the sample starts to
change. The technique tells you nothing about any microaggregation that may
have occurred before that. Of course, using Born aggregometry, all you are
getting is information on the ability of platelets to aggregate together in the
absence of other blood cells, and it turns out that other blood cells are very
important in determining what platelets do. But nevertheless, Born
aggregometry remains the gold standard. 
There are other techniques. I see Rod Flower, who developed the impedence
aggregometer for measuring platelet aggregation in whole blood, which is still
used today. It didn’t take off to the same extent as Born aggregation, simply
because you can’t see the aggregates. You know, you can’t see them visually. I
think the beauty of Gustav’s technique is that you can actually see the
aggregates being generated. 
In our own laboratories, we have done an enormous amount of work over the
years in which we measured platelet aggregation using a platelet-counting
technique. The concept is very simple. As platelets aggregate together, the
number of single platelets in whole blood reduces, and therefore if you
continually monitor the platelet count in the sample, you can get a very good
estimate of the degree of aggregation that occurs. And if you use flow
cytometry in conjunction with that, then you can very clearly see
microaggregates being generated and you can look at the effects of the
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49 Professor Gustav Born wrote: ‘Not so. See Born and Hume (1967).’ Note on draft transcript, 
25 February 2005. Professor Stan Heptinstall wrote: ‘Well, even if this is not absolutely correct there
there is still a huge difference between techniques that rely on light absorbance that can only detect
macroaggregation and, for example, techniques that use platelet counting which detect
microaggregation. With the latter you can see aggregation occurring in the early seconds following
agonist addition at the time the light absorbance is still increasing consequent to shape change. See
Fox et al. (2004).’ E-mail to Mrs Lois Reynolds, 26 April 2005.
pharmacological agents and you can look at the effects of disease states and the
differences that occur. 
The other area I was asked to say something about is platelet biochemistry.
Platelet biochemistry – signal transmission inside platelets – is an area that
continues to develop. Someone finds out something new every week. It’s an
incredibly complex area. Back in the early 1970s, it was known that there were
lots of agents that make platelets aggregate together. It was known that
glycoproteins such as GPIIb/IIIa were involved. We were starting to get an
inkling of the sorts of things that happened inside platelets, such as calcium
mobilization. Stewart Sage over there, who’s done an enormous amount of
work on calcium mobilization in platelets and other cells, may well want to say
something about the history of that later on. I remember people like Tim Rink
being involved in developing the processes for measuring calcium
mobilization.50 Cyclic AMP was also important, of course. 
This is very much a UK gathering, isn’t it? However, a lot of UK people who
have done an enormous amount of work on platelets have actually gone
abroad to do it. Some who come to mind are people like Alan Nurton, Ken
Clemetson, and John McGregor, who went to work in France, and Richard
Haslam, who went to Canada and did a lot of work in the cyclic AMP area. I
will miss lots and lots of people out in this very brief, off the top of my head,
presentation. I really do apologize for that. 
We knew a bit about calcium, we knew a bit about cyclic AMP. Shortly
thereafter thromboxane A2 was identified by Bengt Samuelsson.
51 I am sure
Professor Moncada will put me right if I get anything wrong here. John Vane
and, of course, Salvador Moncada, were very much involved in the aspirin
story and the discovery of prostacyclin and the effects of nitric oxide (NO)
on platelets.
What I would like to say is that I have had the privilege of working on platelets
for over 31 years now, and I have thoroughly enjoyed it. I don’t think I have
personally made a big mark, but I have very much enjoyed watching what
many of you in this room have done. 
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50 See, for example, Rink et al. (1982); Rink (1982, 1987).
51 Professor Bengt Samuelsson shared the 1982 Nobel Prize in Physiology or Medicine 
with Professor Sune Bergström and Professor Sir John Vane for their discoveries ‘concerning
prostaglandins and related biologically active substances’. See http://nobelprize.org/medicine/
laureates/1982/index.html (visited 18 October 2004).
Meade: You have mentioned several people and I think what I will do first of
all is to ask them if they want to comment. Can you make your comments and
any rebuttals very short and snappy, because we have got quite a lot to get
through. John Hampton, would you like to say anything about your work,
particularly with Tony Mitchell, whose name quite rightly has been mentioned
several times.
Professor John Hampton: I joined Tony in 1964, and by then he had been in
platelets quite a long time already.52 In the nature of things in those days, Sir
George Pickering [see Figure 10] and his department in Oxford, was interested
in a lot of different topics. He had somebody working on body temperature,
somebody working on endothelial cells, and he was doing a lot on blood
pressure, and different things of that sort. Now these were little groups of two
or three people and I just turned up on the Monday morning, my first day,
and Pickering looked at me and said, ‘John, oh yes, I think you had better join
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Figure 9 (left): Professor Tony Mitchell, c. 1960s.
Figure 10 (right): Professor Sir George Pickering at the Garden Party at Wadham College,
Oxford, on the occasion of the celebration of the Tercentenary of the foundation of the
Royal Society, July 1960. © Oxford Mail.
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53 See Appendix 3, note 255 and Glossary, page 160.
54 Professor John Hampton wrote: ‘Hampton and Mitchell developed a tedious visual method of
measuring the rate of movement of platelets in an electric field. They found that low concentrations
of agents that caused aggregation in platelet-rich plasma (PRP) increased platelet surface charge (an
unexpected finding), but higher concentrations caused a decrease in surface charge, which might
allow aggregation to occur.’ Note on draft transcript, 7 March 2005.
Tony’. And so I became a ‘plateleteer’, and joined Mike Harrison, who had
been there a year longer.
Tony, who was so much at the beginning of platelets, had been involved in two
things: one was aggregation, which he had started, and Gustav might be able
to put the dates on this. Tony had started doing aggregation by holding
platelet-rich plasma up to the light and shaking tubes to see when they went
clear. When you could see through the tubes of platelet-rich plasma, the
platelets had aggregated. This was a much better technique than Gustav’s
because the plasma either had aggregated or it hadn’t. There was no argument
about time course or anything of that sort. He got from there into aggregation
in vivo and then to his second technique. John Honour had started a technique
with an anaesthetized rabbit, where we took a piece of bone from the skull and
looked at the blood vessels on the surface of the brain. He pinched an artery
with a pair of microtweezers and you could see platelet clumps form and these
platelet clumps embolized downstream in the way we now know applies to
acute coronary syndromes. One of the things that was of great interest at that
time was how these two techniques related to each other, because it became
fairly clear that although they had a lot of parallels, there were a lot of
differences. Mike should talk about the Persantin ® story, because there was a
great debate as to why Persantin ® inhibits platelets in the rabbit and did not
work in aggregation.53
I was given the job of a new technique which was measuring platelet
electrophoresis. This was Tony’s idea: if two charged cells stuck together then
something must happen to their charge when they did so. He had found some
weird machine used for other purposes where you peered down a microscope
with a stopwatch and you watched platelets float back and forth under an
electric field,54 and again we tried to correlate that with aggregation and to
some extent it did and to some extent it didn’t. It was a terrible technique, and
it drove you mad. It got dropped for the next 30 years after I had finished with
it, until Stan Heptinstall produced a paper from someone in the US who had
done the whole thing with a laser gadget which was automated and showed
exactly what I had shown with Tony 30 years previously.55 There was not a
mention of us at all in their paper. And it was Stanley [Peart], who gave this
paper to me to review with a wicked chuckle, and I said, ‘This is old hat’. We
got a charming letter back from the bloke saying he hadn’t checked the literature
that far back. I think Mike Harrison could probably say more about Persantin ®.
Professor Michael Harrison: First, I should say that John’s machine was able to
tell me when I was about to get flu. The electrophoretic mobility of my platelets
changed when I was going to go down with flu, so this technique should not
have been dropped. The interest in dipyridamole was of course because Gus had
just shown that adenosine and 2-chloro-adenosine were inhibitory and
dipyridamole was supposed to be an adenosine–diaminase inhibitor. Tony
Mitchell argued that this should increase the effect of endogenous adenosine and
would be inhibitory, and we struggled to show a small effect in the in vitro
aggregometer but were not impressed by it. As John said, when it was used in the
context of the in vivo model (the injured cortical vessels in the rabbit), it was
inhibitory, and this spawned the idea of its clinical use. But these discrepancies
between what works in the test tube and what works in an in vivo model, and
then what actually works in man, continue to be fascinating I think.
Dr Stewart Sage: I suppose I was lucky to be involved in the calcium story quite
early on. Measuring calcium in platelets is obviously difficult because of their size
[see Figures 1 and 2]. A lot of the earlier techniques precluded their use in
platelets, and although there are a few reports of using aequorin in platelets,56 I
suppose the first advance came with the invention of fluorescent calcium
indicators that were developed by Roger Tsien.57 The important thing about
these is that they can be loaded into the cell non-disruptively. Roger was working
with Tim Rink in the Physiology Laboratory at Cambridge when he developed
his first indicator quin-2 and although the first paper I think was actually using
lymphocytes, the second paper used human platelets and they tended to use
platelets as the favoured cell thereafter.58
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I joined Tim’s lab as a PhD student, two years after that first calcium paper
using platelets in 1981. I was quite lucky to be involved at a very fast-
moving time. Roger started developing a lot of much better indicators and
I think I am probably one of the first people to have used fura-2, perhaps
the most commonly used of the indicators, just because a sample was sent
to Tim by Roger Tsien. As fura-2 is much better than quin-2 (you can load
much lower concentrations and still get a useful signal) I started to get
rather more valuable data. I suppose one of the small contributions that I
made was fairly early in the PhD. Tim was sent a contraption by High-Tech
Scientific, a company that had been supplying stop-flow apparatus to
biochemists and chemists for many years. And Tim said, ‘Why don’t you
play around with this and see if you can use it with whole cells?’ Platelets
are ideal to be fired through a stop-flow machine without falling apart,
which many larger cells clearly do, as has subsequently been discovered. We
started to get some information on the kinetics of early calcium changes
when platelets were stimulated, which started to shed light on possible
underlying mechanisms, and perhaps one of the most important things that
grew out of that work was the discovery of what we at the time thought was
a very rapid response to ADP, but it was subsequently appreciated through
the work of Martyn Mahaut-Smith, who’s sitting next to me, it is actually
attributable to contaminating ATP. That led on to work with Martyn when
he came to Cambridge and carried out the first patch-clamp experiments on
stimulated platelets, which is another very important advance, and still a
technique that is not often widely used, and I am sure he would like to say
something about that. That is how I came into the field and how the
calcium story started. Obviously, the use of these calcium indicators has
since shed a lot of very useful light on the signalling pathways that are
involved in platelet activation.
Dr Martyn Mahaut-Smith: I joined the Department of Physiology in about
1988, actually at the invitation of Tim Rink, who phoned me when I was
doing a postdoc in Canada. I had had a very sleepless night after a patching
experiment until about 2 o’clock in the morning, when Tim woke me up and
said, ‘Would you like to come to work in Cambridge on a really exciting
project, to work in collaboration with Stewart Sage who is doing this
wonderful work using calcium indicators in platelets? It would be a real
challenge, that is to try to achieve the first electrophysiological recordings in
platelets.’ As it turned out, a worker in Japan had just obtained recordings of
platelets using the patch-clamp technique, which were published in the
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Journal of Physiology.59 We followed very shortly thereafter with work done in
collaboration with Stewart, showing again what we thought were ADP-
activated ion channels.60 These probably represent one of the first events that
occur following vascular damage because the kinetics of activation, as Stewart
had shown, were within about 10 milliseconds or so and we followed that with
patch-clamp recordings showing that this was due to the opening of an
ionotropic cation-permeable channel, letting calcium and sodium in. To date
we don’t really know the role of sodium. Those were really challenging times,
just because of the technique, but we did manage to get what we believe were
classical recordings. It wasn’t until about 2000 that we realized that it was ATP
contamination within the ADP that was responsible for activation of the ion
channels.61 Thus these P2X receptors, known now to be P2X1 receptors, are
not activated by ADP, but by ATP. I think we still don’t understand the relative
role of ATP in the activation of platelets. It was Professor Born who showed
that ATP goes up quite considerably following vascular damage.62 I think it is
a really exciting area and is still being carried forward now that we know there
are three platelet P2 receptors. Following on from the topic of this meeting
about why particular experiments were done, and how they advanced
knowledge of platelets and platelet ion channels, we now do our
electrophysiological recordings on megakarocytes. They are a 1000 times the
capacitance of a platelet, and we feel that in many respects they represent giant,
nucleated platelets.63 So because of the relative ease of those patch-clamp
experiments on the megakaroctye, I believe that there are exciting times ahead,
particularly for studies of platelet ion channels.
Meade: Colin Prentice, you were mentioned by Stan Heptinstall, do you want
to add anything at this stage?
Professor Colin Prentice: My experience with platelet involvement started
with Stuart Douglas and George McNicol in Glasgow,64 which was another
centre of enthusiasts working away, and certainly Born and Cross’s
The Recent History of Platelets in Thrombosis and Other Disorders
21
59 Maruyama (1987). 
60 Mahaut-Smith et al. (1990).
61 Mahaut-Smith et al. (2000).
62 Born and Kratzer (1984).
63 Mahaut-Smith et al. (2003).
64 Prentice et al. (1966). See also, for example, McNicol and Douglas (1964).
aggregometry was a very powerful tool at this early stage. Another person who
made a big impact in the 1960s was Hellem with his glass-bead columns.65 I
think we must acknowledge one or two of the pioneers, and he really
developed the very exciting work that when you ran the blood through the
glass-bead columns there was platelet disappearance, because the platelets
aggregated due to substances, later found to be ADP, which were released from
the red cells. This was one of the foundation clues that led to the discovery that
ADP aggregated platelets. Another person on the continent was
Bounameaux,66 who I think was probably the first to show that an extract of
macerated arterial vessel was a powerful and permanent aggregator of platelets.
Now I may be wrong, he may not have used the collagenase, but shortly after
that he discovered that this arterial component was collagen. I think it was
these two biological experiments that led to the concept that collagen was a
powerful platelet aggregator. Thus, you have the two components for platelet
aggregation, the ADP short reversible aggregation, and the collagen, which
irreversibly aggregates platelets after a latent period of half a minute or so. This
we now know is due to the release of thromboxanes mediated by the
prostaglandin cycle, which leads to the slower irreversibile platelet aggregation.
I think these individuals were important at the stage when we were working
up in Glasgow.
Our group in Glasgow went on to look at another platelet adhesive factor, the
factor VIII-related antigen, the von Willebrand factor, and that was another
exciting story which developed in the 1970s.67 It took quite a long time to
work out the difference between haemophiliacs and von Willebrand disease
patients, which was a mystery in the 1970s. Inga Marie Nilsson showed in
1957 that if you infused normal serum into von Willebrand disease patients –
an experiment that I don’t think is very ethical nowadays – that it shortened
their bleeding time and this was due to the von Willebrand factor which was
being injected into the von Willebrand disease patients.68 It was later
discovered that von Willebrand factor enables platelet adhesion to take place
in normal people. Lack of von Willebrand factor causes defective platelet
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adhesion and a prolonged bleeding time in affected patients. So I think in
addition to the ADP–collagen story, others would like to take up the von
Willebrand factor and fibrinogen as components of platelet aggregation and
adhesion, and the glycoprotein one as well.
Meade: May I just pause at this moment to say that although this is a UK
audience, we did ask some people from overseas, but they couldn’t come. Of
course, a great deal of the work that we are concerned with has taken part in
this country, but I think we shouldn’t forget that many investigators elsewhere
have made important contributions.69
Professor Peter Elwood: Before we leave the UK, may I mention John
O’Brien? In the year that Gus Born published his landmark paper on platelet
aggregation in 1962, in that same year John O’Brien totally independently
published a paper on platelet aggregation.70 So perhaps what Gus very
graciously said, that it didn’t require a great intellectual leap to develop the
technique, is true. But John O’Brien was an enormous encourager and a
tremendous help to many in their work on platelets and he remained active
working on platelets and on platelet technology up into his 80s.71
Unfortunately, he died earlier this year,72 but he brought out a method of
shear-stress activation of platelets that we incorporated into one of our
epidemiological studies.73 Sadly, it did not predict MI [myocardial infarction],
but neither does the Born method of platelet aggregation.
Born: I have to come back on that. I am sorry that John O’Brien may have
convinced himself that he invented the optical aggregometer, but the fact of the
matter is that it had been demonstrated to him by myself in my department
some time before he published it without acknowledgement to me. This is
confirmed by a letter from Sir John Vane who was present at the same time as
my senior lecturer.74
Professor Donald Chambers: My work on platelets from 1963 to 1969 began
in a fortuitous way. I had a laboratory at the Massachusetts General Hospital,
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Boston, just down the hall from Edwin Salzman. At the time I was working on
proteases and the mechanisms of acute pancreatitis. One morning Ed came to
see me and said, ‘I need your advice. Given the fact that thrombin relates to
platelet aggregation, what do you think would happen if you added proteolytic
synthetic substrate, benzoyl-L-arginine methyl ester synthetic substrate, to
platelet-rich plasma?’ I responded, ‘My bet is that it would inhibit platelet
aggregation, because it would act as a competitive substrate to thrombin’. Ed
did the experiment and returned two days later. ‘You were right,’ he said. That
started a six-year collaboration that subsequently moved to the Beth Israel
Hospital, Boston [now Beth Israel Deaconess Medical Center], examining the
mechanisms of platelet aggregation.75 We asked such questions as: what are the
dynamics of platelet aggregation?; how does ADP aggregate platelets?; what is
the nucleotide metabolism of platelets? At times, we incubated platelets with
14C-labelled ADP and 32P-ADP, lysed them, and found that 14C-ADP was
taken up by platelets, probably in the form of adenosine, but 32P-ADP was not.
Additionally, much of the ADP released by platelets was nonradioactive,
suggesting nucleotide compartmentalization.76 We ended our close scientific
collaboration with a hypothesis about the energy state of platelets and the role
of platelet cell surface ecto-ATPases (published in Nature): we presented the
argument that the non-sticky state of the platelet represented its active state
and when platelets died, they entered a less active state and aggregated.77 That
hypothesis caused a lot of discussion, which I think is a hallmark of science. 
Another thing we were into early was the role of cyclic AMP (cAMP) in
platelet metabolism and function. Ed Salzman was an early pioneer in
investigating that cAMP was protective against platelet aggregation, which I
think was a breakthrough and preceded the mechanistic understanding of how
prostacyclines work.78 By that time I had left Boston, but continued to explore
the role of cAMP in biological systems at Columbia University, New York,
where we studied cAMP in the regulation of the E. coli gene cluster, the lac
operon, leading to the isolation of a cAMP DNA-binding protein, which was
the first positive gene regulatory protein to be discovered and isolated. Since
then I have gone on to investigate interactions between catecholamines and
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cAMP in regulating immune function, and mediating interactions between the
nervous system and the immune system.
Something we need to remember about platelet research in the US in the
1960s is that it was performed by a comparatively small group: Ted Spaet,
Aaron Marcus, Marjorie Zucker and Ralph Nachman were the leading
researchers, and we all knew one another.79 Although there was individual
competition, it was much less than that which I think now characterizes
science; possibly because money flowed from the National Institutes of Health
(NIH) in the 1960s, and those halcyon days are over.
Meade: Thank you very much. My apologies for assuming that this was an all-
Brit[ish] audience. I am very glad that you made that contribution. Michael
Oliver do you want to say something?
Professor Michael Oliver: My contribution, Tom, really is historical. In 1954,
working in Edinburgh, we had pretty well defined the lipoprotein profile in
normal people and in coronary patients. I was working with George Boyd in
considerable isolation and was concerned, maybe because we were in Scotland,
that nobody else seemed to be the least bit interested in atherosclerosis. So I
took myself off to meet John French in Oxford. This was 1958. The Great
Western Railway was late by 20 minutes, and John met me at the station in a
terrible flap, as he had bicycled down from the Dunn School of Pathology. He
said, ‘Could you afford a taxi? Prof has got a lecture at five past 1 o’clock and
he’s waiting for you.’ Now, I hadn’t done my homework, I didn’t know who
Prof was. When I went up the stairs, at the double, there was this steely grey-
haired man whom I later recognized as Howard Florey. He said, ‘If you want
to try to form an atherosclerosis group go ahead, but it won’t work, because
there aren’t more than nine people in the country who are the least bit
interested in the subject, and you have got three of them here, you, French and
me.’ He then produced a bottle of white wine out of his desk with three glasses,
one for himself before the lecture, and one for each of us, and poured half the
bottle into the glasses. He told me to go away and find 20 people, and he told
French to find £250 a year. He told us to come back in three months, which
we duly did. This time French and I met, and prepared our brief before
meeting the Nobel Prize winner. We thought we had better get it right. I found
18 people, and French had got £250 for three years from ICI – a lot of money
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in those days. We went through the list and Florey removed three people,
whom I shall not name, from the list. He asked about Helen Payling-Wright,
Gwyn MacFarlane and Rosemary Biggs. ‘Why hadn’t I included them?’ So
these three replaced the three Florey didn’t like, or who were rivals or whatever,
and off we set with the Atherosclerosis Discussion Group, now the British
Atherosclerosis Society.80 To initiate it, Florey again produced a half bottle of
white wine and three glasses. Now, to this day I do not know whether that was
the same bottle of white wine or not. 
Meade: Stan Peart, you came across platelets in a slightly different context, I
think, earlier on perhaps than we have so far heard. Would you like to say
something about that?
Professor Sir Stanley Peart: I regard platelets as a damn nuisance, actually. The
reason for my saying so is that I was in J H Gaddum’s department in Edinburgh
in 1946 and I was struggling to demonstrate the amines coming off the
sympathetic nerve endings when they were stimulated. I can remember at that
time it was uncertain whether it was adrenaline or noradrenaline. And what I
discovered – because I was using smooth muscle of different sorts, including
isolated arteries to demonstrate what the substances were – that plasma
unfortunately constricted blood vessels and contracted smooth muscle rather
well, except I didn’t know what the substances were and in 1946, it wasn’t very
clear what they were. Spinning the blood very hard to get rid of the platelets did
not remove this effect, and, of course, that led me back into history: first to Otto
Loewi, 1921, who is worth mentioning, because he coined the phrases
acceleranstöf and vagusstöf in relation to quickening and slowing the heart rate
on sympathetic or vagal stimulation. That led me back to Ernest Starling and
the big efforts made to do heart–lung perfusion, which they discovered they
could not easily do. And even if they filtered the plasma to get rid of what they
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thought were small aggregates, it still contracted the heart–lung preparation in
different ways and damaged the heart in various ways. Perfused blood contained
frühgift, which dilated blood vessels and spätgift, which contracted them.81
From my point of view, because of these substances I could not assay what
turned out to be noradrenaline in the plasma after the sympathetic nerves had
been stimulated. I then discovered by chance, not with any hypothesis-driven
ideas, that dihydro-ergotamine would block the spätgift. So I used dihydro-
ergotamine and was able to assay on the smooth muscle of blood vessels, the
noradrenaline and maybe small traces of adrenalin present when you
stimulated the sympathetic nerves. Soon afterwards it was discovered that
platelets released 5-hydroxytryptamine, known as serotonin or spätgift, and it
was this substance that dihydro-ergotamine was blocking.
Professor Rod Flower: I would like to comment on Gus Born’s technique,
because I think that while it obviously had an enormous utility for the study of
events in haemostasis, it has another great utility as well: it was probably the first
technique that was available whereby people could easily investigate the
pharmacology of a single human cell type and as a teaching tool it has been
absolutely fantastic. You can teach many basic pharmacological principles, such
as agonism, antagonism, physiological antagonism and so on, with this very
simple technique, using human cells and since there is only one cell type present
there is no confusion about the results. It has been a really remarkable technique
for all sorts of reasons other than the one for which you invented it, Gus.
Meade: I think we will move on now, and I will say a few words about the
relationship of platelets to thrombotic disorders.
There’s obviously been no doubt for a long time about the involvement of
platelets in thrombosis, and so that does naturally raise the question of whether
there might be some tests that would pick out people who are at risk of
thrombosis and clinical coronary disease, because of the instability or
sensitivity – or whatever the right word would be – of their platelets. In about
1980 we went to see Gustav to introduce platelet aggregometry into the
Northwick Park Heart Study using his method.82 Now I have to say that right
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from the start Gustav said he didn’t think his method had got anything to do
with thrombosis. But I was pretty sure that I had read a paper somewhere that
he had written saying that it did.83 We decided to introduce his methods. I
think probably our data on this are the most comprehensive. We measured
aggregation to platelets using both adrenaline and ADP in plasma that had been
standardized for its platelet count, and we measured the maximum response
and the ED50 [effective dose50 is the amount of material required to produce a
specified effect in 50 per cent of the population being studied]. From an
epidemiological point of view, the first thing is to see whether these measures
are related to other well-known risk factors for coronary disease. What turned
out was that in some respects they were. For example, aggregability seemed to
increase with age and to be less in people according to the amount of alcohol
they took, and that seemed to make a certain amount of sense. On the other
hand, there were some very unexpected findings, of which the most striking
without any doubt at all was that nonsmokers had more aggregable platelets
than smokers. I don’t know what the explanation for that would be.
Incidentally, I think I should mention at this point that of course the platelet
system is only part of the haemostatic system as a whole, and other aspects have
already been mentioned. The effect that thrombin has on platelet aggregability
may be very important and also the effect that the fibrinogen level may have. 
The next stage for the epidemiologist is to look at people who have already had
a heart attack and to compare them with people who haven’t, because that’s
something you can do relatively easily. The problem about that approach is
that of course you can’t include people who have died of coronary episodes,
which certainly are going to be of particular interest. I have always wondered
whether we can pinpoint differences between people who survive heart attacks
and people who don’t, or whether it is just a matter of chance. And then there’s
always the problem in these cross-sectional studies that you can’t be sure
whether what you find may not have been influenced by the previous event
itself, and also by the changes in lifestyle that people have put themselves
through or have been advised to take. Peter Elwood and his colleagues in the
Caerphilly–Speedwell Study84 did that and in a minute, Peter, I will ask you to
say something about that study. 
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But the most important approach for the epidemiologist, short of randomized-
controlled trials, which we will come on to later, is the cohort or prospective
study where you characterize people in a number of ways, including their
platelet function, before the event, and then see what happens to them later
on. That has been approached in two ways: first of all in terms of people who
have actually already had an event and who have been followed up for a
recurrent event. There are two well-known studies on this: one by Trip and
others published in 1990, who found that spontaneous platelet aggregation
appeared to be associated with an increased risk of a recurrent event;85 the other
is the work by John Martin, who unfortunately isn’t here today, and his
colleagues showing that platelet size appeared to be related to a recurrent
event.86 We could have some discussion about what the interpretation of that
observation might be. But that leads on to the second approach, of what
predicts first events, in other words in people who so far have not had a
coronary event. As far as I can see, the first substantial report on this was by a
Norwegian group in 1991, who reported that mortality from coronary disease
was considerably reduced in those with higher platelet counts and also who
had particularly aggregable platelets to ADP.87
By 1997 we had been able to follow up the people on whom we had initially
carried out Gustav’s aggregometry and we found no relationship whatever
between the incidence of coronary heart disease (CHD) and either of the
aggregating agents, nor within each aggregating agent, the different parameters
that we had used, and furthermore, platelet count appeared not to be related
to it either. We had also been using the Hellem technique for platelet
adhesiveness to glass beads.88 From an epidemiological point of view [this] is of
no value, because it is so variable. If you do it on somebody’s sample now, it
will give you quite a different answer in a sample than tomorrow morning or
evening. Peter Elwood can also tell us about the results in the
Caerphilly–Speedwell studies, where they also found no relationship, and I will
give him a chance to go into that in just a moment.89
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So as far as trying to characterize people who are at risk of coronary events
because of anything to do with their platelets, I think we are no further on than
we were when we started. There’s no question about the involvement of
platelets in coronary disease, and that’s something that I think we don’t need
to debate. But I don’t think we have any idea really about how to characterize
people who may have run into trouble because of something to do with their
platelets. That’s my view anyway. Now, Peter, I have mentioned you and you
mentioned your own study earlier, so would you like to tell us about both the
cross-sectional and the prospective findings in that study.
Elwood: Like you, Mr Chairman, we didn’t put a lot of weight on the cross-
sectional data, that is platelet function in men who had already had a heart
attack and I really would prefer not to say anything about that, because I don’t
remember the results. I think far more important is that in the Caerphilly
study we did platelet tests on more than 2000 middle-aged men. We did
platelet aggregation in platelet-rich plasma (PRP), and we did platelet
aggregation in whole blood using the Flower aggregometer method.90 We also
did platelet aggregation by the shear-stress method, developed by John
O’Brien,91 and we did a very crude bleeding time test, but believed to be a
global test of haemostasis, and in particular a measure, however crude, of
platelet function. We looked at the reproducibility of these tests, and a lot of
other tests, both within the laboratory, and over time within subjects. While
reproducibility within subjects over a period of weeks was not as good as other
measures, like cholesterol, blood pressure etc., still the coefficient of variation
was only about 15 per cent and we felt that with the large numbers we had we
should detect any prediction, if there was prediction.92 We have followed up
these men, are still following them up, and we had about 200 new events of
MI and over 100 ischaemic strokes. We found that none of these tests – PRP
aggregation, whole-blood aggregation, shear-stress aggregation and bleeding
time – showed prediction of MI, not even a hint of prediction of MI.93 We did
find a weak prediction of ischaemic stroke, but it was the reverse of what we
had expected. The men with the more active platelets, whether judged in
aggregation or bleeding time, the more active the platelets, the lower the
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subsequent incidence of ischaemic stroke. I have discussed this with a number
of plateletologists, and haematologists, but no-one has come up with any
reasonable explanation of those findings. Unlike what you and Gus Born say
now, I did expect that platelet aggregation would predict MI. Perhaps that just
shows how naive I am, but furthermore, I certainly wouldn’t have expected it
to predict stroke the wrong way round according to what we thought was a
reasonable expectation. 
Born: Right at the very beginning I should have put some kind of toxicity
warning on the method, ‘not good for clinical use’; but you, Tom, and I have
often discussed this and I was with you for trying it out. I am glad to know the
results; they are not surprising, but I simply wondered whether a ruptured
plaque isn’t such an overwhelming pathological event that if you think of the
real situation, with red cells and everything going round, whatever small
changes there may be in platelets would be a rather minor variant in something
which is overwhelming in other ways. 
Elwood: What about stroke? Can I ask Gus about stroke? Why does platelet
aggregation weakly predict stroke the wrong way round?
Meade: Was it a chance finding? What sort of level of significance was there?
Elwood: The significance of some of the tests was below the conventional level,
but it was a consistent trend in four approaches to platelet aggregation, in PRP,
and whole blood, and shear stress, and the bleeding time.
Meade: I suppose it could have been chance.
Elwood: Anything can be chance, but it’s rather strange.
Heptinstall: Some years ago we did quite extensive investigations of post-MI
patients and we thought we had identified something rather interesting. We
had set ourselves up to measure the platelet-release reaction. We labelled
platelets in platelet-rich plasma (PRP) with 14C-serotonin and then looked at
how much of the serotonin was released from the platelets when they were
stimulated with ADP. We compared the results obtained for healthy controls
with those for people studied immediately post-MI, and there was a significant
difference between the two. Significantly more release occurred in the MI
group than in the control group. There was, however, a huge overlap of
individual results within the two groups. About a year later we looked back at
the data, at who in the MI group had survived this event and who had not. We
saw that there was far greater release reaction in the patients who didn’t survive
their MI compared with those who did. We tried to pass that technique on to
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Tom to use in his Northwick Park study but somehow the technique didn’t
transfer very well and they didn’t take it up.94 Nevertheless there was a hint of
something interesting. 
Here is another anecdote. We were asked by our clinical colleagues to look at
platelets from a patient who had a very high platelet count and was having
some sort of neurological problems, despite the fact that he was taking aspirin.
His platelet count was about 1 million platelets per microlitre [the normal
platelet count is 150 000–350 000 per microlitre of blood]. At the time one of
the platelet parameters that we were able to measure was spontaneous platelet
aggregation in whole blood. All we did was to take whole blood, stir it and look
at the disappearance of platelets. It seemed to me that there was no point in
looking at his platelets while he was taking aspirin, because the aspirin might
have interfered with the measurements we were to perform and consequently
his aspirin was withdrawn. We then took a blood sample and what we found
was staggering. As soon as we stirred the blood, all the platelets aggregated
together. There was no need to add an agonist, they just aggregated together
spontaneously. It was the biggest spontaneous platelet aggregation we had ever
seen, and far greater than for other people in the same age range. Clearly the
man’s platelets were very hyperactive. At the same time we looked at the ability
of prostacyclin and prostaglandin D2 to inhibit platelet aggregation, and
basically we couldn’t inhibit the aggregation using these agents. Please bear in
mind that all of this was before aspirin was clearly established as an
antithrombotic agent. About a week following our determinations, the patient
had a stroke and died.
Meade: Because you had taken him off aspirin?
Heptinstall: Well, maybe. What I would say is that I would never ask for
anybody to be taken off aspirin again. But let me also say again, all this
happened before the time that we were convinced of the therapeutic value of
aspirin. I firmly believe that this was a very atypical situation where someone
had a very high platelet count, the platelets seemed to be unresponsive to
natural inhibitors of platelet aggregation, and were demonstrably hyperactive.
I believe that the platelet hyperaggregability contributed to the stroke. 
Meade: That’s a bit like the Trip study, isn’t it? 
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Heptinstall: The Trip people showed spontaneous platelet aggregation in
platelet-rich plasmas.95 I have to say I don’t understand spontaneous
aggregation in platelet-rich plasma. I don’t know what’s causing it. I do
understand it in whole blood to a certain extent, in that it’s almost impossible
to do anything with whole blood without damaging red cells. The red cells
release not only ADP, but also huge amounts of ATP, both of which can cause
platelet aggregation. You may be interested to hear that we have just published
a paper showing for the first time that ATP added to whole blood causes
extensive platelet aggregation, and it does so by virtue of the white cells and
ecto-ATPases which are able to convert the ATP into ADP and bring about the
aggregation response.96
Oliver: Concerning stroke: let’s not lose track of the fact that such a clinical
diagnosis covers at least three major entities and that about less than half of so-
called clinical strokes are thrombotics – haemorrhagic stroke, and stroke
resulting from degenerative cerebral changes with advancing age account for
many. The person who’s shown this most clearly is Jack Strong, with his
enormous survey in the US, with over 20 000 autopsies.97 To wonder why one
cannot see such and such a change in platelets in relationship to stroke, I think,
is naive, because the causes of stroke are multiple and not all thrombotic. The
underlying pathology is the key.
Professor Salvador Moncada: I just wanted to make a comment that follows
on from what you have just said, Michael. It is impossible to predict the
outcome when you are looking at only one of the factors involved in
thrombosis. There are at least three different components that play a role in the
final common event, which is a stroke or MI. The behaviour of platelets alone
would not be an adequate predictor. On the other hand, we are talking about
two things: one is the final event (a thrombotic one) and the other is the role
that platelets play in the development of the disease. The interplay of the two
factors might be different in the two processes and may again differ between
individuals in a population. In the last 25 years we have learnt how important
the vessel wall is – it is not just a surface where platelets stick. 
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So the platelet aggregometry in vitro is a great technique that has been
immensely useful in understanding platelet behaviour. However, what platelets
do in vivo is what matters. Gus probably never thought that aggregometry
alone would be sufficient.98
Meade: I think it’s worth pointing out that the coagulation system actually has
been much more rewarding in trying to explain the thrombotic aspects of
coronary heart disease.
Dr Peter Hunter: I would like to comment on how treatments are actually
discovered as opposed to the published accounts, for example, platelet
aggregation in diabetes, especially in relation to retinopathy. Dr Henry Heath
at the University College Hospital Medical School, London, from 1968 to
1970 worked on diabetes, and the importance of his research turned out to lie
primarily in the experimental design rather than the aggregation results. He
compared 25 diabetics with rapidly deteriorating haemorrhagic retinopathy
with 25 diabetics of more than 15 years’ duration with no or minimal diabetic
retinopathy. They were compared for 80 variables and one of these variables –
cutaneous capillary resistance (the capacity of the capillary wall to resist
rupture by increased pressure in the lumen, or reduced pressure, a vacuum,
outside the vessel, or both) – turned out to be highly significant.99 The patients
who were deteriorating had very low capillary resistance and their capillaries
would bleed very fast. The immune diabetics not only had very high capillary
resistance, but were within the range of the nondiabetic population.
Meade: I am not sure how much progress in terms of actually predicting
coronary events we have made on this front. I think the answer is not much.
Now we will move on to: the platelet release reaction; aspirin in relation to
that; and also some comments about inflammation. I will ask Duncan Thomas
first of all to comment.
Dr Duncan Thomas: I have been asked to concentrate on the start of the story
of aspirin and platelets, mainly because the prime movers are dead or can’t be
with us today. The key observations were made over a short period of time, a
relatively few months in the mid-1960s. 
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For me, the story started in the summer of 1966, when I had just joined Gus
Born and worked in his lab for a year on sabbatical. A paper appeared in
Nature from D C Macmillan, who was working with Michael Oliver in
Edinburgh, and he was the first to show clearly the second phase of platelet
aggregation.100 He showed that there was a primary phase resulting from the
added agonist and then release of the endogenous nucleotides and other
components leading to the second phase of aggregation. We were all a bit
miffed at this, because many of us had seen the phenomenon, as ‘through a
glass darkly’, but hadn’t really appreciated the significance. But Macmillan had,
and this observation became an essential part of the story of aspirin and
platelets. Aggregometry may not be very good at predicting MI, but it works
very well in analysing how aspirin works. 
The next part of the story that I remember was the Miemo meeting101 in Italy
in September 1967, which some people here will recall.102 The only person who
talked about aspirin, platelets and thrombosis was Breddin from Frankfurt,103
who had spotted a letter in the Lancet in the spring of 1967 by C D W Morris,
who said that he had given aspirin to 35 subjects and shown that it had
dramatically impaired aggregation, using the Born aggregometer.104 To the best
of my knowledge, that’s the first published evidence linking aspirin and
impaired platelet aggregation. Breddin had taken it to the stage where he was
routinely giving his patients 1g or 2g of aspirin every day for thrombotic
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disorders, although at no time did he claim that he was doing a clinical trial.
But at this meeting in September 1967 nobody else talked about aspirin and
platelets. However, that very month, Harvey Weiss and Lou Aledort in New
York published a paper in the Lancet which showed that in ten subjects (six of
them were physicians, so it was clearly a lab study) given 1.3g of aspirin a day
for a couple of days, aggregation induced by connective tissue was impaired.105
This was not the case when they used ADP, interestingly, although they missed
that, and they also missed the second phase of aggregation. But they did
conclusively show that aggregation by collagen was impaired by aspirin, and
this is, I think, generally regarded as the first decent paper showing that aspirin
impaired platelet aggregation. 
Now Weiss and Aledort were very restrained. The only thing they said in the
discussion, the final sentence, was: ‘the results suggest that these agents may
have antithrombotic properties’. That was the only comment they allowed
themselves at the time. Later, they went on to demonstrate the second phase
of aggregation, but they did not comment on it in that early paper. A few
months later in January 1968, John O’Brien wrote a letter to the Lancet in
which he showed that the secondary wave of aggregation produced by
adrenalin is inhibited by aspirin.106 And then hot on his heels in March 1968,
an important paper was published by Marjorie Zucker in New York.107 She
gave ten subjects 1.3g of aspirin and showed that secondary aggregation,
serotonin release and platelet factor 3 (PF3) activation induced by ADP were
abolished by aspirin. She concluded that aspirin should be added to the list of
drugs that prevent platelet aggregation induced by ADP. Being a PhD [not an
MD] she didn’t get into the clinical aspects, but she showed how aspirin works
by impairing the release reaction. Quite independently, Fraser Mustard’s group
at McMaster University in Canada was looking at the same problem from an
experimental point of view. They showed that aspirin given to their animals
impaired thrombosis in extracorporeal shunts.108
The next part of the story is in April 1968 when John O’Brien confirmed that
the second wave of aggregation after ADP was abolished by aspirin, and
showed there was also a poor response to collagen after aspirin. And he
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reported that the effect was produced by a small dose of 150mg. Everybody
before O’Brien had been giving gram amounts, but he showed that it only
needed 150mg to have an effect, and to the best of my knowledge he was the
first to show this. His last couple of sentences in that paper are worth repeating
because they are quite prophetic: 
the abnormalities following aspirin ingestion which I have
described are quite sufficient to justify a therapeutic trial of
aspirin in individuals at risk of thrombosis. Aspirin is relatively
safe, and is used probably more than any other drug and nobody
knows whether it decreases thrombosis or not.109
Clearly the ground had been set up for Peter Elwood’s trial, which we will hear
about later. I think one should acknowledge that O’Brien was the first to
suggest that somebody should do a clinical trial to see if these observations,
that everybody by now had seen in the lab, had clinical relevance. It’s very
interesting how quickly all these events happened, in a matter of a few months
in 1967/8.
The next phase in the story is 1970/1, which I am sure Rod Flower will tell us
about, where the mechanism of action of aspirin was worked out by John
Vane, Bryan Smith and Jim Willis.
Meade: Thank you very much, Duncan. We mustn’t overlook the
inflammatory aspect of coronary disease and the effect of aspirin on
inflammation, and so I hope Clive Page will spend just a few minutes talking
about that. 
Professor Clive Page: I am not actually going to talk at all about coronary
disease. I came into the platelet field really working at what is now the
National Heart and Lung Institute, [then called] the Cardiothoracic Institute
at the Brompton Hospital. I was working with Dr John Morley, who at the
time was the Director (1979/80–84) of the Asthma Research Council’s clinical
pharmacology unit. He had been approached by Alan White and Keith Butler
of what was then Ciba-Geigy Pharmaceuticals in Horsham [Ciba Laboratories,
Horsham, later the Ciba-Geigy Pharmaceuticals Division and now Novartis],
to really try and find a way of automating in vivo what Gus had done in vitro.
We established a method to use the lung as a filter to look at the accumulation
of platelet aggregates in the pulmonary vascular bed by monitoring platelets
The Recent History of Platelets in Thrombosis and Other Disorders
37
109 O’Brien (1968b): 783.
radio-labelled with indium.110 This was my thesis work and until that point at Ciba-
Geigy they were actually injecting animals with ADP or some other thrombotic
stimulus and at intervals of one minute, two minutes, three minutes, four minutes,
they were sacrificing animals, taking out lungs, and actually counting the aggregates
histologically, which is a very tedious process requiring a lot of animals. We were, in
effect, asked to try to see if we could simplify this and study platelet aggregation in
vivo in real time, as Salvador said, with all the other components in place. And I
think we were successful in doing that, and we developed what, in effect, became a
noninvasive way of looking at platelet function in vivo. But because we were a lung
group we were interested in also measuring lung function in these animals, and we
found that with certain stimuli, particularly platelet-activating factor (PAF), we not
only got embolization of platelets that was reversible within the pulmonary vascular
bed, but we were getting changes in lung mechanics. 
Going back to 1954 and the work of Professor John Widdicombe, who first
described airway reflexes in response to pulmonary embolism, we had just
assumed that it would be physical obstruction of the pulmonary vasculature
that triggered this.111 It turned out to be far from that and we actually went on
to show, as Boris Vargaftig’s group did in the Pasteur Institute in Paris, that
platelets could, in response to PAF, be found extravascularly alongside airway
smooth muscle tissue with inflammatory cells, and at the time we really didn’t
understand this observation. However, it was clear that there wasn’t a full-
blown thrombosis with coagulation, these were platelets behaving as primitive
leukocytes, and of course many years earlier others had suggested that in
certain lower organisms, platelets can behave as primitive leukocytes.112
We went on from there to really investigate this further, and I think it’s very
clear from the work that we performed with Jim Metzger’s group in the US in
about 1990, if my memory serves me correctly.113 When we made allergic
animals thrombocytopaenic by removing more than 95 per cent of their
circulating platelets, we saw absolutely no recruitment of leukocytes into lung
tissue in response to an allergen stimulus, and we came to the conclusion at the
time that platelets were not just there as innocent bystanders, but were actively
participating in some way in recruiting leukocytes into tissue. 
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Over the last ten years my own group has provided further evidence
supporting this whole idea that platelets are inflammatory cells. We have
recently reported that in patients with clinical asthma, if you take blood
samples from such patients undergoing an asthma attack, you will find
platelets coating leukocytes. You don’t see really thrombocytopaenia and
aggregation, you see platelets coating leukocytes. If we add platelets to
leukocytes in a culture, we get greater leukocyte adhesion to vascular
endothelium as the platelet levels in normal circulating blood.114 From our
pharmacological studies, we know this is completely insensitive to aspirin, so
there’s a novel mechanism underlying this behaviour of platelets in terms of
signaling, in comparison with all of the work that has been discussed prior to
this in the context of thrombosis. 
I think it reflects a completely different function that platelets have in the
body, in that they are actually part of the defence mechanism and in regulating
leukocyte recruitment. Of course if you look at the literature, there are a lot of
parallels with metastasis of tumour cells, where in animal models, if you make
animals thromocytopaenic, the tumour doesn’t metastasize to the same extent,
particularly if you look at lung tumours.115 I think tumour cells often use
similar mechanisms described in leukocytes, such as integrin-type mechanisms
to get out into tissue.116
This is a completely different aspect of platelet biology which we stumbled
upon totally by accident, because we happened to be measuring the lung or
using the lung as an organ for the read-out of the particular phenomenon we
were interested in. 
Meade: Good, thank you very much. Has anybody got any views about
coronary disease and aspirin dose, since this is a question that is often asked?
Moncada: If you are talking about 75mg or 150mg of aspirin a day you are not
going to affect the inflammatory process to any significant degree. The effects
you see with these doses are more related to platelets, rather than to
inflammation. 
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Elwood: I think it was Ridker who looked at the physicians’ aspirin study in the
US.117 There they used alternate doses of 100mg of aspirin and he showed a
significant effect on C-reactive protein, which is accepted as a marker of
inflammation.
Moncada: Whether you are affecting the inflammatory process independently
or you are affecting something which follows platelet aggregation is impossible
to tell from that type of experiment, isn’t it? 
Oliver: To complete the story about Macmillan. It is true, as Gus Born and
Duncan Thomas have pointed out, that his Nature paper was the first one to
show the second phase. All I did was to get hold of a Born aggregometer and
give him a minute amount of lab space. We then published another paper,
which was not about the second phase. Poor Macmillan, a tense man,
committed suicide and so the theme did not continue.118
Prentice: I think there is uncertainty on the question of aspirin dose and
inflammation. Charles Warlow looked at two different doses of aspirin in his
stroke study – 300mg and 1200mg. We found that there was no difference in
the effect on bleeding time, which is quite clear.119
One point to add to Duncan Thomas’s excellent account of the aspirin story. I
think Harvey Weiss and Lou Aledort published in 1967 in the Lancet and,
correct me if I am wrong, I think they were probably the first persons to show
that ingestion of aspirin in humans prolonged the bleeding time by inhibiting
platelet aggregation by collagen, and that correlated with the lack of platelet
secondary response in vitro and a physiological effect in humans.120 I think they
were the first to show prolonged bleeding time with the aspirin patients and
correlate it with collagen inhibition. 
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Thomas: The effect of aspirin on the bleeding time had been known for some
time. You are quite right, they did measure it, and showed it was prolonged by
three minutes on average in their ten subjects. Even dear old Armand Quick
of the Quick test did some studies with aspirin and showed that it prolonged
the bleeding time.121 Perhaps Weiss and Aledort were the first to look at it
systematically. 
Born: I think Clive Page’s story is fascinating, because it’s really an unexpected
new function of platelets and opens up a whole new area to work on, which is
what he does. I asked the question ‘what happens in thrombocytopaenia?’ and
we now have to ask whether people who are thrombocytopaenic, for whatever
reason, are more liable to infections. There are such people, of course. Have
you any answer to that yet?
Page: I haven’t, Gustav, but I think there are some interesting observations in
the literature that people with asthma, when studied at post mortem, very
rarely have, in my understanding from my reading, any evidence of
calcification of major arteries compared with age- and sex-match controls. It’s
almost as though having atopy may be protective against having cardiovascular
problems. Now I don’t know how much of that has been looked into, but there
are now several studies that people with an atopic phenotype have a prolonged
bleeding time using the template bleeding time in the skin.122 You can show
that they also have a mild haemostatic defect, so it may be that in the case of
atopy, this defect protects against cardiovascular diseases.
Harrison: I wanted to go back to the history of aspirin. Did you tell them
about Dr Craven from Glendale, California? He was writing in the Mississippi
Valley Medical Journal, which I don’t peruse every week, and so many of us I
think missed his claim, which was an interesting one.123 He simply said that
people who had their teeth out on aspirin bled a bit, it might stop you clotting
a little. So he gave it to a lot of veterans he was responsible for and wrote a
paper saying that nobody, and it’s an interesting comment, nobody who
religiously stuck to the dosage schedule had a coronary or cerebral thrombosis.
This was an efficacy, not an intention-to-treat approach. We didn’t know about
that report when in 1971 we gave (I kind of invented the n = 2 trial) aspirin
to a couple of patients with recurrent retinal platelet emboli and showed that
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you could switch them off. When you stopped the aspirin, after the
appropriate number of days, the attacks returned. The interesting thing in the
context of this meeting, is that we published the result even though it was only
two observations, to advertise for cases for a trial.124 Of course everyone said,
‘Oh, I can give my patients aspirin’ and referred no more patients to us. 
Meade: I am glad you mentioned the paper in the Mississippi Valley Medical
Journal,125 because I was thinking about it and, as reported, the results seem quite
striking. It’s obviously not a controlled comparison, but nevertheless an early
attempt to look at the aspirin story. What year did you say that was published? 
Harrison: 1953.
Thomas: And it was 1500 patients, which is impressive – a prophet crying in
the wilderness.
Meade: I think we should try to get the reference to that paper into the
proceedings.
Moncada: I was going to say that the 1953 paper certainly is an important one.
I have a copy of it and use it in my talks.126
Elwood: Craven wrote three papers, and two of them have already been
mentioned, but I have copies of all three.127
Dr Y S Bakhle [Mick]: I just wondered, on a slightly philosophical note, as
Duncan has just pointed out how several of these papers came together almost
spontaneously, in a very short time. Is there a reality to the idea of ‘due time’,
a time at which an idea suddenly becomes common and functional and
accepted, or is that just romance?
Thomas: I agree with you, Mick, it is often people knowing each other. Don
Chambers has referred to a group earlier, people like Marjorie Zucker and
Harvey Weiss, who were in New York together.128 The UK is small and
everybody pretty well knows what’s going on. I think you are right, but it’s well
to remember that people speak to each other, quite apart from the journals.
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Meade: I think this phenomenon is sometimes referred to as synchronicity,
and doesn’t always involve people who know each other. Other scientific
advances have been made, haven’t they, in the same sort of way or have been
developed quite independently by different people who happen to have arrived
at the conclusion that that was the right thing to be doing. 
Chambers: On the other hand, there is a whole literature developing, actually
started by a molecular biologist by the name of Gunther Stent, on ‘prematurity
in scientific discovery’.129 I have characterized this actually as the
ligand–receptor argument for scientific acceptance, which postulates that the
audience you are addressing has to be prepared to accept the new discovery,
and thus your comment about Watson and Crick. The initial discovery by
Avery, McCloud and McCarty of DNA being the ‘transforming principle’ was
not accepted by the scientific community. To illustrate this, that discovery was
made in 1943;130 in 1950 DNA was not mentioned at all at a major
international congress on genetics held in Berkeley, California.131 The beauty
of the Watson–Crick discovery utilizing model-building by Watson and the
data of Franklin, Gosling and Wilkins, was that the structure of DNA looked
right for its proposed function as the genetic material. Had the DNA that was
studied by X-ray diffraction been derived from the bacteriophage phiX-174,
which contains single-stranded DNA, the structure would not have been
double-helical and there would be no base complementarity, and thus the
characteristics presumed necessary for the double helix and the association
with the DNA story might have been delayed. Chance, luck and acceptance
are almost intangible qualities for good science.
Moncada: It is well known in science that when you look at a discovery with
hindsight you can trace the background work that led to it. Usually there is an
acceleration of the generation of information leading to the breakthrough. For
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example, Watson and Crick did not arrive at their conclusions in a total
vacuum – other people, including Linus Pauling,132 were also close to it. Some,
like Rosalind Franklin,133 were there already.
Hunter: I would like to comment on what was said about synchronicity, when
several people pay attention to the same fact in a short period of time. There is
a completely opposite phenomenon for which there is no term in pharmacology,
a drug which has a highly important therapeutic effect in fatal illness but is
simply ignored. There are two examples of this: one is streptokinase, isolated in
1946, purified in 1953 and then ignored for two decades.134 The other is
metformin, an effective agent in the treatment of polycystic ovary syndrome
(PCOS). I suggest that there should be a new technical term for this, using the
analogy with obsolescence, which would be somnolescence. 
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Figure 11: Professor Sir John Vane, c. 1986.
Born: Quite a number of years ago, John Vane, when he was Research Director
of the Wellcome Foundation or even before, pointed out that when a
pharmaceutical company was synthesizing analogues, the first was often the
best and remained the best. I can’t think of an example just now, I am sure
other people can. The first analogue is often closest to the natural, endogenous
substance, so that is another way of looking at this.
Meade: We won’t go down that path just now. Are there any other comments on
the topic we have just been discussing? I hope, Tilli, you won’t mind that the last
part of the discussion has been of a rather general nature about how some of these
discoveries come about, but I think that’s very interesting and very important.
Tansey: This is precisely the kind of interaction that we want to record.
Meade: Everybody has been very good about sticking to time, and actually
there are one or two additional topics that people have suggested they want to
bring up. We are very fortunate to have two of the key players in the
prostaglandin story here today, Rod Flower and Salvador Moncada. Rod
Flower, would you please start off the prostaglandin story?
Flower: I suppose it is difficult to know where to start, but since this is a historical
occasion perhaps we could go back very briefly to the 1930s. Two very important
discoveries were made at that time. George and Mildred Burr in the US were
working on fatty acid deficiency in rats, and established that there were some fatty
acids that were essential to life.135 The other important discovery came from the
early work of Ulf von Euler, who was probably the key player in the early
development of prostaglandins.136 He spent some time with Henry Dale and then
with J H Gaddum, and during their time together, he discovered Substance P, and
when he went back to the Karolinska Institute he took with him the knowledge
of bioassay and he began to look at different tissues to see whether they contained
Substance P.137 I have got a nice quote from him here: he said:
After my return to Sweden it seemed natural to continue my
studies on tissue extracts in order to get some idea of the
distribution and possibly the physiological role of the active
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factors occurring in the different organs.…In due time and after
several excursions, using a large variety of organ extracts including
some from accessory genital organs from various animals, I
decided to test human seminal plasma on the blood pressure of a
rabbit. The effect of even a small amount was dramatic. The
blood pressure of the rabbit dropped to very low levels, whilst my
own probably went up some.138
Ulf von Euler was convinced at the time that he was dealing with Substance P
again, but over the next couple of years he effectively ruled that out by showing
that the substance he had was actually an acid and that it could be extracted
into organic solvents. He then went on, just before the outbreak of the Second
World War, to begin some analytical work, but unfortunately the war
supervened. However, he had reached the point where he had discovered that
seminal vesicles contained a very large amount of this bioactive material, and
he had acquired a huge stock of sheep and bovine organs for his work. After
the war when work resumed he opened the freezer, took them out, found they
were still active, and this, I guess, was the foundation of the Karolinska
Institute’s work on the subject. 
One interesting piece of trivia is that he initially thought he had identified this
new hypotensive agent in the prostate gland and so called it ‘prostaglandin’. It
turns out that he was mistaken because the anatomical book he was using was
incorrect, and it was actually the vesicular gland he was using. He later wrote:
In retrospect it would have been better to name them vesiglandin A
and B, since both were prepared from the vesicular gland, or its
homologue, the seminal vesicle.139 
After the war, work resumed. By the early 1960s, he was using a brand new
technique – mass spectrometry140 – which was, I think, probably only available
at the time in two labs in the world, one of which was the Karolinska Institute.
They were able to identify the structure of two prostaglandins, which they
called E and F, because of their relative solubility in ether and phosphate buffer
(phosphate begins with F in Swedish). At that time no one really understood
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how these compounds were synthesized, although by the early 1960s they had
already been infused into man, and the infusion of prostaglandin E caused a
very sharp fall in arterial blood pressure, headache, and, rather ominously I
thought, an oppressive feeling in the chest. I am not quite sure what that was
due to. By the mid-1960s, the Karolinska group as well as a group at Unilever
in The Netherlands, who were also very active in the field, had elucidated the
way in which prostaglandins were synthesized and had identified the nature of
the reaction. Today the enzyme that converts some essential fatty acids to
prostglandins is called cyclo-oxygenase, but in those days it had other names.141
The whole area of prostaglandin research owes a lot to bioassay, and platelet
aggregation, also occupies a very unique position in the whole prostaglandin
story. I will just mention a couple of important findings. One is the description
in 1969 by John Vane and Priscilla Piper of something called rabbit aorta-
contracting substance (RCS).142 This was a very labile substance which was
released from perfused organs, particularly the lung, in response to various
stimuli, and which contracted the rabbit aortic strip very sharply. This was to
prove to be a very important observation in the whole field. As they began to
explore the RCS phenomenon, John Vane’s group noticed that you needn’t have
the perfused organ, but you could generate RCS if you infused crude microsomal
extracts of cells which were known to contain the cyclo-oxygenase enzyme. Later
Richard Gryglewski, working with John Vane, reported in a paper:
This result was interpreted to mean that the process of
prostaglandin biosynthesis includes RCS as an intermediate and
that, once formed, RCS can spontaneously give rise to a
prostaglandin.143 
What they had noticed was that in fresh preparations the RCS disappeared
very quickly, but as it did so the prostaglandin content went up and they
concluded that one thing was disappearing and giving rise to another. The
discovery of RCS in 1969 provided the immediate backdrop to the whole
aspirin story. 
If I can just digress again for a second or two. There were lots of explanations
for aspirin’s action around at the time. Most of them were really wide of the
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mark, but since this is a historical occasion, we should mention Harry Collier’s
contribution, because he had already described aspirin as an ‘antidefensive drug’,
because it could counteract pain, fever and inflammation. He made the
observation that aspirin could block broncho-constriction caused by bradykinin,
and he thought that perhaps there were receptors for aspirin, and he actually
called them ‘A receptors’, the A standing for aspirin. Later on, he abandoned this
idea, and he wrote instead in one of his reviews that aspirin acted:
rather by inhibiting some underlying cellular mechanism that
takes part to different extents in the different responses mediated
by different endogenous substances.144
One of those phrases that rings down the years. 
So to 1971. Of course everyone knows the story of aspirin. The starting point
was that John Vane’s group were looking in the arterial circulation of
anaesthetized dogs for RCS, and they found that it was released into the arterial
circulation when the lungs were mildly hyperventilated. They also noticed that
if they gave the dogs aspirin first, then the RCS disappeared. John wrote:
While I was writing a review paper, including the results of these
experiments, a thought occurred to me that perhaps should have
been obvious earlier on: in all these experiments (and those of
many other workers) the ‘release’ of prostaglandins must in fact
amount to a fresh synthesis.…That is, prostaglandin output in
these experiments, although very low…was still far higher than
the tissues’ initial content of these hormones. Evidently, then, the
various stimuli…which released prostaglandins were in fact
‘turning on’ the synthesis.…A logical corollary was that aspirin
might well be blocking the synthesis of prostaglandins.145
As we all know, he tested this in 1971, using cell-free extracts of guinea-pig
lung,146 and at the same time Sergio Ferreira and Salvador Moncada published
a paper in the same issue of Nature, showing that the action of aspirin and
indomethacin blocked prostaglandin generation by perfused organs.147 Joe
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Collier and I also demonstrated at the same time that oral aspirin reduced
prostaglandins in human seminal plasma.148
I want to mention again one of those odd episodes of synchronicity: also
working in John and Gus’s department, although apparently unaware of these
developments, were Bryan Smith and Jim Willis. They were interested in the
effects of aspirin on platelets and their hypothesis was that aspirin inhibited
platelet aggregation by inhibiting the secretion of phospholipase A1 from
platelets when they aggregated. They did a very simple but elegant experiment
where they gave human volunteers 600mg of aspirin, took the platelets after
an hour, added thrombin, and found that phospholipase levels were not
changed, but prostaglandin levels were dramatically reduced. Their paper on
the action of aspirin on platelets and prostaglandins went into the same edition
of Nature at the same time as John’s paper.149 So the aspirin story began.
A couple of other things about the role of platelets in the prostaglandin story:
one is that platelets played a key role in establishing the fact that
prostaglandins are important in human physiology. This came about because
the Karolinska scientists discovered a family that had a bleeding tendency, and
this was discovered to be caused by platelet cyclo-oxygenase defect and they
found that these platelets could not be found to aggregate with arachidonic
acid, but they could be made to aggregate by adding back the endoperoxide
intermediates that Samuelsson and his colleagues had discovered. 
The next part of the story was trying to identify what Vane’s RCS actually was
and, as I have said, Samuelsson’s group came up with the idea that there was a
labile intermediate in the synthesis of prostaglandins.150 The half-life of this
intermediate, which was prostaglandin G2, was actually much longer than that
of RCS. They employed a very clever technique using platelets, whereby they
added prostaglandin G2 to platelets and they noticed that there was a time
delay in the kinetics of aggregation, and that during this time another
intermediate accumulated. This intermediate was subsequently identified as
thromboxane A2, and turned out to have exactly the same half-life as RCS, and
so the identity of Vane’s RCS was finally established. Again, I will just mention
Jim Willis, because his work is not widely known, I think partly because he did
all his research at night when everybody else was away, and during the day he
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spent most of the time servicing his Allard, of which he was very fond. But he
did do some seminal work and he was one of the first to describe the
generation by seminal vesicle enzyme of a substance that aggregated platelets
very rapidly. He called this factor ‘labile aggregation stimulation substance’
(LASS). And he had also done, interestingly enough, an experiment where he
injected this into mice and found that it killed the mice, because it caused
intravascular platelet aggregation. He pursued this idea, but eventually it got
lost in the torrent of other papers that subsequently appeared, which is a
shame, because I think it was an important observation.
I don’t really want to say any more, because I know Salvador will have a lot to
say on this subject as well, particularly about the discovery of prostacyclin. I
would stress that platelets have been integral to the whole prostaglandin story,
and to the discovery of these labile intermediates thromboxane A2, the
endoperoxides. The discovery of the family with the missing cyclo-oxygenase
was crucial in determining a role for prostaglandins in physiology and I would
be happy to answer questions afterwards.
Meade: Thank you very much, Rod. That’s exactly the sort of thing we wanted
to hear. I will now ask Salvador Moncada to give us his recollections and
interpretations of the other aspects of the story.
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Figure 12: Dr Salvador Moncada performing a
cascade bioassay, 1986.
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Moncada: The story as far as it concerned me started in early 1971 when I
joined John Vane’s group at the Royal College of Surgeons. At that time,
coming from a medical background, I didn’t have any experience in research,
and I was starting from the very beginning. But in the very first few weeks, I
learned to do the cascade bioassay, in John Vane’s style, and one of the first
projects he asked me to do was to hang several tissues on the cascade [see
Figures 12 and 13], put arachidonic acid onto them to see whatever response
they produced and then look at the effect of aspirin. Almost immediately it
was clear that arachidonic acid was producing responses in tissues which could
be blocked by aspirin-like drugs. That was already confirming some results
that John had obtained using lung homogenates and doing biochemical
measurements of prostaglandin synthesis. Because of those results, John
invited me to join him and Sergio Ferreira in doing experiments in the dog
spleen in vivo. We showed that catecholamines release prostaglandins from the
Figure 13:The technique of cascade superfusion. Warmed, oxygenated, physiological saline
trickles sequentially over a bank of tissues.This experiment demonstrates the formation of a
novel prostaglandin that relaxes rabbit coeliac artery, from the endoperoxide precursors PGG2
and PGH2.
Key: PG (prostaglandin);TXA2 (thromboxane A2).
Reproduced with permission, from Vane (1992), Animal Experimentation and the Future of
Medical Research, 46. © Portland Press Ltd.
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spleen and that aspirin-like drugs inhibited that release. That work ended up
as one of three papers that we published in 1971.151
For the next three years Sergio Ferreira and I spent most of our time trying to
elucidate the meaning of these observations in relation to pain and inflammation.
This led us to the conclusion that the prostaglandins were not really acting as
mediators of inflammation and pain, but they were modulating the response of
mediators such as bradykinin. So aspirin-like drugs were not blocking the process
of inflammation, but were taking away this prostaglandin-based amplification
process. I left the Royal College of Surgeons after finishing my PhD and went
back to Honduras for a year. In 1975 I came back, this time to the Wellcome
Foundation. John Vane had moved from the Royal College of Surgeons to be
Director of Research at Wellcome and he had invited a small group of people to
join him. We went with Rod Flower, Gerry Higgs, Geoff Blackwell and Sergio
Ferreira to start setting up the laboratory at Beckenham, Kent. 
On my way back from Honduras I stopped at the Florence meeting on
prostaglandins where Bengt Samuelsson presented the results on thromboxane
A2. It was a fascinating story, as you heard from Rod Flower, and was closely
connected to the work of Piper and Vane on rabbit aorta-contracting substance
(RCS). For this reason, when I arrived at Wellcome we started a project trying
to identify whether there was a separate enzyme that was responsible for the
generation of thromboxane A2. We started to do experiments in which we used
the prostaglandin endoperoxides as possible substrates for a second enzyme in
the platelets. We did this work with Phil Needleman and Stuart Bunting, and
found such an enzyme, which we called thromboxane synthase, that was
responsible for the conversion of prostaglandin endoperoxide to thromboxane
A2. We also identified the first inhibitors of this enzyme, namely imidazole and
some of its analogues. The imidazoles had been described to have different
actions, including effects on bleeding time. Because of that, among the many
other compounds that we tested, we tried the imidazoles, which turned out to
be very good selective inhibitors of thromboxane synthase and were the
starting point for the pharmaceutical industry later on to develop inhibitors of
these enzymes. The results were published in Nature and this time we
published in collaboration with Bengt Samuelsson and Mats Hamberg from
the Karolinska Institute, who had supplied the prostaglandin endoperoxides.152
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Towards the end of this project we thought that it would be worthwhile
mapping the distribution of the thromboxane synthase in the body. We started
to do a systematic study; however I was specifically interested in the vessel wall
for several reasons. The first was that I was always thinking about
platelet–vessel wall interaction and not just platelet aggregation per se. The
second reason is that Sergio Ferreira and Fernando Ubatuba in our laboratory
were trying to develop a measurement of bleeding time in the rat by
superfusing the tail and measuring the amount of haemoglobin in the fluid
with a photocell. Surprisingly, in some of these experiments the bleeding time
was arrested very rapidly, suggesting vasoconstriction, rather than formation of
a haemostatic plug. This made me think that the vessel wall might also be
making thromboxane A2. So, when Richard Gryglewski joined us for a
sabbatical, I suggested to him a project looking for the formation of
thromboxane A2 in the vessel wall. We looked for thromboxane A2 and for the
classical prostaglandins using an enzyme preparation from pig aorta together
with the bioassay cascade. We found that there was indeed an enzyme in the
vessel wall that was metabolizing the endoperoxides, but the product, whatever
it was, was not thromboxane A2 or any of the known prostaglandins that we
could detect by bioassay. And that was the beginning of the discovery of
prostacyclin, which we started to call PGX [prostaglandin X or PGI2].
153 We
knew we were generating a substance that relaxed the vasculature, but so did
prostaglandin E2(PGE2). We managed to distinguish between PGX and PGE2
using a strip of bovine coronary artery, which fortuitously contracts to PGE2
but relaxes to PGX. At some point we thought that PGX might be HHT
[12(S)-hydroxy-5Z,8E,10E-heptadecatrienoic acid], a known metabolite of
prostaglandin endoperoxides, but this turned out not to be the case. The
breakthrough came by chance in a discussion with Stuart Bunting and Richard
Gryglewski over a cup of tea. I said that we had been looking for thromboxane
A2, which is a vasoconstrictor and a proaggregating substance, and we might
have found exactly the biological opposite in the vessel wall. Stuart Bunting and
I tested the idea that same afternoon and we found that, indeed, whatever we
were making from the vessel wall was probably the most potent inhibitor of
platelet aggregation that had been described – about 50 times more potent that
PGE, as we calculated it. That is the story of how we discovered prostacyclin.154
Meade: Which is what this is about, so thank you, Salvador.
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Born: I don’t know if I am allowed to make this remark, but considering the
number of people who are here who were in my department at the College of
Surgeons at that time, I would just like to say that it was an amazing heyday,
with both the platelets and the prostaglandins, and Bryan Smith and Salvador
and Rod, Lawrence Youlten and Nicky Begent, and many others. So, it ought
to be pointed out and kept on record that it was a remarkably good time.
Yesterday, Bryan Smith sent me his historical sketch of the time which I can
make available.155
Meade: Yes, I think that’s a very important point.
Professor Sir Christopher Booth: The College of Surgeons was very active in
researching in John Hunter’s time. I don’t know what their contributions have
been in recent time, but what was it about the College of Surgeons that
produced that remarkable laboratory at that moment?
Born: It’s a good question. I hadn’t thought about it quite like that. I got there
in 1960 as Professor of Pharmacology in succession to Bill Paton. John Vane
was already there as senior lecturer. We had been friends, John and I, for nearly
ten years and our friendship continues to this day. There was an easy-
goingness; we were very open and totally at ease with everybody, and if
anybody was difficult, we soon cured them.
Meade: I think we should say that it’s a pity that John Vane isn’t here, and I
am sure that we would all like to send him our very best wishes.156
Thomas: May I just add a comment to what Gustav said, as one who spent a
year there? It was a remarkable department. I think the surgeons didn’t really
know what they had, but they appointed some outstanding people. That’s
what it boils down to, it is the people, not the College of Surgeons as such.
Meade: We will tell the College what you have said.
Hunter: This is a relatively small point, but the man who triggered off all this
activity was Lord Webb-Johnson, and he insisted that there should be proper
scientific training for people before they took the Fellowship of the Royal
College of Surgeons (FRCS), and this led to their having research interests
there. Lord Webb-Johnson approached the Royal College of Physicians, so
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that the Royal College of Surgeons could be in the same place, could share
laboratories, and the Physicians, I am ashamed to say, refused. 
Bakhle: Might I make a comment about the bioassay system.157 I think that
what is very important is that both thromboxane A2 and prostacyclin are short-
lived, and what’s even more important, they decay to biologically inactive
products, so any bioassay process that requires extraction, an extract and then
testing, would have given you a nil result. I think that was the power of what
we, at the College, had. We had this semi-instantaneous assay system that would
demonstrate, immediately as it was generated, some sort of biological activity.
What Samuelsson158 at the Karolinska Institute in Stockholm had was a fantastic
analytical mass spectrometry system which could only work obviously on
extracts, something which had decayed, and so he couldn’t detect biological
activity, and we couldn’t detect structure. It was this curious thing, we, the
department, had to demonstrate that there was an activity there to look for, and
by the time that Samuelsson had got to it, of course, the activity had gone. You
had to work backwards from the stable compound, from 6-oxo-PGF1α, or from
thromboxane B2, to what the activity might have been, which, of course, was
done, but what was interesting was this dichotomy of abilities.
Moncada: Certainly that’s one of the great things about the bioassay system, and
I don’t think that all these discoveries could have been made at the time they
were made, if it hadn’t been for the flexibility of the bioassay system. I remember
the first experiments with trying to measure thromboxane A2. It was so labile
that, in order to detect any activity, we had to put the enzyme on ice to slow
down the breakdown of the biological activity generated. With a half-life of 30
seconds or less, it was incredibly difficult to work with. However, I always think
that the experience we gained working with thromboxane A2 was extremely
useful when we began to work on endothelium-derived relaxing factor
(EDRF)/nitric oxide (NO), which, as you know, is even more unstable.159
Flower: Could I just add that the short-lived nature of these compounds,
specifically prostacyclin, was one of the problems that led us to look for a way
of measuring platelet aggregation in blood, which didn’t necessitate us spinning
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blood for 20 minutes to get the PRP. That’s how we came initially to develop
the whole-blood aggregometer. It was specifically designed so that we could
infuse prostacyclin into animals or people, take blood samples and straight
away measure the antiaggregatory response without having to go through a
preparative phase where often the effect of short-lived intermediates was lost. 
Professor John Dickinson: Can I ask how the funding of that famous laboratory
came about? In other words, how many full-time people were paid by the
College of Surgeons, not to do anything very specific, but to foster research, to
teach young surgeons its own methods? One can see how once the great
discoveries were made, people joined in, and all sorts of grants came in. But are
we saying three, six, ten full-time staff, got the whole thing off the ground?
Meade: Gustav, what’s the answer to that?
Born: I have to think rather hard. The College of Surgeons paid160 for my chair
from the Vandervell Endowment, and for John Vane as a senior lecturer; and we
had two other lecturers, John Thompson and John Gardiner. So there were four
academic staff by the College, plus technicians, who were permanent and our
most delightful cleaner, Scotty Fenn, who became a close personal friend and
godmother to one of our children. That describes the atmosphere I think. We
attracted many grants. From the time I came to the College in 1960 I headed
the Thrombosis Research Group of the MRC until John and I left in 1973. John
attracted a lot of money, but I am not quite sure now – I don’t want to be
inaccurate – where that came from. We were pretty well funded for that period.
Meade: That’s a very good answer to the principles at any rate, and we can
perhaps fill some of those points later. John Hampton, while we are on the
subject of funding, you were going to say something about that anyway. 
Hampton: When I was listening to the other presentations, and thinking what
happened when I was young and doing all this, the funding wasn’t really an
issue, because the universities were much wiser. They appointed the best guy
they could get to head a department and they gave him a senior lecturer, a
couple of lecturers, a technician, and a washer-upper, and told them to get on
with it. Whereas now, if you are lucky, you get the chair and you are on your
own.161 And I think the result is obvious. I have children who are doing PhDs
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Figure 14: Royal College of Surgeons’ Laboratory, c. 1963.
Standing, L to R: Gustav Born, John Thompson (lecturer, later Professor of Pharmacology at
Newcastle), Olive Nialls (Professor Born’s secretary), Durwood Smith (visiting Professor of
Pharmacology from Vermont), John Vane (senior lecturer, later personal chair, Nobel Laureate,
1982), John Haynes (technician, who moved to Newcastle with John Thompson), Michael Cross
(co-worker of Professor Born killed in 1964 aircrash),162 Victor Clark (technician), Peter
Gorinski (technician), Zigi Sabikowski (workshop mechanic who built aggregometers),
Domenico Regoli (from Lausanne, Switzerland, co-worker of John Vane), Geoffrey Langston
(chief technician), Scotty Fenn (Mrs Isobel Mills-Fenn, departmental cleaner). Sitting, L to R:
Shirley Cross (wife of Michael Cross, later Mrs James Sherwood), Oleh Hornykiewicz (co-
worker of Professor Born from Vienna,Austria, who later discovered the dopamine deficiency in
the brain of Parksonian patients), Derek Nichol (technician), Margaret Day (research student),
Anne Stockbridge (Margaret Day’s technician), Sue Glover (Michael Cross’s technician).
and they will not go into the academic world, because they see how you have to
fight every inch of the way for funding, and they say that it’s not worth it. I think
everything we have been hearing today really depends on the time when wise men
appointed other wise men and let them do their best. There was a phase of MRC
funding: Tony Mitchell had a ten-year MRC grant for the set-up at Nottingham,
but that all went, and the MRC lost interest in anything that didn’t have a
molecule attached to it. As for the role played by industry, it is interesting that for
all the things we have heard about earlier, industry hardly came into it. We had a
little bit of industrial money in Oxford and then Nottingham from Boehringer
relating to Persantin® (dipyridamole) and its relations. To the best of my
knowledge, aspirin didn’t have any industry money. And the industry didn’t get
interested until we had clopidogrel and the CAPRIE study,163 which I was
involved in, which was US $250 million for one clinical trial. Then, of course,
they got interested in the 2B3A antagonists, and goodness knows how many
noughts are on the end of the grants for that. But I think it is interesting that
everything we are talking about was done on an old-fashioned funding system.
Peart: I had the unfortunate task of spending four years of my life helping the
College of Surgeons to run down the Institute in 1992.164 It is a sad thing to
say, but that’s the truth of it. The College actually put a lot of money into the
Institute, it changed it’s name of course to the Hunterian Institute, but there
were a lot of chairs, and there were many extremely good people in the
Hunterian Institute. But there was always this imbalance between the surgeons
and the research that was going on. The teaching was relatively easy, in the
sense that anatomy, physiology and even ophthalmology had their chairs, and
there were some eminent anatomists and physiologists who held those chairs.
So there was a lot of tradition, and yet that tradition was not enough to help
the Institute survive, because the amount of money required just could not be
found from the College of Surgeons’ finances. For example, you have got to
remember that Down House, Charles Darwin’s house in Kent, was actually
rescued from dereliction by a surgeon, Sir Buckston Browne, and there was a
very large animal facility there.165 I should think there were not less than 500,
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which were being used to produce a dental vaccine. I was never too keen
personally on the idea of a dental vaccine, but there it was and it had to be shut
down because it was too expensive to run. 
The tradition that I clung to in pharmacology and physiology was to keep
something going that kept running. There was even a department of
biophysics, an extremely good department, which I moved to the Institute of
Child Health, because I felt it deserved to be perpetuated. Of course the staff
fought very hard for their existence, and very successfully, because they
continued to produce lots of extremely good work. Priscilla Piper has been
mentioned already. But it’s to the great credit of the College of Surgeons that
the Institute survived as long as it did.
Meade: I think we will have one final comment from Gustav and then we must
move on. 
Born: I was going to suggest moving back to a platelet topic again. John
Hampton mentioned dipyridamole as a drug, Persantin®. This is an interesting
short story, from the time we were working on various inhibitors. One of them
was dipyridamole as inhibitor of adenosine uptake by platelets and red cells in
order to increase its potency as a platelet inhibitor. I had a lovely lady called
Dinah James, an Englishwoman, working with me for a year. She was Professor
of Pharmacology from Ibadan [Nigeria], an authority on African
trypanosomiasis, and she told me that trypanosomes cannot make purines de
novo. They have to take up purines from the tissues. So we thought, ‘Let’s try
dipyridamole and see if we could stop the uptake of adenosine by trypanosomes.’
We did that and published a paper on it in Parasitology,166 showing an effect. I
said in the ‘Afterword’ review that I didn’t know whether anybody took this
further, or I would have heard about it.167 It turns out that Peter Richardson
[present in the audience] went to the Internet (about two years ago) and found
that there were 33 papers based on our finding. In other words, something that
had happened with platelets has become a big story in African sleeping sickness,
and which is still going on. At least two colleagues are working on this in Britain,
Professor Keith Gull in Oxford and Professor Simon Jarvis in London.168
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Meade: We may have a chance for some sort of general discussion at the end
and, Peter [Elwood], you might comment on that, but I think we must move
on now to the whole question of aspirin and the prevention of thrombotic
disorders. Peter Elwood is going to introduce the topic on the arterial side.
Then Colin Prentice is going to discuss the venous side and then we will have
further discussion.
Elwood: May I say first of all that in her invitation to this meeting Tilli Tansey
said that among the questions she asks are: ‘How is research funded and why?’
‘Who are the influential individuals and groups involved, for example, a lab
technician?’ I would like to state that if I say ‘I’ or ‘me’, do record it as ‘we’,
because there is a whole team behind everything that I say. 
May I mention Lawrence Craven again, because in his first paper (which was
not published in the Mississippi Valley Medical Journal), he makes a lovely point
that women take aspirin rather often for their pains and aches, while men tend
to scorn such an ‘effeminate’ remedy.169 Craven went on to wonder if this
difference might explain the sex difference in the incidence of heart attacks.170
The bottom line of course is that despite the fact that he advised 8000 friends
and patients to take an aspirin a day, Lawrence Craven himself died of MI.
There are obviously several strands in any trial, and that’s certainly true of our
first trial of aspirin and MI. But from our general reading of the literature, our
interest in aspirin goes back I think at least to the mid-1960s, and at that time
I suggested to Archie Cochrane, the Director of the MRC Epidemiological
Research Unit (South Wales), that we set up a prospective study in which we
would do tests of platelet function and test the prediction of subsequent
vascular events. Then in the classical epidemiological fashion we would look
for the dietary and lifestyle determinants of platelet function.171 I went round
the experts in this country and abroad, and there was no test of platelet
aggregation which we judged at that time would be suitable for a large
epidemiological study based on 2000 to 3000 men. Platelet aggregation in
platelet-rich plasma (PRP) had been described by Gus Born and by John
O’Brien, but we felt this test could not be done on sufficient numbers of men.
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Later we did platelet aggregation in 2500 men in the Caerphilly study.172
Professor Serge Renaud supplied his mobile laboratory, which was installed in
the Caerphilly Miners’ Hospital for five years. Andrew Beswick, who is with us
today, did the aggregation tests, using PRP first of all, and later whole blood.173
But to go back to the aspirin story, we felt in the mid- to late 1960s that there
was no test of platelet aggregation that we could do on a large enough cohort
for an epidemiological study. So we suggested to Archie Cochrane that as a
‘second best’ we thought we would hit the platelets with aspirin. Aspirin was
getting into the literature, and we were influenced among others by O’Brien’s
paper in 1968, in which he called for a trial of aspirin.174 Harvey Weiss had
called for a trial of aspirin.175 So as ‘second-best’ to an epidemiological study,
we suggested to Archie Cochrane that we set up an aspirin trial, and over the
next few years we admitted 1400 post-MI patients and the results of that trial
were published in 1974, the first randomized trial of aspirin.176
The results were in terms of total mortality. We were very exacting
epidemiologists in those days and we felt that total mortality should be the
index of success or otherwise, but although we didn’t publish it, total incidence
of MI did show a highly significant benefit of aspirin, but total mortality was
not quite statistically significant. Nevertheless, the trial was published and it
excited tremendous interest. By 1980 the results of six trials were published. We
did an overview of those six trials on the back of an envelope and presented the
results at meetings. Richard Peto picked this up and he presented a paper to the
inaugural meeting of the Society for Clinical Trials, based on those six aspirin
trials.177 This gave momentum to the Society for Clinical Trials, and to the idea
of doing overviews of all the relevant evidence. Now over 140 randomized
control trials of aspirin and vascular disease have been reported, and a number
of people have pointed out that aspirin is certainly the most well-established and
the most cost-effective prophylactic available in clinical practice.178
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As the Chairman mentioned at the beginning, aspirin is now of interest in
cancer and other conditions, but that’s not a topic of this meeting. Some of the
things that I have learnt today from Clive Page and others would give a possible
mechanism for that reduction of cancer risk by habitual aspirin-taking.
When we published our paper, we were aware of two other studies: one was by
Breddin, who did studies of platelet aggregation, but using a different method.
He had a rotating glass container, which he rotated and watched the platelets
aggregate. We surmised that CO2 was probably being driven off from the
plasma and the platelets were aggregating because of the change in pH. Breddin
set up a randomized trial of aspirin, but it was a very small and rather flawed,
published very shortly after our trial.179 The other study was by Hershel Jick,180
who conducted a study of hospital patients, questioning them on what drugs
they had taken before they came into hospital. He questioned them on about
the third or fourth day after admission.181 He got a whole series of diagnoses,
and he looked at the matrix with many hundred cells, searching for unknown
relationships between diseases and drugs taken before admission for various
conditions. The one thing that stood out in his table like a sore thumb was a
very marked negative association between taking aspirin before admission to
hospital and a confirmed diagnosis of MI. He immediately realized that there
were two explanations: one was that aspirin was protective and people who took
aspirin were not coming into hospital with MI. But the other explanation was
that aspirin taken in the prodromal period before an MI was killing patients,
and people who had taken aspirin didn’t survive to be questioned on the third
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or fourth day. That put him and us in an enormous dilemma. We were two-
thirds of the way through our trial and we actually broke the randomization
code. We felt that if aspirin was killing people, we wanted to know whether or
not to continue our trial. We were much criticized later for breaking the code,
particularly by Sir Richard Doll, but we felt that we just had to do it. 
Meade: Thank you very much. That makes an excellent introduction and there
will be lots to follow that later on. Colin, would you like to speak now for a
few minutes about the effect of aspirin on the venous side.
Prentice: Thank you very much, Tom. I think for a time there was a thought
that arterial thrombosis is platelet led and is reduced by antiplatelet agents and
venous thrombosis is fibrin/red cell led, produced by thrombin. Therefore
anticoagulants such as warfarin and heparin would be effective in venous
thrombosis and the antiplatelet agents effective in arterial thrombosis. Well,
the truth is more complex than this and as you have shown yourself, Tom, and
as a number of Norwegian and Dutch studies have shown, carefully
administered anticoagulant therapy after MI seems to be an effective
treatment, and anticoagulants are in use in Holland and Norway, but not too
much in the UK, because we use aspirin.182 So there is a discrepancy there. 
The venous thrombosis story really started when Rory Collins and his
epidemiologists carried out the meta-analysis in 1988 in the New England
Journal of Medicine, showing that if you took all the postoperative deep vein
thrombosis prevention trials in which aspirin had been compared with placebo
or heparin, there was at least a one-third reduction in deep vein thrombosis by
aspirin and a 50 per cent reduction in pulmonary embolism.183 We were
discussing this, and Rory was lamenting the fact that most of the endpoints
have been surrogate endpoints, that is radioactive-labelled fibrinogen-I125 or
venography, rather than patients getting a swollen leg through deep vein
thrombosis or falling dead with pulmonary embolism. I think the strength of
the big studies using clinical endpoints was actually indicated by the
streptokinase studies, and when two large studies were done showing that
streptokinase reduced mortality after MI, it was used by virtually 100 per cent
of doctors after that time.184 The next stage of the story, I think, took place as
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all the best things do, in the bar, and that was a tapas bar in Barcelona. It was
during the XIVth Congress of the European Society of Cardiology [1992] and
Mike McMahon from Australia was there. He had been in discussion with
Rory Collins, an epidemiologist, and Anthony Rogers, also from Australia,
and they said in view of Rory’s and my interest in doing a clinical endpoint
study, why didn’t we get together and do a big prospective study, rather like
Peter Elwood had done many years previously?185 Which is essentially what we
did, and in the year 2000 we published the Pulmonary Embolism Prevention
(PEP) study.186 We looked at 13 500 patients having surgery for fractured hip,
divided randomly into placebo or 150mg aspirin a day, starting
preoperatively, and continuing for 35 days. To cut a long story short, using
clinical endpoints with an independent clinical judging committee, the
incidence of clinical deep vein thrombosis (DVT) was reduced by over one-
third, the incidence of pulmonary embolism by almost half, and the
incidence of fatal pulmonary embolism, which is the thing that interests most
patients postoperatively, was reduced by almost 60 per cent. So we had a very
similar picture to the heparin story and I think this is where the situation
rests. It looks as though aspirin is an effective agent clinically after surgery, to
prevent pulmonary embolism and deep vein thrombosis. Heparin is also an
effective agent in this situation, just as in MI, so that both aspirin and
anticoagulants appear to be effective agents.
I think the only sad thing is that it’s difficult to combine two effective agents,
because then you run the risk of untoward haemorrhage, and it always brings
us back to the point that we are looking at haemorrhagic risk versus
thrombotic benefit. 
Meade: Thank you very much. As you say, the idea that aspirin might affect
venous thrombosis was really not accepted, certainly not in this country, for a
long time, until the developments that you described came about. Of course,
all the interest in aspirin has now led on to primary prevention trials, in other
words trials in people who have not yet had an event, but who might later on.
And by and large the results of those trials have been similar to the secondary
prevention trials, but they are important, because secondary prevention trials
can only be done on the people who survive. Since a very high proportion of
people who have their first coronary event die in that event, it is obviously
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important to see what happens in those who have so far remained free of
clinical coronary disease. But of course these trials have their problems, because
the incidence of the event is much lower. There’s also the problem now, in both
primary and secondary prevention, that aspirin can be purchased over the
counter, and I suspect that there are a lot of people taking aspirin who don’t
realize that, particularly in primary prevention, the balance between the benefit
and the risk is not as obvious as most people assume it is. In other words,
there’s a fairly low benefit to be set against a not insubstantial risk. There have
now been five primary prevention trials, and they are being looked at in an
overview by Colin Baigent in Oxford, and I think they will probably be
published in an overview sometime in the next year or two. As far as coronary
disease is concerned, I think the answer is very much the same as we have been
hearing so far, but why is it that aspirin appears to reduce nonfatal events to a
much greater extent than fatal events? That I think is a fairly consistent finding
from both secondary prevention trials and particularly from the primary
prevention trials. Salvador, you’ve got the answer.
Moncada: I think that it is because we may be looking at two different problems.
The hypothesis that platelets might be playing a role in the developing
atherosclerotic plaque, slowly aggregating on the vessel wall, is one thing. Aspirin
might well have an effect on this process. However in the final event, when there
is plaque rupture, many proaggregating substances are involved, including those
that are not inhibited by aspirin. Then the possibility of affecting this with
aspirin is less likely. That’s what I would venture as a hypothesis. If you were to
design an ideal antiplatelet agent for an in vivo effect it would be difficult to
improve on aspirin. It acts at very small concentrations for as long as the platelets
are in the circulation and it probably acts on platelets in the presystemic
circulation, thus sparing the vessel wall. So, for prevention of the development of
the plaque, if platelets are involved, aspirin might be the ideal drug.
Meade: Part of the story is the decline in what people regard as the required
dose of aspirin. People were using gram amounts to begin with, as we have
heard several times this afternoon already, and now I suppose 75mg or 100mg,
not more than that, is probably what most people would consider effective and
obviously safer than the larger dosage.
Moncada: The studies of Carlo Patrono are very clear.187 If what we are
intending is to inhibit thromboxane formation, then 75mg are good enough.
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You don’t need any more than that dose, since it will specifically and selectively
block thromboxane A2 formation and the second wave of platelet aggregation.
The clinical trials seem to support the fact that a small dose of aspirin really
works and that the pharmacological action can be linked to a therapeutic effect. 
Thomas: May I just ask you a question, Tom? You rightly pointed out the pros
and cons of taking aspirin, and that it is a fine balance, but I thought you had
shown that it is in people who are hypertensive that the risks outweigh the
potential benefits. Did I get that wrong?
Meade: We showed that people who are hypertensive didn’t derive any benefit.
They didn’t actually experience any additional risks, but they didn’t benefit.
The people who derived the benefit seemed to be the people who are
normotensive. A lot of these questions are going to be settled more firmly and
more conclusively when Colin Baigent’s overview comes out soon, which I
think will be very important in terms of indicating who should or should not
be taking aspirin. 
Moncada: Do you know what doses of aspirin were used in those five trials?
Meade: There has been quite a wide range. We used 75mg in the Thrombosis
Prevention Trial. The Physicians’ Health study used 325mg on alternate
days.188 Richard Doll’s trial in the doctors’ study used 500mg a day.189 So the
answer is that there has been a wide range of doses. 
Moncada: This is important to determine since as you increase the dose of
aspirin the risk of side-effects increases. Let me remind you that at very high
doses aspirin also has a certain fibrinolytic effect and this has not been
discussed yet. 
Meade: Over tea Alison Goodall mentioned to me the question of aspirin
resistance, which is receiving a lot of attention at the moment. Is there such a
thing as aspirin resistance that is actually any different from the fact that not
everybody responds totally to almost any medicine, or is it something that is
really a feature of aspirin?
Professor Alison Goodall: I was making the point from two perspectives. One
is a reflection that, just at a time when data coming out from both primary and
secondary prevention trials really do demonstrate that aspirin is effective, we
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seem to be getting rather negative comments in the literature about the effects
of aspirin, both in terms of the bleeding risk and aspirin resistance.190 I think
this reflects the haemostatic balance. If we go back to the points that were
being discussed earlier about the platelet response in relation to disease
progression and risk, there’s clearly a wide range of platelet response in all
populations. The data from populations that are post-MI, and from
prospective studies all seem to be indicating that there is a very wide range of
platelet response. This comes back to comments by Professor Born and
Professor Moncada that the overriding event, which is plaque rupture, may
subsume any antiplatelet effects of aspirin. This raises the issue of whether we
should be perhaps now considering treating the individual rather than the
population, because I think the approach until now has been to use one dose
across the population. Maybe we are moving towards dosing that is related to
the individual in relation to the level of their platelet response, which does
appear to be consistent within individuals, and possibly also inherited. 
The other point in terms in of aspirin resistance, is whether this phenomenon
really does exist. I think the jury is definitely out as far as that is concerned
[Moncada: Can you tell me what you mean by aspirin resistance?]. Aspirin
resistance, as I understand it, has been defined in two ways. One is in
epidemiological terms, looking at events in subjects who are on aspirin. There’s
conflicting data in the literature that suggests that in patients on long-term
aspirin (this particularly seems to be associated with elderly patients with
cerebral vascular disease) both the incidence of cerebral vascular events and the
platelet response to agonist stimulation seem to decline over time. But there is
an equal body of data suggesting that that doesn’t happen. The other area that
has become of immediate interest in the literature is a so-called aspirin
resistance during or postsurgery. And there’s a very open story there as to
whether it’s linked to some kind of expression of COX-2 in the platelets.191
Moncada: Quite. This brings us back to a previous point. Do we want to treat
the platelets, in which case aspirin is ideal, or do we want to treat the vessel
wall, in which case an anti-inflammatory action would be better? The
complication of inhibitors of COX-2 is that the vessel wall makes prostacyclin
using this enzyme and this might be the origin of the suggested ‘vascular side-
effects’ related to the use of these drugs.
192 Charman et al. (1993).
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Peart: May I just say that surely the dose must be very important, and the
variability of 75mg requires a bit of analysis. If you follow the reason for the
introduction of 75mg by Garret FitzGerald, it was so that there was a small
amount of aspirin which affected the platelets flowing through the gut, the
vascular system.192 And that the larger doses, as I am sure a lot of people here
will say, affected the vessel wall. So you have got two pharmacological effects
here. Do people still actually believe that what FitzGerald said was the case? It
seems to have stood the test of time, and you must take account of that, surely,
in so-called resistance, because the drug that has to go through the gut wall
must be subject to all sorts of variables in that aspect.
Heptinstall: Very briefly, I believe that ‘aspirin resistance’ is difficult to define.
For some it means that some people still get events while they are taking
aspirin. On the other hand we have looked at hundreds of blood samples from
people taking aspirin and I can categorically say that you get inhibition of
thromboxane synthesis in everybody. Fullstop. I would make just one addition
to that. I think Salvador said that he felt that 75mg produced good inhibition
in everybody. I think on one occasion we looked at a blood sample from a lady
with pregnancy-induced hypertension, and we did not see complete inhibition
in that case. We had to increase the dose to get complete inhibition of
thromboxane synthesis. 
Meade: Just one more comment from Salvador. This discussion is getting too
scientific and not historical enough.
Moncada: I was just going to repeat the comment that I made before. The evidence
for platelet sensitivity versus vessel wall lack of sensitivity to aspirin is clear from
many different experimental and clinical data. The evidence that all inhibition of
platelets might actually occur in the presystemic circulation is also clear. And the
inhibition of platelet aggregation by aspirin is permanent, while inhibition of the
vessel wall, if it occurs, is short-lasting. That’s why I was saying that if we ever
thought about a drug to inhibit platelets, we couldn’t have invented it better. 
Meade: That’s a reassuring note on which to move on to our last topic. This
is, of course, to do with one of the other effects of platelets, and that is in the
question of bleeding. That is obviously related partly to the aspirin story, which
we have been hearing about, but there are other aspects of platelets that affect
the bleeding profile of some patients and which have quite an interesting
historical background. Peter MacCallum is going to tell us a bit about that.
193 Bowie et al. (1963). 
194 Hughes (1993).
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Dr Peter MacCallum: Thank you, Tom, for asking me to say a few words
about this. I hope others will pick up the baton when I finish. I think I am
probably fairly unique in this symposium, being the only person who has made
no contribution at all to the subject I am going to speak about. So, I can’t give
you any sort of inside information on historical advances, but others may well
be able to contribute. 
When we think about bleeding problems and platelets, we really divide them up
into two broad categories: those that are caused by deficiencies in platelet
numbers, thrombocytopaenias; and those that are caused by defects in platelet
function. Compared with the other subjects that we have been hearing about this
afternoon and the immense work that’s been done in the UK over the last 40 or
50 years, and reading through the literature in preparation, when I was asked to
talk about this topic, it appears that there has been a smaller contribution from
British scientists to the hereditary aspects of platelets than there has been to
prostaglandins, aspirin and other aspects of platelet biochemistry. 
Sticking to the brief of British haematologists, as far as I could, talking first
about thrombocytopaenia, of which the most common cause by some margin
is immune thrombocytopaenic purpura (ITP). There’s one cause of this
condition where there has been a substantial UK input. Although the majority
of the problems that we see with ITP are bleeding related, the condition I’m
thinking of more commonly causes a thrombotic problem. This condition is
called the antiphospholipid syndrome (APS), a name that has emerged over the
last ten or 15 years to describe a problem that was first recognized back in the
1960s when Walter Bowie, a UK graduate who spent his career at the Mayo
Clinic, Rochester, Minnesota, described the presence of a coagulation inhibitor
in patients with systemic lupus erythematosus (SLE), which appeared to be
associated with a thrombotic problem:193 a paradox of abnormal coagulation in
the test-tube with clotting in the patient and occasionally with
thrombocytopaenia. And in the late 1970s and early 1980s, Graham Hughes
at St Thomas’ Hospital, London, was instrumental in introducing a test for
this particular condition by identifying cardiolipin antibodies194 [cardiolipin
being derived from an alcohol extract of bovine heart mitochondria that was a
component of the original Wassermann reaction (WR) reagent used in the
syphilis test and was responsible for the false-positive tests for syphilis
sometime found in these patients]. The St Thomas’ unit, among others, has
been important in furthering our understanding of a condition in which
patients develop an antibody-mediated process that leads to a prothrombotic
problem. That’s one aspect of thrombocytopaenia which has a UK
contribution. Another comes from the haematology department at the Royal
Postgraduate Medical School, Hammersmith Hospital, London, where Sir
John Dacie,195 a very eminent haematologist from the 1940s through to his
retirement in 1977, was very instrumental in setting up a group of
haematologists who made an immense contribution to UK haematology.196 In
particular, he described and took forward our understanding of another
condition that can give rise to thrombocytopaenia and also to thrombosis,
called paroxysmal nocturnal haemoglobinuria (PNH), where again, as you
sometimes see in the anti-phospholipid syndrome, both thrombocytopaenia
and thrombotic problems occur. So thrombocytopaenia and thrombosis can
clearly coexist. The group at the Hammersmith have been instrumental in
identifying this and wrote a very significant paper, I think probably the world’s
largest collection of a very rare condition, in the New England Journal of
Medicine in 1995.197 Interestingly the causes of death in these patients was of
interest – they had a series of 80 patients, 60 of whom had died, including
about 15 deaths from thrombotic events, and ten from haemorrhagic events in
relation to thrombocytopaenia – another significant UK contribution. 
Moving on to disorders of platelet function I think there are one or two people
in this audience who’ve described platelet abnormalities in the context of
common medical conditions, in which platelet function is impaired and
haemostasis is a problem. Duncan Thomas described problems of platelet
function in patients with liver disease, if I remember rightly, and George
McNicol and Stuart Douglas likewise for scurvy, back in the 1960s.198 When
one comes to discussing hereditary disorders of platelet function then a lot of
the eponymous conditions come into textbooks and I don’t think that the UK
contribution has been so significant here. Glanzmann’s thrombasthaenia was
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described by a Swiss paediatrician, Bernard–Soulier syndrome by two French
haematologists, Chediak–Higashi syndrome, a problem of dense granule
secretion, by a Cuban and a Japanese, and Hermansky–Pudlak syndrome, by
two Czechs, a range of very exotic names to a number of very rare conditions.
In the coagulation field, as opposed to the platelet field, deficiencies of
coagulation factors, haemophilia in particular, clearly aided the understanding
of the coagulation cascade.199 In contrast, and perhaps it is because these
conditions are much rarer, it is not clear to me that the eponymous conditions
of the hereditary platelet dysfunctions actually aided understanding of platelet
biochemistry, and the recognition of the glycoprotein receptors and granules,
but others may have different views.
Prentice: A question arising from the issue of haemorrhagic aspects and platelets.
For many years the International Society of Thrombosis and Haemostasis (they
might still be doing it) were looking at post mortem examinations of patients with
von Willebrand’s disease and haemophiliacs, because the positive side of having a
platelet defect might be that you get less atherosclerosis and thrombosis. I am just
enquiring from the audience whether any of those studies were completed or
whether it was too difficult to find enough subjects for this study. Does anyone
know the answer to that? [Meade: No, I think not]. I suppose now there’s going
to be so much treatment for these patients that the opportunity to study them in
the sort of untreated state has been lost. 
Goodall: One comment in relation to the contribution of the UK’s
haematologists to the study of rare inherited platelet disorders, and that is the
name of Roger Hardisty.200 Perhaps it is worth noting that I got into platelet
research because Roger and I had a joint Wellcome Trust grant back in the
1980s to study the weak agonist response defect. Roger made a magnificent
contribution to the understanding of all the rare platelet disorders.
Heptinstall: May I tell you just a very short story? Some years ago we wanted
some platelets from a patient with Bernard–Soulier syndrome, because we had
an antibody that we wanted to test to see if we could detect Soulier’s syndrome
by flow cytometry, and indeed we were able to do that.201 The patient was a
gentleman called Alfred and he was 80 years old. As we were taking blood and
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obviously we were chatting to him, it intrigued me that a man with a bleeding
problem should live to the age of 80. In conversation he told us that he had a
twin brother who died as a child from bleeding after a tooth extraction. That
shows how a situation can manifest itself differently in different people, even
in twin brothers. But the interesting story, coming back to aspirin, is that
Alfred had a painful back. We talked about this, and I said, ‘I don’t suppose
your doctor gives you any aspirin as an analgesic, given the fact that you have
got Bernard–Soulier syndrome?’ He said, ‘Absolutely right, my doctor has
always said I should avoid aspirin. I should never take any aspirin for pain.’ So
I said, ‘Well, what do you take?’ His answer was indomethacin.202
Meade: Peter, would you put disseminated intravascular coagulation (DIC)
into this category of rather anomalous situations where a low platelet count
could also be associated with a thrombotic element?
MacCallum: Yes, I would, and also thrombotic thrombocytopaenic purpura
(TTP) and heparin-induced thrombocytopaenia (HIT). There’s a whole host
of conditions.
Meade: And who described those first of all?
MacCallum: Well, TTP was described by Moschcowitz in the 1920s.203 DIC
was described by a number of workers in the 1950s, while the term DIC was
probably first coined by Hardaway and McKay. A number of clinicians were
involved in defining HIT, but the original description was by two US
surgeons, Weismann and Tobin, in 1957.204
Meade: It is interesting that this is a group of rather anomalous conditions
where a low platelet count can also be associated with a thrombotic risk. 
Oliver: Are we going to see more haemorrhagic events, with the increasing
consumption of very long-chain fatty acids and fish oils? I would predict we are.
The more consumption of dodocosahexanoate and pentanoate acids by those
who are taking aspirin, it is likely that there will be more haemorrhagic events.
Meade: Ask the younger epidemiologists in ten years’ time and they may be
able to tell you. We have got one or two other topics that people have alluded
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to or asked me about over tea which I think it may be nice to come back to.
First of all, Peter Richardson, are there any further comments you want to
make on the trypanosomiasis or dipyridamole stories?
Professor Peter Richardson: I think in the interests of time, it is better to
defer the trypanosomiasis–dipyridamole story to another occasion, as it is a bit
complicated.205 I think it might be better to get to the other topic, artificial
organs. The advent of blood-handling artificial organs presented a big clinical
challenge, which only a few people get to see directly, but nevertheless it has
been a considerable challenge. The pivotal timepoint, for example, for artificial
kidney use for dialysis is 1961, with the invention of the percutaneous shunt
by Belding Scribner in Seattle, which allowed for repeated connection of an
artificial kidney to the circulation. 
Cardiac surgery was being developed in the early 1950s, and increasingly it
relied on evolving technology to provide manufactured components to be in
contact with flowing blood. Denis Melrose in the UK was first to describe
elective cardiac arrest to improve conditions in open-heart surgery.206 The
American Society for Artificial Internal Organs was initiated with a small
meeting in 1954. Blood oxygenators for cardiac surgery were initially filtering
devices, supporting blood in direct contact with oxygen, then disposable bubble
oxygenators were made possible with the advent of defoaming chemicals.
Dialysers intrinsically require membranes between blood and dialysate, and a
California-resident Briton designed a highly successful membrane-based blood
oxygenator, which was used by J Hill in San Francisco, not only in surgery but
also in the first clinical attempt at multi-day support of a chest-trauma victim
with acute loss of adequate respiratory function. The designer was M L
Bramson, better known as the engineer who, in the 1930s, made a positive
assessment of the prospects of Whittle’s proposal for the jet engine.207 His
analysis of Whittle’s project led to it being developed in the UK. His oxygenator
design used 6m2 of silicone-rubber membrane, and required fresh, sterile
assembly on site prior to use, therefore lacking the convenience of disposable
units. Other designs were developed, using typically less than half that area of
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expensive membrane material in disposable units but having a higher bloodflow
resistance and, in many cases, a higher tendency to problems with thrombosis
although the blood was typically heparinized during use in bypass.
And so a big effort had to be made to study the materials, the junctions of
materials, and various design and manufacturing processes that would
diminish the extent of thrombosis.208 And this took place largely within the
aegis of the Artificial Heart Programme, part of the US National Institutes of
Health, run at the time by Frank Hastings, who unfortunately died of a stroke
at a rather critical time. Because the artificial heart itself was not showing
much promise (there were big thrombotic problems, embolization problems,
associated with it) there was a need to get some useful science into this. I think
the critical piece in this was a paper, which was produced and published in
Nature in 1970, by Nicky Begent and Gustav Born, who made studies of the
effect of bloodflow rate on thrombo-stroke.209 The experiments were
intravascular, they were performed in venules, and they provided extensive
quantitative information about thrombus growth, exponential in time as you
increase the blood flow rate the exponential coefficient increased with blood
flow rate up to a maximum, but then diminished as you went to higher blood
flow rates. Understanding some of the consequences of that behaviour was
very important in being able to design channels successfully in artificial organs
that diminished the prospects of thrombosis being a clinical problem.210
It has got to the point where if you don’t hear much about it, then it’s not a
major presence in the literature. There will be, I think, a reflection on this in
the coming year, 2004, because it is the 50th anniversary meeting of the
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American Society of Artificial Organs, and they are calling for abstracts of
papers which will include historical reviews.211
Moncada: Is the reason that you don’t hear very much about it because the
problem has been solved, or because people don’t recognize the problem?
Richardson: The problem has largely been solved by a combination of
procedures. The whole preparation of a circuit for use in bypass is itself a skilled
process – shall we say, acquired through experiment. The materials and the
manufacturing conditions have been refined to the point where most of these
organs don’t have thrombus problems in the time in which they are used, and
some of them are used for days. With a pumpless procedure for chronic bypass
with an artificial lung, for example, I have seen 50 days of continuous bypass.212
Moncada: We used to collaborate with a surgeon, Donald Longmore, who used
to say that the problem existed and it was serious, but was largely ignored.213
Richardson: It was discussed back then, and it’s being discussed again, curiously
enough. There were researchers who were seeking information in the earlier trials,
which were not planned out very well. They gave intelligence tests to the patients
before and after surgery, and very often the patients appeared to be more
intelligent after the surgery. The theory then was that we caught them in a nervous
state in anticipation of the surgery and they did not perform very well, but having
survived the operation, they were much more comfortable with the testing.214
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We tried to see what might be sent into the patients from the extracorporeal
circuits that might lead to neurological deficits, by building an ultrasound
device to examine the bloodflow being returned to patients.215 It could detect
bubbles, emboli, even small loose pieces of plastic. A company was formed to
commercialize the technology, but it found a profitable niche in quality
control in photoresist electronics manufacture, and in secondary oil recovery,
and built no more units for heart bypass circuits. 
I’ll take this opportunity to mention that Marjorie Zucker and other
haematologists were much involved with groups examining blood-materials
interactions.216 I think her name was mentioned earlier, and I just thought I
would make that link. 
Harrison: For the last ten years we have been addressing this issue by
neuropsychological testing patients before and after coronary artery bypass
surgery. The change is not related to anxiety or depression levels. If you ask the
patients, what they report is not accurate. You need to ask the spouse. There is
real evidence of a decline in cognitive performance postcoronary artery bypass
surgery, not in the majority, but in the minority of patients, and using that as
an endpoint it has been possible to help the surgeons tighten up their
technique, so that it is now getting increasingly rare. We hoped to use it as a
model for neuroprotection, but as yet nothing has been found to act as a
neuroprotective drug in this context. One of the problems now is that the
incidence has fallen, and the studies are getting more and more difficult to do. 
Meade: I think there’s one more topic that I want to raise, and that’s one that
Stan Peart mentioned over tea, the question of retinal emboli. 
Peart: Sorry to be talking so much. The thing that has always intrigued me
about thrombosis is the way in which it disappears, and I noticed that there’s
not been much discussion about those sequences that follow thrombosis. You
can’t help but be impressed when you look at the retina – and I used to look
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at them very frequently – and observe those little white emboli in the retinal
arterioles and they would disappear in days or weeks. And, of course, we
probably now believe that most of them come off the atheromatous plaques in
carotid or other arteries. But this process also applies to much larger blood
vessels. I mean in the early days of arteriography it was pointed out that quite
extensive thromboses in the middle cerebral artery could actually dissolve and
disappear. Therefore I don’t think any discussion about what actually happens
with platelets and the interaction with the vessel wall is complete without
being able to try to explain that, because that’s one of the other big variables,
surely, in the subject we are talking about. 
Meade: Has anybody got the answer? 
Born: Of course, I haven’t got the answer, but the process probably turns
largely on things like nitric oxide. If the vessel wall hasn’t been visibly damaged
and you still have intact endothelial cells, then I don’t know how it is in the
retinal vessels, but the emboli come from down in the carotids, don’t they? You
are saying that they disappear and that there might be something different in
the retinal vessels; or could it be some change in the origin of the emboli?
Moncada: I think what Gus Born is saying is probably right. We carried out
many studies that remain largely unpublished, investigating the reversibility of
platelet aggregation. The evidence suggested that in vitro, in the platelet
aggregometer, the platelet aggregate can initially be dissociated by increasing
cyclic AMP (cAMP) or cyclic GMP (cGMP); however, later on the aggregate
becomes irreversible. Therefore, in vivo the clumps seem to be ‘organized’ very
rapidly. I presume that the vessel wall is different since there the platelets are
subjected to the actions of prostacyclin and NO throughout the process. I
agree that this whole process is not understood very clearly. 
Meade: To the extent that the platelet aggregate may also be bound up with
fibrin, we shouldn’t overlook fibrin deposition and fibrolytic activity as well.
Bakhle: Might I make a historical and a general point. At the same time as all
the work on platelets was going on in the department, we had also stumbled
on the idea that the endothelium was, biochemically, a very active cell. For
instance, it clears 5-HT (5-hydroxytryptamine). Val Alabaster’s PhD was on
the clearance of 5-HT in the pulmonary circulation,217 which was why Starling
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and Verney needed to keep the lungs in their perfused kidney circuits.218 We
also looked at the mechanisms of that clearance.219 The other very important
clearance function of the endothelial cells,220 as Jeremy Pearson and I know, is
that there are ecto-ATPases, -ADPases, and -AMPases, on the outside of the
endothelial cells. So all those phosphates go down very rapidly to adenosine
which actually can also be cleared by the endothelial cells. So I think what
happens to the platelet is not just what the platelet is doing, but crucially how
it interacts with the endothelium. And I think perhaps some of the divergencies
that we have heard about between assays of platelet aggregation in vitro or ex vivo
and what happens in vivo may be because at certain times what the endothelium
is doing is crucial and may, if you like, overcome what the platelet is doing. So
that now we hear about endothelial dysfunction as being a disease and perhaps
being responsible for some of the cardiovascular effects of diabetes. And it’s
certainly true that in diabetics the output, I think, of NO, certainly of
prostacyclin, from the endothelium is decreased. I think that the platelets story
grew up in this atmosphere where we knew that platelet function could be
affected by endothelial function. Now that, I think, was perhaps what Gustav
meant when he said he didn’t think that the aggregometer could necessarily
predict clinical behaviour. That interaction between platelets and the
endothelium was a background part of the department and is not obvious unless
you were there at the time.
Meade: You have ended on a historical note, and I think that’s where we
should finish. We were beginning to make a very good case for a scientific
meeting on the endothelium and all sorts of other things, which I hope the
Wellcome Trust will take due note of. But we have come to the end of our
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programme. I personally have enjoyed it immensely, I think it’s been a very
interesting one. Thank you all for coming, and to everybody for their
contributions, particularly to the lead discussants. I would like to thank
Gustav, who really was the organizer of this meeting, and the key person who
thought that it would be a nice one to have, and also of course the Wellcome
Trust Centre people who have given us an excellent afternoon in terms of the
arrangements that they have made: Tilli Tansey, Wendy Kutner, Daphne
Christie and Lois Reynolds. Thank you one and all, and drinks are now served.
Tansey: On behalf of the History of Twentieth Century Medicine Group, may
I thank you all for coming and talking. It has been a great privilege to listen to
you all. The work is not over, because we will be sending you the transcripts
and we will be asking you to add, if you have anything else to add, to the
transcripts; these can go as footnotes. Please also think about depositing your
archives in the library here. This is not a ridiculous idea, we do want
contemporary records in the library. And I would like to add the gratitude of
this meeting to our Chairman. I think he has done an admirable job, so thank
you very much.
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An edited and annotated extract from an interview with 
Professor Peter Elwood by Dr Andy Ness, 28 February 2001221
Caerphilly cohort study, 1979–ongoing
We had a post for a junior epidemiologist and it was largely looked on as a
training post by the MRC, which had been awarded to a series of people, David
Bainton and Ian Baker, for example. I advertised and we appointed John
Yarnell,222 a very bright person, who wanted to work on his own and he set up
several studies. He did a bit of work on urinary incontinence, and then he put
forward a proposal to look at high-density lipoproteins (HDL) in women.
HDL cholesterol was a big item in the literature at that time, but almost entirely
in men, and I thought, ‘Yes, this is worth doing’. So he got a bit of money to
employ four women and he set up a study in 800 women in Caerphilly. 
I saw the potential in that study, and I urged John to set up a major heart disease
study in men, testing a range of hypotheses and taking additional samples of
blood, and asking additional questions to give a basis for testing new hypotheses
which would come up in the future. It was always in my mind that any major
study like that should always have the potential for testing new hypotheses. 
If I can extrapolate just a little, it always seemed to me that epidemiology
studies are so large and so unwieldy that they pick up a question like the
relevance of HDL and it can be 10 or 15 years before any answers emerge. The
answers are incredibly valuable, but by then the medical thinking has moved
on and other questions have arisen, so any big epidemiological study has to be
hung on one or two hypotheses in order to get funding. Those questions that
the original study included are of very little value in the end, because the
results take so long to emerge. If extra blood samples are taken, so that,
retrospectively, new hypotheses which arise in the future can be tested, is a very
necessary aspect of epidemiological studies. 
221 The full texts of the 15 interviews conducted by Dr Ness have been deposited along with 
papers and documents for the Witness Seminar, ‘The MRC (South Wales) Epidemiology Unit’, held
on 23 March 1999, in Archives and Manuscripts, GC/253, Wellcome Library, London. 
Selections from some of these interviews have been published in Ness et al. (2002). 
See also www.epi.bris.ac.uk/mrc-caerphilly/ (visited 11 October 2004).
222 See biographical note, page 156. 
John put forward a [second] proposal to look at about 2500 men in Caerphilly.
John Yarnell has always been given credit for setting it up and for doing a lot
of the basic thinking and organization, and drawing up the sample, but I
always insisted that it was a unit project, that we all had a part to play in it.
And that’s certainly how it turned out. 
We all saw tremendous value in collaboration and so we drew in a number of
people on lipids, on haemostasis. John O’Brien was one of the people, whom
I collaborated with on aspirin and cardiovascular disease and he’s very much a
lateral thinker and so he was involved from the very beginning. He suggested
a small package of haematological tests. Others, like Gordon Lowe in Glasgow,
and then Rod Flower in Bath were drawn in later.223 It was called the
Caerphilly Collaborative Study, because I felt the real value would come from
collaboration with men like Serge Renaud on platelets, John O’Brien on
haemostasis, and Barry Lewis on lipids. 
The involvement of other people in the unit was, of course, absolutely
essential. Janie Hughes and Marion Jones looked after the records and the
response rate. Marion followed up men who refused to come to the clinic, and
offered to do the investigations in their home. I would take their blood, so we
got the whole range of data from them. Without Marion and Janie, the study
would have been an average, or below-average study, but they put in such a
consistent effort without being asked, a product of their training over the years,
in working with Archie [Cochrane] and others. It turned it into a very fine
study, with a very high response rate, and a very careful documentation. 
The study was launched in 1979, and it took four years to see the men, until
1983. John Yarnell chose the sample using the electoral register, and some of
the doctors’ lists. We wanted a complete sample of men within the age range
45 to 59 years of age. A questionnaire asked a few general questions, such as
the age of the respondent, which was a key factor in identifying this particular
age group within the community. Letters were sent to virtually every male on
the electoral roll, in order to pick the sample, and get a complete sample
between those age groups. We set up the study in church halls, the YMCA, and
in doctors’ surgeries, moving around the town, seeing people in the different
areas. We had one dedicated person who visited the men to persuade them to
come to the clinic, and there were six stations in the clinic where different tests
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were done. We piloted all this with my friends and contacts. Later, friends from
church and the neighbourhood would ask me at intervals, ‘Well, what’s
happening up in Caerphilly? You haven’t had us up for a long time.’ We timed
everything and tried to envisage delays in the procedure so that men went
through as smoothly as possible. 
The record-keeping and other details were developed ad hoc as we went along,
and one of the very, very big mistakes we made, which we bitterly regretted, was
the use of numbers from 1001 upwards. It was discovered later that in the
Speedwell study in Bristol, the same numbering had been used with an overlap
in the numbers. I had always suggested within the unit that each research topic
have a unique number – for instance our study on school children was 32s, 33s,
and 34s followed by 01, 02, 03, for the different subjects. Janie and I developed
this system to enable us to immediately identify the study from the number on
the questionnaire. When Caerphilly was being set up, we just used straight
numbers and got into a terrible situation later when the samples from Caerphilly
and Speedwell were stored together, which has been very difficult to unscramble.
In those days a sample of 2500 wasn’t particularly small. We would have liked
it to be bigger, but I insisted that it should be intensive and that we should
collaborate with as large a number as possible and add in as many tests as
possible. For instance, at a later stage, we added in lead, arthritis with
Silman,224 and other things. It was a very intensive study and we were prepared
to go on for a long time, rather than have large numbers. 
South Wales was a very stable area. Some of the cohort studies in London and
places like that [other large conurbations] got into trouble trying to follow up
their sample. We knew that Caerphilly was a very stable area and we expected
it to be a very long-term study. Initially we had thought of ten years, but I don’t
think we had thought of that as an absolute end to the study. 
With regard to women, we were aware of the opportunity that we were missing
in not looking at [both] men and women, and so towards the end of the study
we added a sample of 250 women, but to my knowledge sadly nothing has ever
been published about those women. When we started to analyse them – I took
a personal interest in those 250 women – I looked at a number of things, but
Peter Sweetnam pointed out the drift by the laboratory estimations. There was
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always a drift over time and the women came in at the end of the study, so we
would either have to compare the women with the last 250 men in the
Caerphilly sample, or we would have to indulge in some rather dubious
standardization process to take account of the drift and the changes in the
laboratories. It was so difficult. So, yes it is a small study, but I think we have
gained in other ways in that we have contributed to a very large number of
hypotheses and to discussions about a large number of topics. Because John
Yarnell’s main interest was in HDL cholesterol and he teamed up with Barry
Lewis in London and with Colin Bolton in Bristol, we had very detailed
measurements. We also put in the upper lipid proteins, which were very new
in those days, and we could have made it a lipid study. Ten years later we had
difficulty in publishing the results of this wretched HDL fractions 2 and 3,
which had been done for us. They were ‘old hat’ people said; ‘Those methods
are not appropriate now’, [especially as] the protein’s not in HDL-2 and HDL-3.
I think the haemostatic and thrombosis evidence, [along with] platelets [are]
the most valuable areas within the whole of the Caerphilly studies.225
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Facsimile copy of Dr Lawrence Craven’s 1953 article 226
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Professor Brian Pentecost (Chair): One tends to think of the development of
thrombolysis in clinical practice, as dating back to the late 1980s, when the big
studies – the International Study of Infarct Survival (ISIS), Gruppo Italiano
per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI) and Global
Utilization of Streptokinase and tPA [tissue plasminogen activator] for
Occluded Coronary Arteries (GUSTO) – were published.228 But in fact
streptokinase had been around for a very long time. I looked at its history with
the licensing authority. It was being used intermittently in varying doses, for
various conditions before drugs were licensed in the UK. In 1973 it was issued
with a Licence of Right, which was simply an acknowledgement that it had
been in use and it didn’t imply efficacy. It was nearly 20 years on, in 1991,
when it was given a full licence after review.229 The studies I have mentioned
played a large part in obtaining that full licence. The drug, of course, was
Streptase by Hoeschst.
Professor Desmond Julian: The first presentation on the subject of
streptokinase and myocardial infarction (MI) was by Fletcher and Sherry in
1957.230 Their paper was published in 1959. Some people were quite quick off
the mark, including Dr Dewar, and I am very happy to see him in the
audience, because in 1961 along with two other groups, he published a pilot
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Appendix 3
An edited and annotated extract from the Witness Seminar,
‘Thrombolysis’, 28 January 2003227
Streptokinase Trials (1986–96)
study on the use of streptokinase in myocardial infarction and then he
expanded the series. Please correct me if I have got this wrong, Hewan. He
expanded the series a couple of years later into a study of 75 patients.231
Unfortunately, perhaps because the study was small, or perhaps using the wrong
preparation, that was not positive. And over the succeeding years there are quite
a large number of studies, some randomized, some mis-randomized, and some
truly randomized. In 1967 we held what happened to be the first conference on
Coronary Care in Edinburgh. At that meeting Chazov,232 whose name you may
know having won the Nobel Peace Prize, who at that time was the cardiologist
to the Kremlin and all the leaders of the Soviet Union and on the Politbureau,
told us that streptokinase was widely used in the Soviet Union in 1967, that it
made the electrocardiogram (ECG) evolve more quickly, the infarct healed more
quickly, and all sorts of things which were rediscovered ten or 15 years later by
everybody else. But it was widely used in the Soviet Union at that time.233
Then there were a number of major studies in the succeeding years. There was
one in 1971, which showed a significant benefit.234 There was a European
cooperative study in 1979, which I think raised eyebrows because the
mortality in the control group was 30 per cent and the mortality in the
streptokinase group was 15 per cent.235 We found that very difficult to believe,
and we thought these patients were not being very well looked after. Actually
they had excluded low-risk cases, so I think it’s probably not quite as bad a
reflection on management at that time as it might appear. And then in the late
1980s, GISSI and the Second International Study of Infarct Survival (ISIS-2)
came along.
I am very pleased to see Sir Richard Doll in the audience, because he can
correct me. Doll was the leader of the data monitoring committee, I have
forgotten what we called it then, Sir Richard, but whatever it was. You all
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know, of course, the results of GISSI and ISIS-2, but we were faced with a
particular problem during the conduct of the trial, when in the first 4000
patients treated under four hours,236 there was a very, very highly significant
reduction in mortality.237 The decision was taken to publish a letter in the
Lancet to inform people of this result, and suggest that it was up to the
individual physician to decide whether they should continue that therapy in
that subgroup of patients or not. As it happened, Sir Richard, you can correct
me, but I think most physicians continued to prescribe, at least to enter
patients into the trial, and as a consequence there were quite a lot of patients
who died not having received streptokinase, who might not have died had they
done so. I must say I feel rather uncomfortable about the decision and I would
be very interested to know what Sir Richard feels about that. But I think once
we reached that publication in 1988 the situation was quite clear, that the role
of thrombolysis had been clearly established.238
One other issue and that is the use of intracoronary streptokinase, because Dr
Dewar here perhaps was the pioneer in doing this on seven cases, I think, and
Roger Smith, who’s sitting there, did the work of pushing the streptokinase
into the coronary arteries. Rentrop239 gained a great deal of reputation later on,
and indeed an international reputation for doing the same thing eventually in
a large number of patients. Of course, intracoronary streptokinase was
eventually found to be no better perhaps than intravenous streptokinase, but
it’s an interesting chapter in the history of thrombolysis.
Dr Arthur Hollman: I think Bill Fulton – Fulton and Sumner in fact – made
an immense contribution to the understanding of coronary thrombosis while
working in Glasgow in 1976, perhaps surprisingly late in a way. We have heard
that Dr Hewan Dewar was working in 1961, and Fulton and Sumner
published in 1976 in the British Heart Journal.240 But for those who don’t know
the work, very briefly, they did what I think was really a rather remarkable
thing. Everybody who came into their hospital in Glasgow with an acute
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myocardial infarction had an injection of radiolabelled fibrinogen.241 I am not
sure that would get past the ethical committees these days, but that’s what was
done. Maybe it was explained to them [the patients]. And then the thrombus
in the coronary artery related to in the infarct of those who died was examined
to see which bits of it, if any, were radioactive. If the thrombus has been the
result of the infarction, then the whole of the thrombus would have been
radioactive, because the fibrinogen was given beforehand. In fact, they found
the reverse, they found that the thrombus related to the infarct was
radionegative, so that indicated very clearly indeed it was a thrombus that gave
rise to the infarct and not vice versa. 
Dr Hewan Dewar: The first thing that I did was a pilot study of intravenous
streptokinase in 1961 and a full one in 1963.242 As Desmond has hinted, there
were defects in this study and I think it’s worth considering whether the
publication did more harm than good. There were quite a large number of
patients when we did the proper study – 75 of them – well divided between
the two groups of treated and controls, and we went to a lot of trouble to study
their progress by electrocardiograms, transaminase studies, and so on, and
there was really no difference. 
There were one or two defects. One was the fact that we really hadn’t
appreciated how important it was to get patients treated early, and we thought
in those days that we did quite well if treatment started up to about 12 hours,
and the median was about six hours, so that really wasn’t very good. The other
defect that Desmond hinted at was that we actually used something that the
firm said was plasminogen activated by streptokinase, and I think most people
thought there was an awful lot of streptokinase in it, whereas most of it was
plasmin.243 We hadn’t at that time realized how unsuitable plasmin is for
systemic injection. It’s extremely good for local injections into arteries, but it’s
very unsatisfactory for systemic use, because it becomes so diluted and then
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comes against antiplasmin. For these reasons, the study produced a negative
result. It was worse than that in one sense, because when I presented it
somewhere I was congratulated on the design, they thought it was really an
excellent way of presenting a negative result, and yet I think it probably held
back the use of streptokinase for many years. 
One of the rather interesting things is that just a few years after this, in 1966,
a number of German and Swiss doctors published a study in which they had
done very much the same thing, not quite so carefully, because their
randomization wasn’t so marvellous, but they had done quite a large number,
some of them with what today you would call a pain-to-needle time of three-
and-a-half hours, which was really, I think, absolutely wonderful.244 But, of
course, nobody had ever bothered with it, as it was published in a German
periodical, and as far as I know has never seen the light of day or been quoted
since. But then what it is that enables something to be quoted I think has
already been well described in the Lancet. For an article published before 1966
to be quoted, it might just as well have been published before 1066.245 I think
if somebody had really persevered in the study of streptokinase after the
publication of our negative result, and had paid attention to the German and
Swiss study, then we could have had these treatments available earlier and it’s
a great tragedy. I can’t help wondering if a negative trial isn’t sometimes a
disaster, even if it’s quite well devised. But I would be interested to know what
the rest of you think about that. 
Our intravenous study had begun in 1961, and I did a variety of things
between those years in the fibrinolysis sphere and was also very interested in
coronary ambulances. I enlisted the help of Roger Smith, who had acquired
the expertise of catheterizing coronary arteries while working in Edinburgh.
The two of us, plus a very good radiologist, treated eight early cases of acute
MI in 1976 by direct catheter injection of streptokinase and in 1977 showed
the results to a joint autumn meeting of the British and Swedish Cardiac
Societies. We had successfully lysed thrombi in three out of six, two having
shown only coronary stenosis,  that is a 50 per cent success rate. They were
only temporary successes, because we did not give heparin at the same time for
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fear that the sites of catheter entry in the femoral arteries would bleed
uncontrollably. In their cases, the Russians did follow with heparin. Our cases
therefore did mostly clot up again, but at least they did demonstrate some
clearing of the previously blocked coronary artery. They are shown in the book
that Desmond [Julian] has very loyally brought with him today.246
The effect of our demonstration to the Cardiac Societies wasn’t a bit electric,
it felt like a damp squib. Only two questions were asked: one person asked me
whether I had got the permission of the ethical committee, of which I am glad
to say the answer was yes. The other was a much more doubting chap from
Glasgow who asked me, quite sensibly, what I hoped to achieve by it. I didn’t
like to tell him that I hoped to shake the British Cardiac Society a bit and
perhaps make some go into the whole subject of fibrinolysis in more detail. I
don’t remember quite what answer I gave him. I had difficulty in publishing
it, because in the end the British Medical Journal thought it was too specialized,
and the American College of Cardiology thought it wasn’t really important
enough and advised me to show it somewhere else. I had already given a
demonstration on it to a meeting of fibrinolysis experts in Czechoslovakia, and
they asked me for a text, so I gave them the article and that’s where it now is,
in the proceedings of that conference.247
I knew that the Russians were interested. There was this chap, Chazov, who
had been a cardiologist in Stalin’s reign, so he was evidently a man of courage.
By the time I had dealings with him Stalin had died and perhaps the
succeeding era required even more courage. I corresponded with him, because
he had done two cases (originally I thought it was only one) of intracoronary
injection of a fibrinolytic agent, with one success.248 He had used something
that he called fibrinolysin, and I finally found out what this was. It was human
plasmin, derived from placentas that had been activated with trypsin and of
course it might have just as well been plasmin from any source, and he had one
success out of these two. I did ask him some questions, and he replied, giving
me some details as to why he had used this particular preparation. He was
anxious not to have to use streptokinase, because there might be antibodies in
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the blood stream, which was perhaps a fair comment. But in the last bit of his
letter to me, which did surprise me, he said that he thought that this method
of treatment had a long-range future. Coming from a cardiologist at the centre
of Russia, you may wonder what was meant by long-range usefulness of
intracoronary fibrinolysis for coronary thrombosis.
Pentecost: Actually you do have a publication in the British Heart Journal, in
the Proceedings, it’s the autumn meeting of 1977. It’s where these beautiful
pictures were shown.249
Dewar: Yes, but the full description is in this rather forgotten Proceedings of
the Fibrinolysis Society, whose total title I have forgotten.
Sir Richard Doll: I had some ethical difficulty in taking on the chairmanship
of the Data Monitoring Committee (DMC) of this trial, because I was quite
convinced that both aspirin and streptokinase were useful and in fact I made
it a condition of being Chairman of the DMC that if I had a MI during the
course of the trial I was to have aspirin and streptokinase. So that put me in a
slightly difficult position. But I have always thought that ethical considerations
of an individual physician and of a DMC for a big trial are different. The
clinician to my mind, as soon as he has any gut feeling that one treatment
probably is better than the other, he will probably want to give it to the next
patient, and he may well do that when there are statistical differences
significant only at the 5 per cent level in favour of a particular treatment in a
trial. For the ISIS trial, the situation seemed to me quite different. I think other
people on the committee also agreed with me that the evidence was already
pretty clear, and of course the evidence was made available to all the clinicians
that admitted patients to the trial, they had the results of the meta-analysis
which Collins and Peto had carried out, which showed the beneficial effects.250
But there were occasional cases of cerebral haemorrhage and this apparently
put off a lot of cardiologists, certainly in Sweden. I know that from a discussion
with Lars Wilhelmsen. The Swedes were very concerned with the possibility of
cerebral haemorrhage. They were not admitting patients to the trial. Well our
view on the DMC was that we would report the results, we weren’t responsible
for continuing the trial or stopping it, but we would report the results to the
management committee, when in our view the results were such as to be likely
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to change medical practice. There’s no point in doing these big trials unless the
results are going to be taken notice of, and we therefore said we will report the
results when in our view they are such as will change medical practice. Eventually
we confidently reported to the management committee that treatment, I think
under six hours, was very clearly beneficial. To our astonishment, the
management committee didn’t pay any attention to that. Or rather they paid
some attention, but they didn’t stop the trial. What they did was to inform
people of the results that we reported, and the result of it was that actually a
higher number of patients were admitted, particularly in Sweden, where they
had been so frightened of the risk of haemorrhage, and the trial was continued.
Our view of the evidence that it would change medical practice turned out to be
wrong. It still wasn’t strong enough to do so. 
If I may just add one side comment? The other drug that was being used in
that ISIS-2 trial was aspirin and the DMC were seriously criticized for not
having stopped the trial earlier because the benefits of aspirin were so clear.
The interesting thing is that at the time the final report was made to the
management committee when they did stop the trial, the data in the hands of
the DMC showed only marginal benefit from aspirin, and it was just the
results that came in after we had reported to the management committee that
swung the results in favour of aspirin to such an extent that people asked, not
unreasonably, ‘Why the hell did you go on and allow treatment without
aspirin to be carried on for so long?’ I think those are the points I wanted to
make and they do, I think, raise some quite important issues in relation to
what the function of the data monitoring committee is and I wanted to put
them before you.
Julian: First, I was wrong, it was six hours and not four.251 Yes, I remember the
aspirin business very clearly, because this is, I think, quite an interesting point
for a data monitoring committee. We actually looked at data of hospital
discharge, because a lot of the benefit was in the remaining period between
discharge and 35 days. So when they told us the results I was personally very
surprised that it was as positive as it was.
Pentecost: We will come to the large trials that we have been mentioning a
little later, but are there some more comments on the very early periods of
thrombolysis, pre-ISIS-2? 
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Professor John Hampton: I remember going to a meeting in Phoenix,
Arizona, in 1969, when this was discussed, and as I remember it there were two
things discussed there. One was a belief that thrombosis was something to do
with platelets and fibrinolysis was something to do with clotting and therefore
probably wouldn’t work. The other thing was a really marked worry about
bleeding. And it was the fear of bleeding that really put people off using
thrombolysis on the basis of the sort of evidence we have heard so far.
Pentecost: There was a very good review paper published in 1985 by Yusuf,
Peto and Collins in the European Heart Journal.252 They identified about 6000
patients with myocardial infarct (MI) who had been randomized to treatment
with streptokinase, but they pointed out that the dose regimes were extremely
variable. The usual regime – I think it may have been so in your study, Hewan
– was 250 000 units over 30 minutes, that’s one-sixth of the dose used in the
major studies that we are coming to in a moment. [Dewar: I think it was
500 000 over about ten hours]. But the point is that it would not have been
possible in the mid-1980s, I think, to advocate routine use, because there
simply wasn’t a dose regime worked out. The other big problem was, as John
and Sir Richard have referred to, the fear of bleeding. Has anybody else
anything to contribute to this early story?
Doll: John Honour was doing the experimental work and he certainly
demonstrated an effect,253 but I think the demonstration of an effect on
platelets presumably in vitro had been done a lot earlier and was what made
most people want to use it. But people were not using aspirin and the first,
what we now call meta-analysis, I don’t like the term, that was done in this
country in the modern efficient way was done by Richard Peto, but he
published it in an unsigned editorial in the British Medical Journal, so people
don’t know that it was his work. He analysed six studies of aspirin.254 And of
course, the last, the biggest one, the American study, had not shown a positive
result, and people all believed this last big study and not the six studies which
when taken together clearly showed a benefit, as Elwood and Cochrane had
originally shown that it would. But it was the meta-analysis of these six studies
that convinced us of its benefit. But when I spoke to the Cardiological Society
before we started our randomized study of the possibility of preventing MI by
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people taking aspirin prophylactically, how many were using aspirin in the
treatment of myocardial infarction? The answer was 5 per cent. But following
ISIS-2 it changed to 95 per cent within a matter of months, but it was 5 per
cent before.
Hampton: If I could just comment on Arthur’s question and Sir Richard’s
memory of John Honour’s work, which was done before Sir Richard took the
department over – it was done in George Pickering’s time.255 What they were
mainly interested in when I joined the department was Persantin ®
(dipyridamole), which of course is now much more widely used. But it was the
rabbit ears’ model that really demonstrated that dipyridamole had an effect.256
I don’t remember them ever testing aspirin on that model. 
Pentecost: I wonder too if there wasn’t a rather negative view of treatments for
MI in the 1970s, after the introduction of the defibrillators led to coronary
care units. There were a lot of false dawns – prophylactic use of anti-
arrhythmics, glucose, potassium, insulin and others. There was a sceptical
attitude around, which might have made it a little more difficult to enthuse
over thrombolysis. Desmond, do you think that’s possible?
Julian: You are quite right. I think it is true that there was some scepticism. In
fact, the concentration in the 1970s was entirely on arrhythmias, probably
inappropriately. But as we pointed out, I think what the issues were, the
variability of dose, the very varying results in the different trials, Hewan’s
already referred to them, quite a number of negative trials; the rather dubious
character of the trials in terms of randomization. I think the quality of the
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research, generally speaking, was not of a high order, the risk of bleeding was
considered to be substantial. There was the question of whether thrombosis
had anything to do with it. So a whole range of reasons why there was
scepticism I think.
Doll: May I just add, of course, that John Hampton is correct. I apologize,
John Honour’s experimental work was on Persantin®, not on aspirin.257
Hampton: The other thing was of course that the world got totally hooked on
the β-blockers, did it not? And therefore lost any interest there might have
been in coronary care units and thrombolysis and what have you. I think it’s a
good example of fashions in medicine, that the fashion became β-blockers.258
Pentecost: Do you mean β-blockers in the acute stage?
Julian: Yes, and that’s very interesting and actually you will remember only too
well. It happened to me in Phoenix too, what they were concerned about was
infarct size limitation and they were talking about β-blockers and calcium
antagonists and so forth, whereas the important thing about infarct size is
thrombolysis.
Pentecost: A lot of that followed the Sobell work didn’t it? I mean the
experimental work?
Julian: In fact none of it worked.
Dr Roger Smith: Yes, I was there and for the record I would like to say that it
was one of the most horrific moments in my life when my boss, Dr Dewar,
said that we would take the next patient with a myocardial infarction to the
cath lab and stick a coronary catheter down the appropriate artery and infuse
it with streptokinase, and I can’t describe the sweaty fear I felt through all the
cases. We did do one quite interesting case. Actually it was my fault. I knocked
a clot off a prosthetic aortic valve down the coronary artery and we gave that
patient streptokinase and dissolved the blockage. There was indeed a frosty
reception at the Cardiac Society. My second fear was that Dr Dewar, as he went
off to India, gave me the spool of film and the paper to read at the Cardiac
Society, and those of you old enough will remember that it wasn’t the nice,
kind, society it is now. Dr Dewar said he hoped to arrive back from India in
time to come along to the meeting and give the paper, otherwise I would be
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giving it. I remember a third comment, somebody suggested that all we did
was push the clot down the artery.
Dewar: It took him 25 years to confess to me that he thought at the time that
I was mad. 
Pentecost: Tom Quinn, you were not there at the time.
Professor Tom Quinn: No, I feel humbled really, as I was only just born when
Dr Dewar’s paper was published in 1961. I want to ask if you were to attempt
to do some of these things today, then the regulations around informed
consent for patients would make things quite difficult. What was your
experience of getting the patients on board to agree to undergo what was
essentially very, very experimental stuff in the early days?
Smith: Dr Dewar will have to forgive me once again. It’s really quite amusing
in retrospect. I remember he got the consent from the patient, certainly for the
first patient I know. I remember vividly his saying to the patient: ‘You are
having a myocardial infarction, which is caused by a clot in your coronary
artery, and we propose to unblock it.’
Dewar: There were various ways of describing our intentions. I think I was
rather economical with the whole truth. 
Julian: I think this point of patient consent is a very interesting one, because I
talked to Professor Rutishauser who was in Zurich at the time when Grüntzig
was doing his first angioplasty and he said, ‘Thank God we didn’t have an
ethical committee in Zurich. It would never have got past.’259
Professor Andrew Stevens: I am much too young for this as well, but as a
public health physician looking back on this now and having read up on meta-
analysis and all that I am not surprised that there was no meta-analysis, I am
not surprised that no one read the German literature. What surprises me is the
total absence of the drug companies in all of this. If you look at the battles these
days between the different preparations in thrombolysis, they are all there, loud,
clear and bell-like and arguing it out in fine detail, but I am amazed that there
wasn’t a company pushing streptokinase at us and funding large trials at the
time. Was there something very different about the world then?
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Pentecost: I don’t think so. I believe the answer is that by the early 1970s there
was a Licence of Right, there was no patent on the drug and therefore not a lot
of money to be made. 
Dr Robin Norris: I don’t think ethics change, but our perception of them
certainly does. In a trial of coronary surgery in Auckland in the early 1970s we
randomized patients by the envelope method to surgery or no surgery.260 We
said to the patients that we are offering this operation to some but not all
patients because we think it might help, but we didn’t know. That’s all we did.
I have made out a list [Table 1, page 106] of what I think are the main trials
and I won’t say any more about the pre-GISSI ones, except that I think that
the modern history really starts with GISSI in 1986. There are two things that
paved the way for that. One has been discussed – the knowledge that coronary
thrombosis causes infarction, not the other way round. If one thought that the
thrombus came after the infarct, then the whole rationale would change. The
thrombolytic agent is something that you can give over 36 hours, and there’s
no great urgency. The ‘time is muscle’ idea has come in since GISSI. The
second thing was the perception of the type 2 error, the β error, in clinical
trials. Although this was known, it was not appreciated by many of us, and
many trials were far too small. So GISSI was the first of the mega trials. Having
said this, the trial that hasn’t been mentioned that is scientifically valid is the
Western Washington trial by Ward Kennedy et al., in which intracoronary
streptokinase was shown to reduce mortality and with only 250 patients.261
And then GISSI (11 000 patients), and ISIS-2 (17 000), which is perhaps the
most important of all the trials because it established that aspirin as well as
streptokinase reduced mortality.262 Then there was the Anistreplase
Intervention Mortality Study (AIMS) trial that Desmond, I think,
instigated.263 This was a much smaller trial that was stopped early because
mortality was reduced by 50 per cent. Then came the Anglo-Scandinavian
Study of Early Thrombolysis (ASSET) in about 13 000 patients using
alteplase.264 These trials all showed with complete unanimity that mortality rate
was reduced, as shown subsequently by meta-analysis, by about 30 per 1000
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Table 1: First use and development of thrombolysis on case fatality post-myocardial infarction,
1979–89. 270
Source: Dr Robin Norris
Trial
266
European
Meta-analysis
Western 
Washington
GISSI
ISIS-2
AIMS
ASSET
Drug
267
SK
SK
SK (IC)
SK
SK+ASA
Anistreplase
Alteplase
Reference
NEMJ
1979; 301:797
NEMJ 
1982; 307:1180
NEMJ 
1983; 309:1477
Lancet 
1986 i: 397
Lancet 
1988 ii: 349
Lancet 
1988 i: 545
Lancet 
1988 ii: 525
Number of
patients
315
3277
250
11,712
17,187
1258
7527
Fatality(%)
Control
19
17
11
13
13
12
10
Fatality(%)
Treated
12
14
4
11
8
6
7
Short-term fatality (about 30 days)
Trial
White
O’Rourke
Simoons
Drug
SK
Alteplase
SK
Reference
NEMJ 
1987; 317:850
Circ.
1988; 77:1311
JACC 
1989;14:1609
Number of
patients
194
128
533
Ejection
Fraction
269
Control
53 (14)%
54 (12)%
Survival at 3–7
years was related
to LV function at
discharge.
Ejection
Fraction 
Treated
59 (11)%
61 (13)%
265 Topol (2000).
266 For details of trials, see note 235, Stampfer et al. (1982), notes 261, 237, 274–7.
267 SK = streptokinase; SK (IC) = intracoronary streptokinase; SK + ASA = streptokinase and
acetylsalicylic acid (ASA or aspirin), LV function = left ventricular function.
268 For full details of trials, see notes 272, 282, and 238.
269 See Glossary, page 161.
270 Table distributed at the Witness Seminar, ‘Recent History of Thrombolysis’, 28 January 2003.
GISSI, ISIS-2, AIMS and ASSET all showed that early fatality reduction had been maintained but
not increased.268
Thrombolysis is the most intensively studied intervention in the history of medicine.
More than 200 000 patients have been enrolled in large-scale trials worldwide.265
Long-term fatality (6 months – 10 years) 
Left ventricular function 
patients treated if it was given within six hours.271 These trials were all followed
up long term, which meant in the case of GISSI, AIMS and ASSET being only
six months to a year or so.272 But ISIS-2 followed up patients for ten years. This
was published in the British Medical Journal in 1998, and showed pretty clearly
that although early fatality had been reduced, if you took the survivors of 35
days and then looked at them again after ten years, the benefit was maintained
but not increased.273
This came as a shock to some of us, because my own involvement was with
Harvey White in Auckland. I think ours was the first trial to show that
intravenous as opposed to intracoronary streptokinase reduced damage to the
left ventricle of survivors. We showed a 6 per cent absolute improvement in
ejection fraction, 53 per cent vs 59 per cent.274 We also looked at end-systolic
volume of the left ventricle, which we had shown was a better prognostic
indicator than ejection fraction, and that was reduced in treated patients as
well.275 Then Michael O’Rourke in Sydney did the same with tPA and found
a 7 per cent improvement – 54 per cent in control, 61 per cent in treated
patients.276 In the long term, Martin Simoons and colleagues showed that
survival at three to seven years was related to left ventricular function after
treatment.277 This, of course, is the whole basis for the ‘time is muscle’ adage.
Thrombolytic treatment is not only saving lives, it’s reducing left ventricular
damage. I thought and wrote a viewpoint paper at the time arguing that you
could save on numbers in trials by looking at left ventricular function as a
surrogate for mortality.278 I don’t think anybody followed our suggestion, and
it may be that although an improvement in ejection fraction from 53 per cent
to 59 per cent, or from 54 per cent to 61 per cent in the average patient was
in the right direction, the cut-off for late mortality is really lower than this. You
have to get below 50 per cent ejection fraction to reduce your longevity and
our results related to the flat part of the curve. 
271 Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group (1994).
272 GISSI (1987); AIMS (1990); Wilcox et al. (1990).
273 Baigent et al. (1998).
274 White et al. (1987b). Double blind, streptokinase, propranolol, heparin.
275 White et al. (1987a).
276 O’Rourke et al. (1988). 
277 Simoons et al. (1989).
278 Norris and White (1988).
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I would just like to talk about the door-to-needle-time enthusiasm, which I
think is partly misplaced, because there again it’s looking at the flat part of the
curve. There is a ‘golden hour’, and if you can give thrombolysis within the
golden hour after onset of symptoms and use a fast-acting plasminogen
activator, then you will save more lives. But at the time that patients are getting
to hospital at two or three hours after the onset, an extra 15 minutes to half an
hour probably doesn’t make much difference.
Julian: I agree, although there is a benefit obviously from earlier treatment. Can
I say a bit about pre-hospital treatment? If you put the pre-hospital and in-
hospital trials together, it’s fairly clear that gaining an hour, say, or so is valuable
and it’s also valuable later on. It isn’t only valuable in the first hour. What was
quite interesting about the pre-hospital studies was the study from Aberdeen –
is John Rawles here? [No] – which had roughly 311 patients and was stopped
prematurely, was published immediately in the British Medical Journal.279 The
study we did, the European Myocardial Infarction Project (EMIP) study of
5500 patients, which was not positive, was immediately rejected by the Lancet.
You can speculate as to why this differential occurred. Actually it was quite
funny, because I wrote to complain to the editor of the Lancet about this, and
he wrote a charming letter back saying he would reconsider and let his better
nature prevail and look at it again. Actually I was able to write back to him and
say that it had been accepted for the New England Journal of Medicine.280 But I
think it’s very clear from this that you can demonstrate in those trials the benefit
of earlier treatment, which may be maximum in the first hour, but certainly is
present in each of the succeeding hours up to at least six hours. 
Pentecost: So we had one clear message emerging from these studies, and that
was the importance of avoiding delay and of aiming for the first hour if possible.
But the studies brought in uncertainty and confusion on two counts. Which was
the best drug and regime? And what was the place of heparin? John, you were
involved in GUSTO, what are your feelings now, looking back in a totally
dispassionate and disinterested way on what has happened during that period?
Hampton: If I can just start a bit further back from that? Desmond and I were
saying a little earlier on that there are fashions in medicine and the fashion of
the 1980s was β blockers, calcium blockers and anti-arrhythmias, was it not?
And Desmond and I argued particularly about anti-arrhythmias. ISIS used
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atenolol, and the acronym, of course, stood for the International Study of
Infarct Survival and we in Nottingham were running a study called the
TRENT study and we thought this was terribly clever because, for those of you
whose geography isn’t too good, the Trent is the river that runs through
Nottingham. So we had ISIS versus TRENT and at that time (it’s hard to believe
it now) there was a sort of equal belief that either could be the winner. TRENT
was the abject loser because nifedipine did absolutely nothing. Desmond was on
the Data Safety and Monitoring Board (DSMB) that actually turned it off.281
ISIS went on to ISIS-2 (the Second International Study of Infarct Survival) and
there was nothing we could do with TRENT, because it was with nifedipine. We
went on to ASSET [Anglo-Scandinavian Study of Early Thrombolysis].282 I
remember very well when GISSI came out, ASSET had just about started and
there was an element of ‘we have started so we will finish’, because there was a lot
of debate as to whether having one big trial which was positive with
streptokinase, was it ethical at all to continue with the study of alteplase, which
had only just got going. I can’t quite remember how we rationalized it, but we
felt I think that one study wasn’t enough, and then ISIS-2 beat us to finishing. I
remember Peter Sleight telling me the answer in the Oxford Union when there
was a debate debate, I think, on cholesterol. Peter Sleight and I were talking at
the back of the room, and he told me the results of ISIS-2. Again we were very
worried as to whether we should finish off alteplase or not. By that stage, we
really had pretty well finished recruiting and we decided that it should go on. I
think that with this talk we have had of ethics up until now, it is interesting as to
whether we should have carried on even after GISSI, because it could well be
argued now that ASSET should never have been completed. If it hadn’t been
completed, then we would never have had a comparison of a drug other than
streptokinase against placebo. One of the interesting things that came out was
that alteplase did not look as if it was any better than streptokinase, and the hope
was, of course, that it would be. So GUSTO got organized after that. 
We then got into the phase of comparative trials and this was basically
streptokinase versus something else with various sorts of heparin and what have
you. It was that at this point around 1980–85 that drug company involvement
became so much more important than it had been. I think up until this stage
drug companies were very laid back, very hands off, saying, ‘Oh that will be a
good idea, why don’t you do it?’ Certainly with the TRENT trial the company
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was never seen again really, once they said we could do it, they paid the bills
and kept clear. But after that, particularly with alteplase, and particularly since
at that point the Americans suddenly discovered clinical trials (which up to the
time of GUSTO had been mainly English). From GUSTO onwards, it
became American, American, American, and American, and that was really
because of the market and the involvement of drug companies who were now
driving clinical trials.283 I think that all the trials that went on after that –
Robin has listed some of them here [see Table 1, page 106] – the comparative
studies were led by drug companies, who saw a market for their products. 
We went on to do a study called INJECT where we had the prospect of seeing if
streptokinase and alteplase were equivalent.284 This was a totally new idea and we
learned as we were setting it up that equivalence is in the eye of the beholder and
not in the eye of the statistician, although you can wrap it up in statistical terms.
And the equivalence went on and eventually it reached its reductio ad absurdum
with COBALT (Continuous Infusion versus Double-Bolus Administration of
Alteplase), which tried to show the equivalence within half a per cent and just
failed to show that the two regimes were equivalent, which they really were.285 The
development from GUSTO onwards, I think, has been the reflection of the
overriding importance of drug companies and that has shown itself in the next big
treatment, which, of course, was ACE [angiotensin-converting enzyme] inhibitors
and then statins, always drug-company led, always ‘Is my drug better than
somebody else’s?’ I think the whole philosophy changed somewhere around
GUSTO from a purely academic exercise to a much more commercial exercise and
all the implications that that had. That was how I saw it from that point onwards.
Norris: Just to add to what John said, a lot of these trials now show a reduction
in mortality from 5 per cent to 4 per cent, and to show this needs 10 000
patients or more. In public health terms that may not be very productive.
Julian: Yes, I can correct John. AIMS actually compared anistreplase with
placebo, so there was another.286 I think one of the most interesting trials was
ISIS-3, comparing anistreplase with streptokinase with duteplase.287 What was
The Recent History of Platelets in Thrombosis and Other Disorders – Appendix 3
110
283 For example, ISIS-3.
284 Hampton (1996).
285 Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators.
(1997). Further details at: http://content.nejm.org/cgi/content/full/338/8/545 (visited 23 May 2005).
286 AIMS Trial Study Group (1988).
287 ISIS-3 [Third International Study of Infarct Survival] Collaborative Group (1992).
extraordinary was the superimposition of the three blinds that made it appear
as if those three drugs were equal. Now I think that’s absolutely amazing
because, as was apparent from GUSTO, in fact the regime of tPA that was used
in ISIS-3 was not optimal we now know, and the regime used of anistreplase
was also not optimal. But the fact that they were superimposed meant that
there were suboptimal of the two comparative drugs with streptokinase and
they were identical. It seems to me to be quite extraordinary, and I think if the
trial had been done with the optimal doses of the two other drugs, the results
would have been quite different. I have a recollection that INJECT was
actually on reteplase, and not on alteplase. 
Quinn: This isn’t an original observation. Brian and I discussed this on the
phone the other day, but I wonder if we had spent as much money as the
pharmaceutical companies do on drug development, on developing ways of
getting streptokinase into people an hour sooner, whether we would have seen
much more benefit from that drug. That’s not an original comment, I know
someone, it may be someone like John Rawles, who wrote that, but it’s worth
throwing into the discussion.288
Smith: What’s interesting in the days of threats from the Government and minor
audit figures in the newspapers, is that if you took part in a trial you added 20
minutes to your door-to-needle time, so we could have done even better in the
trial if we didn’t have quite difficult randomization. I think it shouldn’t go
without saying that it was a great privilege to work with the Nottingham group
and Bob Wilcox and Professor Hampton really forged a quite remarkable group
of collaborators in the UK that started with ASSET, and the development of
TRENT, and which developed into a very large number of district general
hospitals in the UK that provided large numbers of patients. That was important
too, wasn’t it, large numbers of patients from each centre into good quality trials.
It did something very important, certainly for me as a young consultant trying
to get things to be as good as they could be, and that was that the trials imposed
an enormous discipline on coronary care units, and also forged something that’s
talked about a lot today and that is multidisciplinary working, with the nurses
and others. I think it had a remarkable effect on cardiology.
Pentecost: We ought to say that streptokinase is only used once, because the
antibodies seem to persist almost forever.
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I would still like to discuss the question of the preferred regimen. Should
streptokinase be used the first time, because you don’t think the differences are
very great? Do we still believe there’s a slight increase in the risk of stroke with
tPA? What’s the position with heparin? What has history answered?
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Professor Michael Harrison
DM FRCP (b. 1936) trained in
London and Oxford, where he
worked on inhibitors of platelet
aggregation. In 1973 he became
Consultant Neurologist at the
Middlesex Hospital, London, 
and later at the National Hospital,
Queen Square, London. He was
awarded a personal chair at the
Royal Free and University College
Medical School, London, in 1988.
His research interests are in stroke,
the cerebral complications of
cardiac surgery and the neurology
of HIV infections and AIDS.
Professor Stan Heptinstall
PhD MBE (b. 1946) trained 
in chemistry before moving to
Nottingham in 1972 to work on
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platelets as a postdoctoral research
fellow, later Lecturer (1975–85),
Senior Lecturer (1985–90), Reader
(1990–94) and has been Professor
of Thrombosis and Haemostasis
there since 1994. He was appointed
editor-in-chief of the new journal,
Platelets, in 1990 and has continued
in that role to the present day.
Dr Arthur Hollman
MD FRCP (b. 1923) was a
cardiologist at Hammersmith
Hospital, London, when the first
open-heart operations were done in
1957. Subsequently he was on the
staff of Great Ormond Street
Hospital for Children, London, and
University College Hospital, London.
Dr Hollman is the official archivist of
the British Cardiac Society.
Dr Peter Hunter
MRCP (b. 1938) qualified 
from Middlesex Hospital, London,
in 1963 and was Consultant
Physician at the Royal Shrewsbury
Hospital, from 1974 to 1993.
From 1994 to 1997 he read
pharmacology at King’s College
London as preparation for full-
time research on the history of
discovery of drugs and medicines
in the modern era.
Professor Desmond Julian
CBE (b. 1926) trained in
cardiology. He was Professor of
Cardiology at the University of
Newcastle upon Tyne from 1975
until his retirement in 1986, later
Emeritus. From 1986 until 1993
he was the Medical Director of the
British Heart Foundation. His
research was mainly in the field 
of coronary heart disease and 
he was the first to propose the
concept of the coronary care unit.
He was President of the British
Cardiac Society from 1985–87 and
Vice-President of the Royal College
of Physicians from 1991–92.
Dr Peter MacCallum
FRCP FRCPath (b. 1958) trained
in haematology in Manchester and
London, Since his appointment 
to St Bartholomew’s and the Royal
London. Since his appointment 
in 1995 he has been a Senior 
Lecturer in Haematology at St
Bartholomew’s Hospital (Bart’s)
and The London, Queen Mary’s 
School of Medicine and Dentistry, 
London, and Honorary Consultant
Haematologist at Bart’s and The
London NHS Trust, London.
Dr Martyn Mahaut-Smith
PhD (b. 1962) Following
postdoctoral studies (1987–92) in
Bristol, Cambridge, Toronto and
San Diego, CA, he returned to
Cambridge, held a British Heart
Foundation Science Lectureship at
the University of Cambridge from
1992 and has been a Senior
Lecturer in Physiology since 2004.
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Professor Thomas Meade
CBE FRCP FMedSci FRS 
(b. 1936) was Director of the
MRC Epidemiology and Medical
Care Unit from 1970, first at
Northwick Park Hospital, Harrow,
later at the Wolfson Institute of
Preventive Medicine when it
moved in 1992. He retired from
the MRC in 2001 and is Emeritus
Professor of Epidemiology at the
London School of Hygiene and
Tropical Medicine.
Professor Denis Melrose
MRCP FRCS (b. 1921) was
Professor of Surgical Science at 
the Postgraduate Medical School,
London, and Surgical Registrar 
at the Hammersmith Hospital,
London, from 1968 to 1983, later
Emeritus. See Melrose (1953); Melrose
et al. (1953); Cleland et al. (1968).
Professor J R A (Tony) Mitchell
(1928–91) was Foundation
Professor of Medicine at the
University of Nottingham, from
1968 to 1990. See H(ampton)JR
(1991); Mitchell (1987). See also
Figure 9.
Professor Salvador Moncada
FRCP FMedSci FRS (b. 1944)
trained as a medical doctor in 
El Salvador, then did a PhD at 
the Royal College of Surgeons,
London. From 1975 to 1996 
he was at the Wellcome Research
Laboratories, Beckenham, Kent,
where he was Director of Research
from 1985. He moved to
University College London 
where he has been Director of the
Wolfson Institute for Biomedical
Research since 1996. See Figure 12.
Dr Robin Norris
MD FRCP FRACP FAHA (b.
1931) trained at the Universities 
of Otago, New Zealand, and
Birmingham, and was Cardiologist
in charge of the coronary care unit
at Green Lane Hospital, Auckland,
NZ, from 1967 until his
retirement in 1992, and tenured
investigator for the New Zealand
Medical Research Council 
from 1970 to 1992. He has 
been Honorary Professor of
Cardiovascular Therapeutics at 
the University of Auckland and
Honorary Consultant Cardiologist
at the Royal Sussex County
Hospital, Brighton, and Director
of the UK Heart Attack Study 
and a subsequent study based in
Brighton from 1992–99, and
Consultant to the UK Myocardial
Infarction National Audit Project
(MINAP) from 1999–2003. His
interests are in acute coronary care,
pathophysiology of MI and the
epidemiology and clinical audit 
of ischaemic heart disease.
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Dr John O’Brien
(1915–2002) haematologist, qualified
in medicine at Oxford, later
trained in haematology under
Professor R G Macfarlane. O’Brien
was among those who published
the first description of Christmas
Disease (now known as Factor IX
deficiency, see Biggs et al. (1952)),
and he went on to develop a
method to measure how platelets
form blood clots and contributed
to the discovery that low-dose
aspirin could reduce this. He was
consultant haematologist at the
South Devon and East Cornwall
Hospital from 1945 to 1951 and 
at St Mary’s Hospital, Portsmouth,
until his retirement. See Elwood
and Lewis (2002).
Professor Michael Oliver
CBE FRCP FRSE (b. 1925) was 
the Duke of Edinburgh Professor 
of Cardiology at the University of
Edinburgh from 1976 to 1989, later
Emeritus. He has been President of
the British Cardiac Society from
1980 to 1984; of the Royal College
of Physicians of Edinburgh from
1986 to 1988; and Director of the
Wynn Institute for Metabolic
Research from 1990 to 1994.
Professor Clive Page
PhD (b. 1958) trained as a
pharmacologist and has been
Director of the Sackler Institute of
Pulmonary Pharmacology at King’s
College London, and Professor of
Pharmacology at King’s College
London, since 1986.
Professor Sir William Paton
Kt CBE FRCP FRS (1917–93)
was on the scientific staff of the
National Institute for Medical
Research from 1944 to 1952;
Reader in Applied Pharmacology 
at University College Hospital,
London, from  1952 to 1954; 
held the Vandervell Chair of
Pharmacology, Royal College 
of Surgeons, London, from 1954
to 1959; and was Professor of
Pharmacology at the University 
of Oxford and Fellow of Balliol
College from 1959 until his
retirement in 1983. He was a
member of the MRC from 1963 
to 1967 and a Trustee of the
Wellcome Trust from 1978 to
1987. His papers are held in
Archives and Manuscripts,
Wellcome Library, London, as
PP/WDP, with further papers in
GC/68/ and GC/154/A/11.
Professor Sir Stanley Peart
Kt FRCP FMedSci FRS (b. 1922)
was Professor of Medicine at St
Mary’s Hospital Medical School,
University of London, from 1957
to 1987, later Emeritus. He has
been Master of the Hunterian
Institute, Royal College of Surgeons
of England from 1988 to 1992;
Trustee of the Wellcome Trust from
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1975 to 1994, Deputy Chairman
from 1991 until 1994 and
Consultant from 1994 to 1998;
and a Beit Trustee from 1986
to 2003. He delivered the
Goulstonian Lecture in 1959, the
Croonian Lecture in 1979, and was
a Founder Member of the Academy
of Medical Sciences in 1998.
Professor Brian Pentecost
OBE MD FRCP (b. 1934)
qualified at St Mary’s Medical
School, London, in 1957, 
was Consultant Physician 
and Cardiologist at the United
Birmingham Hospitals from 1965
until 1993, Dean of Postgraduate
Medicine and Dental Education
from 1987 to 1991 and Honorary
Professor of Medicine from 1991
until his retirement in 1998, later
Emeritus. He has been Advisor 
in Cardiology to the Department 
of Health’s Chief Medical Officer,
1986–93, a member of the
Committee on Safety of Medicines
from 1984–89 and 1996–98,  the
Royal College of Physician’s Linacre
Fellow (Director of Training),
1991–94, and Medical Director 
of the British Heart Foundation,
1993–99.
Sir George Pickering
Kt FRCP FRS (1904–80) was 
an assistant for eight years in Sir
Thomas Lewis’s Department of
Clinical Research at University
College Hospital, London, moving
to St Mary’s Hospital Medical
School, London, to head the
Medical Unit in 1939. The MRC
established a Group for Research
on Body Temperature Regulation
(later Unit) under his direction in
1954. He went to Oxford as
Regius Professor of Medicine in
1956 until his retirement in 1969.
He was a member of the University
Grants Committee from 1944 to
1954, and of the MRC from 1954
to 1958. A collection of his papers,
CMAC/PP/GWP, is held in
Archives and Manuscripts,
Wellcome Library, London. 
See Figure 10.
Professor Colin Prentice
MD FRCP (b. 1934) was a
Lecturer in Medicine at the
Glasgow Royal Infirmary between
1964 and 1971, with Professor
Stuart Douglas and George
McNicol. He was a research
student in 1964–5 with Professor
Oscar Ratnoff at Case-Western
Reserve University, Cleveland,
OH. In 1971 he became Senior
Lecturer in Medicine in Glasgow
and in 1983 he was appointed
Professor of Medicine at Leeds
General Infirmary and the
University of Leeds, until his
retirement in 2000, later Emeritus.
He was a Wellcome Research Fellow
between 1971 and 1975, funded 
by the Wellcome Trust.
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Dr Armand James Quick
(1894–1978), an American
physician and physiologist, who
developed three tests: a one-step
test to measure the amount of
prothrombin present in blood
plasma to determine prothrombin
clotting time; a liver function test;
and an intravenous hippuric acid
test for liver function. He drew
attention to the effects of aspirin on
haemostasis and was able to show
that aspirin could prolong the skin
bleeding time. [Quick (1966).]
Professor Tom Quinn
MPhil RN FESC (b. 1961) has
been Professor of Cardiac Nursing 
at Coventry University since 2003
and has been closely involved in the
development of the National Service
Framework for Coronary Heart
Disease and the Myocardial Infarction
National Audit Project. He is a past
Chairman of the working group 
on cardiovascular nursing of the
European Society of Cardiology.
Professor Peter Richardson
FCGI FRS (b. 1935) has been
Professor of Engineering and
Physiology at Brown University,
Providence, RI, since 1984.
Dr Stewart Sage
PhD ScD (b. 1962) has been
Reader in Cell Physiology at 
the Department of Physiology,
University of Cambridge, since 2003,
and Fellow and Tutor for Research
Students and Director of Studies in
Natural Sciences (Biological), at
Queens’ College, University of
Cambridge, since 1987. 
Professor Bengt Samuelsson
(b. 1934) studied medicine and
biochemistry at the Karolinska
Institute. The structural work 
on prostaglandin was conducted
there with Sune Bergström from
1959–62. He was appointed
Professor of Medical Chemistry at
the Royal Veterinary College in
Stockholm in 1967, returning 
to the Karolinska Institute as
Professor and Chairman of the
Department of Physiological
Chemistry from 1973 until his
retirement. He shared the 1982
Nobel Prize in Physiology or
Medicine with Sune Bergström
and Sir John Vane. His interests
have been in the transformation
products of arachidonic acid,
which led to the discovery of
endoperoxides, thromboxanes 
and the leukotrienes, and his 
group has studied the chemistry,
biochemistry and biology of 
these compounds and their role 
in biological control system. 
See http://nobelprize.org/
medicine/laureates/1982/samuelss
on-autobio.html (visited 18
October 2004).
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Dr Belding Scribner
(1921–2003), nephrologist,
developed the Scribner shunt in
1960 while working with Wayne
Quinton and David Dillard. The
shunt was made of Teflon, but
never patented. He shared the
Albert Lasker Award for Clinical
Medial Research for 2002 with
Willem Kolff, for the ‘development
of renal dialysis, which changed
kidney failure from a fatal to a
treatable disease, improving the
lives of millions of patients’. 
See Couser (2003).
Dr Roger Smith
MB (b. 1945) has been Consultant
Cardiologist at the University
Hospital of North Tees since 
1979, previously Senior Registrar
at the Newcastle Teaching
Hospitals from 1976 to 1979. 
He has been Secretary of the Royal
College of Physicians of Edinburgh
and their Vice-President.
Professor Andrew Stevens
FFPHM (b. 1954) has been
Professor of Public Health at 
the University of Birmingham 
since 1997 and is also head of
Department.   His personal 
interests centre on health
technology assessment and
healthcare needs. He is Chairman 
of a NICE appraisals committee
and co-director of the National
Horizon Scanning Centre at the
University of Birmingham. Before
coming to Birmingham he was 
the first director of the National
Coordinating Centre for Health
Technology Assessment
(NCCHTA) at the University 
of Southampton.
Dr Duncan Thomas
MD DPhil FRCPath (b. 1929) 
was Associate Professor of
Medicine at Tufts University
School of Medicine in Boston,
MA, from 1963 to 1970. From
1976 until his retirement he was
Head of the Department of
Haematology at the National
Institute for Biological Standards
and Control (NIBSC), Potters Bar,
Hertfordshire. See Bloom and
Thomas (eds) (1987).
Professor Sir John Vane
Kt DPhil DSc FRS (1927–2004),
pharmacologist, discovered the role
of prostaglandins in the human
body in response to illness and
stress and later demonstrated
aspirin’s mechanism of action [Vane
(1971)]. He shared the 1982 Nobel
Prize for Physiology or Medicine
with Sune Bergström and Bengt
Samuelsson. A student in Professor
J H Burn’s laboratory at the
University of Oxford, he gained 
his second BSc in Pharmacology 
in 1949, followed by a DPhil 
with Dr Geoffrey Dawes at 
the Nuffield Institute 
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for Medical Research, Oxford, 
and later held the Royal Society’s
Stothert Research Fellowship. 
He was Assistant Professor of
Pharmacology at Yale University,
Newhaven, CT, from 1953–55,
moving to work with Professor Sir
William Paton at the Royal College
of Surgeons’ Institute of Basic
Medical Sciences, London, in
1955, first as Senior Lecturer,
Reader and as Professor from 
1966 to 1973. He became 
Group Research and Development
Director at the Wellcome
Foundation, Beckenham, Kent,
from 1973 to 1985, moving to the
William Harvey Research Institute
as Director in 1986 and Chairman
from 1990 until his death. He was
also Professor of Pharmacology 
and of Medicine at the New York
Medical College (1986–2004). 
See Anon. (2004). See also
http://nobelprize.org/medicine/
laureates/1982/vane-autobio.html
(visited 18 October 2004) and a
transcript of an interview with
Max Blythe in Oxford, 24 February
1988 at www.brookes.ac.uk/
schools/bms/medical/synopses/vane
.html (visited 22 November 2004).
Moncada (2005), also at
www.nature.com/cgi-taf/DynaPage.
taf?file=/nature/journal/v433/n702
1/full/433028a_r.html&filetype=&
dynoptions (visited 15 March
2005). See Figures 8 and 12.
Alfred Edward Webb-Johnson
Bt KCVO GCVO CBE FRCS
(Baron Webb-Johnson of Stoke-on-
Trent from 1948) (1880–1958),
surgeon, was Hunterian Professor
of Surgery and Pathology at the
Royal College of Surgeons of
England, 1917; Vice-President 
and Consulting Surgeon to the
Middlesex Hospital, London, 
and Dean of the Middlesex
Hospital Medical School from
1919 to 1925; Surgeon to HM
Queen Mary from 1936 to 1953;
President of the Royal College 
of Surgeons 1941 to 1948. See
Anonymous (1958). 
Dr John Yarnell
(b. 1945) worked as an
epidemiologist at the Medical
Research Council Epidemiology
Unit (South Wales) from 1975 
to 1993, initially in studies of
respiratory disease and the health
of women, but in 1979 initiated
and worked extensively on the
Caerphilly Collaborative Heart
Disease Study. From 1993 he
became Senior Lecturer in
Cardiovascular Epidemiology at
Queen’s University Belfast, and 
a member of the MRC’s Steering
Committee on the Use of the
Caerphilly Collaborative Database.
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5-hydroxytryptamine 
(5-HT, also called serotonin)
A monoamine neurotransmitter
also stored in non-neuronal tissue,
including platelets where it is
released during aggregation and 
is itself proaggregatory. 
14C-5-hydroxytryptamine 
(5-HT, also called serotonin)
A radio-labelled form of serotonin 
used to trace the distribution and
metabolism of 5-HT (serotonin).
12-hydroxyheptadecatrienoic 
acid (HHT)
One of the three major 
metabolites of arachidonic 
acid in human platelets
[12(S)-hydroxy-5Z,8E,
10E-heptadecatrienoic acid].
adenosine deaminase (ADA)
An enzyme involved in the
production of inosine and
ammonia. In the present context
adenosine is an endogenous inhibitor
of platelet aggregation and is
produced by the breakdown of ADP
released during platelet activation.
Deamination of adenosine by ADA
is one of the normal pathways of
inactivating adenosine.
alteplase 
(Actilyse, Boehringer Ingelheim)
A streptokinase–plasminogen
complex used to treat acute MI,
and pulmonary embolism. 
anistreplase 
(Eminase, Monmouth)
A tissue plasminogen activator
produced by recombinant DNA
technology used to treat acute MI. 
antiphospholipid syndrome (APS)
A disorder characterized by
recurrent arterial or venous
thrombosis and associated with 
the presence of lupus anticoagulant
or antiphospholipid antibodies.
arachidonic acid
An omega-6 fatty acid normally
stored within the cell membrane
and found only in animal fats. It 
is the precursor of prostaglandins,
prostacyclin and thromboxanes.
See Figure 15 on the next page.
aspirin 
(acetylsalicylic acid or ASA)
A non-steroidal anti-inflammatory
analgesic that blocks the action of
cyclo-oxygenase and prevents the
production of prostaglandins,
prostacyclin and thromboxanes.
For platelets, the most relevant
Glossary
Bold text within a definition indicates another glossary entry.
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action is to prevent production of
thromboxane A2 by the platelet
during aggregation, decreasing
overall platelet aggregation. This is
the basis of its use as prophylaxis
against coronary thrombosis.
aspirin resistance
This usually refers to patients 
with coronary artery disease 
having ischaemic events despite
receiving aspirin.
Bernard–Soulier syndrome
An autosomal recessive platelet
disorder characterized by
thrombocytopaenia with giant
platelets.
β error, see type 2 error
bleeding-time (blood)
The blood issuing from a small
puncture in the skin is called 
the bleeding time and bleeding
normally stops in less than 
ten minutes.
blood oxygenators
Devices which take a flow of blood
with a low oxygen content, usually
venous blood, and by direct or
indirect contact of the blood with
a flow of oxygen-rich gas, discharge
the blood with a higher oxygen
content. They are used as artificial
lungs, particularly during coronary
artery bypass.
Figure 15:The metabolism of arachidonic acid to form prostaglandins, prostacyclin
and thromboxanes.
Key to enzymes:
(1) prostaglandin synthase (cyclo-oxygenase) (5) endoperoxide reductase
(2) prostaglandin synthase (peroxidase) (6) prostaglandin-E2 9-reductase
(3) prostaglandin-H2 D-isomerase (7) prostacyclin synthase
(4) prostaglandin-H2 E-isomerase (8) thromboxane synthase
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British Postgraduate Medical
Federation (BPMF)
An association of postgraduate
research Institutes located in
London, mostly focused on a
speciality: Orthopaedics
(1946–87), Dental Surgery
(1948–99, from 1992 as the
Eastman Dental Institute),
Psychiatry (1948–97), Child
Health (1949–96), Neurology
(1950–97), Urology (1951–88),
and the Institute of Basic Medical
Sciences (1941–86). It was
disbanded in 1996, when the
Institutes became constituent parts
of the University of London. See
www.lon.ac.uk/Colleges_Institutes/
home.asp (visited 22 June 2005).
See also the Institute of Basic
Medical Sciences, Department 
of Pharmacology below.
C-reactive protein
A protein produced by liver cells in
response to inflammation and used
as a marker of an inflammatory
state. See de Maat and Trion (2004).
cardiolipin antibodies
Their presence in human serum
can be used in conjunction with
other serological tests and clinical
findings to assess the risk of
thrombosis in individuals with
SLE or lupus-like disorders. Anti-
cardiolipin antibodies have been
strongly associated with venous
and arterial thrombosis. 
Cardiothoracic Institute of the
Brompton Hospital, London
See National Heart and Lung
Institute, London.
Chédiak–Higashi syndrome
A rare and often fatal childhood
autosomal recessive disorder, whose
clinical characterization includes
immune deficiency and decreased
pigment in the eyes and skin
compared to siblings. The patient
bruises and bleeds easily as a result
of deficient platelets.
clopidogrel (Plavix, Bristol-Myers
Squibb, Sanofi-Synthelabo Ltd)
An analogue of ticlopidine that
irreversibly modifies the platelet
ADP receptor. It is an inhibitor of
platelet aggregation and because it
is not related to aspirin it can be
used in patients with an
intolerance, or with contra-
indications, to aspirin.
cyclo-oxygenase 
(COX, also known as
prostaglandin-endoperoxide
synthase/synthetase (PGHS), fatty
acid COX, and PGH synthase)
A key regulatory enzyme in the
production of prostaglandins,
prostacyclin and thromboxane.
Aspirin [Vane (1971)] blocks the
enzyme COX-1, first purified in
1976 and cloned in 1988. COX-2
[Vane et al. (1998); Smith et al.
(2000a)] was identified in 1991,
ATPase ADPase AMPase
ATP ADP AMP adenosine
and COX-3 in 2002
[Chandrasekharan et al. (2002)].
cyclic AMP 
(adenosine-3,-5 cyclic-
monophosphate)
A second messenger that acts 
intracellularly to regulate various
metabolic processes.
defibrillator
A machine producing an electric
shock to stop cardiac fibrillation.
During fibrillation the ventricular
muscle does not contract adequately
and cardiac output fails. The electric
shock converts the fibrillation into
normal contractions and cardiac
output is restored.
dialysers
Also known as artificial kidneys,
although not fully replacing kidney
function, this machine brings the
blood stream into contact with a
flowing aqueous solution of salts
through a hydrophilic membrane,
resulting in progressive removal of
dissolved substances in the blood
up to molecular weights somewhat
exceeding 1 kDa. 
dipyridamole 
(Persantin, Boehringer Ingelheim)
A vasodilator launched in 1960
that decreases platelet adhesiveness
thereby inhibiting the formation 
of clots in the arteries and used
primarily in clinical practice as an
antiplatelet agent. It interferes with
platelet function by increasing the
cellular concentration of cyclic
AMP and increases coronary 
bloodflow. 
disseminated intravascular
coagulation (DIC)
An uncommon condition in which
generalized intravascular blood
coagulation occurs resulting in
spontaneous bleeding. 
ecto-AMPases, -ADPases,
-ATPases
The AMP-, ADP-, and ATPases
are enzymes (phosphatases)
hydrolysing the terminal phosphate
in each substrate. 
Acting in sequence these enzymes
can break down ATP to adenosine 
[see below] which can then be
taken up into endothelial cells 
or be metabolized further by
extracellular adenosine deaminase.
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The prefix ‘ecto’ refers to the
location of these enzymes on the
outer surface of the cell membrane
with free access to extracellular
substrate. In the present context,
ecto-ADPase on the luminal
surface of the endothelial cell
provides a mechanism for the rapid
inactivation of proaggregatory
ADP released from platelets.
ejection fraction
A measure of left ventricular
function. The estimated volume of
the left ventricle at end-diastole
minus the volume at end-systole is
expressed as a percentage of the
end-diastolic volume. Normal
ejection fraction is about 60 per
cent; below 50 per cent is
considered to indicate impairment.
electrophoresis
A technique used to separate a
mixture of molecules by their
differential migration through a gel
in an electrical field. In platelets
this provides a measure of the
surface charge of platelets in
diluted platelet-rich plasma. 
factor VIII 
(antihaemophilic globulin)
A plasma coagulation factor whose
inherited deficiency is responsible
for the most common form of
haemophilia.
fibrinogen 
A circulating protein, which is the
precursor of fibrin in clot
formation.
fibrinolytic drugs
Drugs used to dissolve clots
include alteplase, anistreplase,
reteplase, and streptokinase.
firefly luminescence method
A method for estimating amounts
of adenosine-triphosphate (ATP),
by measuring the light generated
by the reaction of the enzyme,
firefly luciferase, with the ATP.
flow cytometry
The measurement of single cells as
they flow, one cell at a time,
through a beam of laser light.
Their signals are picked up by
detectors, converted for computer
storage and data analysis to provide
information about cell constituents
and properties.
Glanzmann’s thrombasthaenia
A genetic platelet disorder which
leads to defective platelet
aggregation and subsequent
bleeding. The condition is rare and
inherited in an autosomal recessive
pattern.
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glycoprotein (GPIIb/IIIa)
A conjugated protein, a
component of the plasma
membrane, that functions as a
platelet receptor for fibrinogen and
von Willebrand factor and plays
an important role in platelet
adhesion and aggregation.
haemophilia
A hereditary bleeding disorder
which affects the clotting of blood.
Patients with haemophilia A are
deficient in factor VIII and those
with haemophilia B are deficient 
in factor IX (Christmas disease).
haemostasis 
The stopping of haemorrhage.
heparin
A glycosaminoglycan
(mucopolysaccharide)
anticoagulant found in mast 
cells, used in vitro to prevent blood
clotting, and to treat venous 
and arterial thrombosis. 
heparin-induced
thrombocytopaenia (HIT)
An immune-mediated adverse drug
reaction that may be associated
with limb- or life-threatening
thrombosis. The reaction occurs
about five days into heparin
treatment. The side-effects include
deep vein thrombosis, pulmonary
embolism, and disseminated
intravascular coagulation. See
Pentecost, page 111.
Hermansky–Pudlak syndrome
(HPS)
An autosomal recessive genetic
disorder described in 1959 that
consists of visual and skin
dysfunctions, prolonged bleeding
time and defective platelet
aggregation. Patients often have
pulmonary fibrosis, granulomatous
enteropathic disease which
resembles Crohn’s disease, and renal
failure. HPS is frequent among
Puerto Ricans. Further information
can be found at http://falcon.
roswellpark.org/HPSD/HPSD.htm
(visited 31 January 2005).
HHT
See 12-hydroxyheptadecatrienoic
acid
immune thrombocytopaenic
purpura (ITP)
An immune disease that attacks
platelets, reducing the platelet
count (normal range is from
150 000 to 350 000 per millilitre)
causing bleeding, bruises and tiny
red dots (petechiae), on the skin.
indomethacin
An indole derivative with anti-
inflammatory effects, more potent
than aspirin, introduced in 1963
as an oral treatment for
rheumatoid arthritis. Its use has
been limited by its toxicity and its
impairment of platelet function. It
is also a robust inhibitor of the
cyclo-oxygenases.
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Institute of Basic Medical
Sciences (IBMS), Department 
of Pharmacology 
The department was established 
by the Royal College of Surgeons
(RCS) in 1954 with Sir William
Paton as Professor of
Pharmacology. G V R Born was
appointed the first Vandervell
Professor of Pharmacology in
1959. From 1961 to 1984 the
department was a constituent part
of the IBMS, which had been a
joint faculty of the RCS and the
University of London since 1941
and was later part of the British
Postgraduate Medical Federation
(BPMF). The IBMS was disbanded
in 1986 and most of the research
departments closed, although some
laboratories remained at Down
House (Downe, Kent) under the
RCS’s newly created Hunterian
Institute, discontinued by the RCS
in 1993. Pharmacology, the last
research department, closed in
1996. See also note 164.
International Society of
Thrombosis and Haemostasis
(ISTH)
Founded in 1954 in Basel,
Switzerland, as the International
Committee for the Standardization
of the Nomenclature of the Blood
Clotting Factors its name was later
shortened to the International
Committee on Thrombosis and
Haemostasis (ICTH). The ISTH
was organized in 1969 in the US
and the ICTH acted as its working
arm, renamed in 1987 as the
Scientific and Standardization
Committee (SSC) of the ISTH. 
A comprehensive nomenclature of
quantities and units in thrombosis
and haemostasis can be found at
www.med.unc.edu/isth/ (visited 
1 February 2005). 
ischaemic heart disease 
(IHD, also coronary artery
disease; coronary heart disease)
Heart dysfunction caused by
narrowing of the coronary arteries.
lupus
see SLE
meta-analysis 
A systematic review or overview
that uses quantitative methods to
summarize the results of many
studies into one set of conclusions.
Michaelis–Menten kinetics
An equation that describes the
relationship between the rate of an
enzyme-catalyzed reaction and the
concentration of free substrate.
myocardial infarction 
(MI, also heart attack)
The death of cardiac tissue
following interruption of the
blood, usually caused by
obstruction of circulation due to
thrombosis in a coronary artery.
Infarction can result in permanent
damage to an area of the heart.
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National Heart and Lung
Institute, London
Formerly the Cardiothoracic
Institute of the Brompton
Hospital, London, renamed as the
Faculty of Medicine in 1991,
affiliated to Imperial College
London in 1996 and part of the
Imperial College School of
Medicine since 1997.
nitric oxide (NO)
Formerly known as endothelium
derived relaxing factor (EDRF),
NO is an important regulator of
vascular and inflammatory
functions; a key intermediate in
the action of certain nitro-
vasodilating compounds; and an
inhibitor of platelet aggregation
and an inducer of bronchodilatation. 
paroxysmal nocturnal
haemoglobinuria (PNH) 
An acquired haemopoietic stem
cell disorder which results in
haemolytic anaemia or the
increased destruction of red blood
cells. A clinical characteristic is
very dark urine (haemoglobinuria).
patch-clamp recording technique
An electrophysiological technique
that allows the direct study of ion
channel activity in membrane
patches and small cells. 
pentanoic acid
An aliphatic carboxylic acid
containing five carbon atoms.
Persantin, see dipyridamole
plasmin 
An enzyme that digests fibrin, and
thus dissolves blood clots.
plasminogen
A single-chain glycoprotein which
is converted to plasmin when
activated.
platelet 
A blood cell that plays an important
role in blood clotting. Once
activated they can change shape,
aggregate, and release several
bioactive substances. Their properties
of adhesion and aggregation facilitate
haemostasis when the vascular
endothelium is damaged, and also
promotes clotting. 
prostacyclin (PGI2, also known 
as PGX)
A prostaglandin synthesized 
by endothelial cells lining the
cardiovascular system. It is the
most potent known inhibitor of
platelet aggregation, a powerful
vasodilator and opposes the actions
of thromboxane A2. It causes
relaxation of arterial smooth
muscle and inhibition of platelet
aggregation, degranulation, and
shape change, and is therefore
thought to be important in
maintaining vascular homeostasis.
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prostaglandin (PG)
Any of a group of chemicals
derived from unsaturated 20-
carbon fatty acids, primarily
arachidonic acid via the cyclo-
oxygenase pathway. See Figures 17
and 18. See also COX.
Specific prostaglandins are
designated by adding a letter to
indicate the type of ring structure
and a numerical subscript to
indicate the number of double
bonds in the hydrocarbon skeleton.
For example, PGE2 [Figure 18]
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Figure 17: Structural differences between the E, A and B series prostaglandins.
Figure 18: Structure of the prostaglandin PGE2
(11α,15α-dihydroxy-9-oxo-5-cis-13-trans-prostadienoic acid)
E A B
Figure 16: Structure of prostacyclin, 1978.
causes vasodilation, inhibits gastic
secretion, modulates inflammatory
pain and oedema and induces
fever. Most naturally occurring
prostaglandins have two double
bonds and their actions and effects
vary with concentration,
environment, and cell type.
rabbit aorta-contracting
substance (RCS)
Now known as thromboxane A2
or TXA2.
rare inherited platelet disorders,
See, for example, Bernard–Soulier
syndrome; Glanzmann’s
thrombasthaenia; von 
Willebrand’s disease. 
reteplase 
(Rapilysin, Boehringer Mannheim)
A recombinant plasminogen
activator used to treat acute MI.
serotonin, see 5-
hydroxytryptamine (5-HT)
streptokinase (Kabinkinase,
Pharmacia & Upjohn; Streptase,
Hoechst Marion Roussel)
An enzyme released by streptococci
that converts plasminogen to
plasmin, thus dissolving blood
clots. Given intravenously it
dissolves clots in venous
thrombosis, pulmonary embolism
and coronary thrombosis; it is also
used with arteriovenous shunts and
in acute MI. See Appendix 3.
systemic lupus erythematosus
(SLE)
A long-lasting autoimmune disease
that can affect virtually any system
in the body. The immune system
for unknown reasons becomes
hyperactive and attacks normal
tissue (may include the skin, joints,
blood, lungs, kidneys, heart, brain
and nervous system), causing
inflammation, pain, and often
organ damage.
thrombasthaenia
An autosomally inherited
haemorrhagic disease with
abnormalities of platelet function.
thrombin
An enzyme that induces clotting
by the conversion of fibrinogen
to fibrin. 
thrombocytopaenia
A low platelet count often
associated with haemorrhage.
thromboxane A2 (TXA2)
A lipid synthesized from
arachidonic acid by COX with a
chemical structure related to the
prostaglandins, although having 
an endoperoxide ring instead of
the five-carbon ring, an unstable,
short-lived molecule.
Thromboxane A2 is synthesized
predominantly by platelets and
induces vasoconstriction, platelet
aggregation and bronchoconstriction
in lung. Thromboxane A2 degrades
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spontaneously to the inactive
TXB2. See Figures 15 and 19.
tissue plasminogen activator 
(tPA; recombinant tissue
plasminogen activator, rtPA)
An enzyme, serine protease,
released from endothelial cells in
response to signals including
circulatory stasis produced by
vascular occlusion. It binds to
fibrin and converts plasminogen to
plasmin. It is widely used in the
treatment of acute MI, and if given
within the first three hours of a
thrombotic stroke, tPA may reduce
permanent disability through the
fibrinolytic action of plasmin.
type 2 error or β error in 
clinical trials 
A statistical error, where the null
hypothesis is accepted, giving a
false negative result. The power of
clinical trial is determined by the
probability (β) of this error
occurring, since this measures both
the size of the trial and the amount
of actual change in a particular
subgroup.
von Willebrand’s disease
An inherited bleeding disease
resulting from a deficiency or
abnormality of the von Willebrand
factor, part of the plasma
coagulation factor VIII complex.
Clinical features include prolonged
bleeding time and reduced platelet
adhesiveness.
Figure 19: Structure of Thromboxane A2, 1978.
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